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PREFACE 
Food allergies are widespread in industrialized nations. The reasons of this phenomenon have 
been attributed to different factors: the consumption of new products, the evolution of food 
production techniques and the increase of the sensitivity to pollens’ allergens that has brought 
an increase of food cross-reactions. Conduct studies document a 1-2% incidence of food 
allergy in the adult and 2-8% in the child (Pizzin G. et al., 2003). However, this reference 
value seems to be underestimated for an objective diagnostic difficulty. The scientific 
community has paid attention to this subject, that only recently has been recognized as a 
public healthiness problem, and currently the food allergies are object of normative activity at 
a communitarian level and extra communitarian too. 
On March 2005 a trans-sectorial European research project, called EuroPrevall (“The 
Prevalence, Cost and Basis of Food Allergy across Europe”) has been financed. The project’ 
aim is to deliver the information and tools necessary for policy makers, regulators and the 
food industry to effectively manage food allergies across Europe and hence deliver an 
improved quality of life to food allergic consumers. Improved quality of life, including 
reduced risk, will be delivered by integrating information and developing tools for use by 
European food allergy scientists, health professionals, food and biotech industries, and 
consumers those who are food allergic and those who are not. One of the project objective 
concern the structural determination of allergens to provide a  library (collection) of highly 
characterized, well defined  food allergens which will allow the development of component 
resolved diagnosis, to developed novel methods with improved diagnostic power for food 
allergy. So, food sciences have to face the technology troubles concerning  the protein 
structure characterization which can’t be simply identified with the amminoacidic sequence. 
In fact, it’s known that the BSE ezyologic origin is imputable not to a protein mutation but to 
a structural alteration which diffuses to the naturally presented molecules in healthy bovines 
(Chakraborty et al., 2005; Concepcion et al., 2005). Other studies have highlighted that certain 
molecular associations between milk proteins (α-lactalbumin) and unsatured fatty acids 
(C18:1) cause alterations in the protein structure that induce cellular death (Svensson et al., 
2000). For this reason it is necessary to pay attention in the formation of “food experts” to 
improve their "familiarity" with techniques and approaches concerning the proteins structure 
characterization. 
This last necessity is strictly connected with the developed PhD activity, whose aim is the 
study of the existing relations between the sequence of potential allergenic proteins and their ii 
structure, easily connectable with the biologic activity. The application field has been focused 
on the calcium binding proteins, and in particular on those belonging to the EF-hand 
superfamily, one of the principal classes of calcium-binding macromolecules causing food 
allergies (i.e, parvalbumin and psoriasin).  
The first identified calcium-allergen is the fish parvalbumin, that contains three EF-hand 
motives, one of which silent. Since then many calcium allergens have been described with 
different number of EF-hand. In many cases, it has been demonstrated that the loop-calcium 
bond induces conformational changes that causes the recognition of the IgE-allergen. These 
results indicate that the interaction of these proteins with the physiological calcium plays an 
important role in the biologic and allergenic activity (Hebenstreit D. et al., 2005). 
The magnetic nuclear resonance (NMR) is used to value also small structural changes 
determined by different environmental conditions (temperature, pH and ionic concentration), 
also in relation to the peculiarities concerning the different specific sequence of each 
organism and then of the derived food. In fact, the real allergenic action is determined by the 
presence of specific protein surface regions, called epitopes, which could result deeply altered 
by the interaction of these macromolecules with ions or other molecules present in the 
environment. So, still once, the only information relative to the amminoacidic sequence 
results insufficient for this of proteins class that can undergo dramatic open-closed 
conformational changes depending on the interaction with the physiological targets. 
The NMR study requires millimolar protein concentrations, correspondent to milligrams of 
protein, not easily obtainable by the direct extraction from natural matrixes. The alternative 
way is the protein over-expression by opportunely recombined bacteria and optimizing the 
extraction and purification conditions to obtain molecules with the same structural proprieties 
of the native protein. This strategy also allows to obtain protein samples enriched with 
magnetically active isotopes necessary to resolve the soluble structure. 
The gene selection has been based on some protein requirements: 1) the protein, with 
unknown structure, must contain the EF-hand motive; 2) the protein must bind calcium; 3) the 
protein must be flexible so as to alter its structure with calcium-binding. 
Additionally, to increase the number of soluble samples, many different cloning and 
expression conditions were tested, according to Gateway technology. The Gateway 
technology is a universal cloning method based on the site-specific recombination proprieties 
of bacteriophage lambda, that provides a rapid and highly efficient way to move DNA 
sequences into multiple vector systems for functional analysis and protein expression 
(Gateway Technology, 2003). The genes coding for selected proteins were recombined into iii 
five different expression vectors (pETG-20A, pETG-30A, pETG-60A, pDEST17, pDEST15) 
carrying specific protein fusion tags. For proteins expression three different E.coli host strains 
were used (BL21 Gold, pLys, Codon plus). The proteins mainly expressed in a soluble form 
were produced on a large-scale and purified for spectroscopic analysis. 
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1. INTRODUCTION 
1.1 FOOD ALLERGY  
Food allergy is an IgE-mediated abnormal response to a normally tolerated food protein. The 
reasons for an individual to become intolerant towards a specific food protein are unclear. The 
amount of protein required, the threshold, to elicit an allergic response in a sensitized person 
varies considerably from patient to patient and protein to protein (Sathe SK et al., 2005). 
IgE-response is generated in presence of a target macromolecule. IgE-mediated food allergies 
consist of two phases, the first involving sensitisation. The second phase occurs on re-
exposure to an allergen. In this phase an allergic reaction takes place, causing the release of 
histamine and other inflammatory mediators, and producing the physiological changes that 
are manifested as allergic reactions. The spectrum of food allergy symptoms may include 
flushing, urticaria, angioedema, laryngoedema, diarrhea, nausea/vomiting, bronchospasm, or 
hypotension (Roux KH, et al, 2005) and in rare instances some individuals manifest 
anaphylactic reactions. 
IgE binding per se is not indicative that an allergen is able to elicit an allergic response. In 
fact, peanut allergic patients have serum IgE which cross-reacts with soy proteins but 
generally they don’t suffer allergic reaction when they eat foods containing soy. 
The sensitisation to the classical food allergens (milk, egg, peanut and fish) occurs via the 
gastrointestinal tract, while other types of food allergy (fresh fruits and vegetables) occur as a 
consequence of prior sensitisation to inhaled allergens such as pollen. 
The cross-reactive allergy syndromes occurs for when individuals sensitised to an allergen, 
for exemple birch pollen, develop IgE to the major birch allergen Bet v 1, which also 
recognises homologous proteins present in fresh fruits and vegetables. In the same way, 
individuals with latex allergy develop IgE to the chitin-binding domain of the hevein 
polypeptides which make up the rubber latex network. An almost identical domain is found in 
the class I chitinases of a number of fruits including avocado, chestnut and banana, which the 
anti-latex IgE recognises, resulting in allergic reactions to these foods (Mills et al., 2005). 
Only some types of foods are responsible for causing the majority of food allergies, including 
a number of foods of plant origin such as peanuts, tree nuts, wheat and soy, together with 
allergens of animal origin including cow’s milk, egg, fish and shellfish (Bush et al.,1996). 
It has been estimated that food allergies are most prevalent during infancy, affecting up to 6% 
of young children (Breiteneder H et al., 2005).  
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Although sensitivity to most food allergens such as milk, wheat, and eggs tends to remit in 
late childhood, persistence of certain food allergies such as peanut, tree nut, and seafood most 
commonly continues throughout one’s lifetime. The most common food allergens in children 
in the United States are egg, milk, peanut, soy, and wheat. In a prospective study of adverse 
reactions to foods in infants, 80% of confirmed symptoms developed in the first year of life. 
Sensitivity of some food allergens (especially cow’s milk, wheat, and egg) tends to remit in 
late childhood. For example, most infants who are sensitive to cow’s milk lose their 
sensitivity by 2 years of age. However, persistence of childhood food allergies is common 
with certain foods, especially to peanuts, tree nuts, and seafood. Children diagnosed as having 
food allergy after 3 years of age are less likely to lose this sensitivity. Furthermore, children 
who develop one IgE-mediated food allergy have an increased risk of developing allergies to 
other foods and inhalant allergens (Bernstein IL et al., 2006). 
 
1.1.1  Allergenic foods of animal origin 
The major allergen in fish is parvalbumin, which acts as a calcium buffer protein in fast 
muscle, binding the Ca
2+ ions by the EF-hand calcium binding motif. Parvalbumin is widely 
conserved across fish species (cod, salmon, mackerel, herring and plaice). This aspect is 
responsible for the cross-reactive nature of allergens. The cod allergen, Gad c 1, possesses 
five IgE-binding regions evenly distributed along the length of the protein, one of which 
encompassed one of the Ca
2+ binding sites. Like other calcium binding proteins Gad c 1 is 
heat-stable, with the holo-form being both more IgE-reactive and more heat-stable than the 
apo form (Bugajska-Schretter A et al.,2000;  Poulsen et al.,2001). 
Cow’s milk allergy is a common disease of infancy and childhood. Goat’s milk cross-reacts 
with cow’s milk. Ninety percent of cow’s milk allergic patients will react to goat and/or 
sheep’s milk (Bernstein IL et al., 2006). 
Allergens are found in both the casein and whey fractions (h-lactoglobulin, a-lactalbumin).  
h-Lactoglobulin is highly resistant to proteolysis. The IgE epitopes have been identified in 
four main regions located on the more mobile surface loops of the protein. The caseins also 
appear to contain thermostable epitopes, with IgE binding located in around seven different 
regions of the protein (Wal, 2002). 
There is significant cross-reaction between different species of fish, including salt and fresh 
water (eg, salmon, trout, perch, carp, and eel) (Bernstein IL et al., 2006). 
Ovomucoid (Gal d 1) and ovalbumin (Gal d 2), constituting the 10% and 50% of white 
proteins respectively, are the major allergens originate from egg white. Both proteins are  
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heavily glycosylated with 25% of the mass of ovomucoid comprising carbohydrate. In 
ovomucoid IgE epitopes are resistant to enzymic digestion and denaturation. They are also 
clustered in seven regions of the protein, in the N- and C-terminal regions but do not include 
glycosylation sites. Ovotransferrin (Gal d 3) and lysozyme (Gal d 4) are two minor allergens, 
identified in egg white. Cooking has been found to reduce allergenic activity of egg (Poulsen 
et al., 2001). The major cross-reacting antigens between hen’s egg protein and bird dander are 
Livetins. Various bird egg whites (turkey, duck, goose, and seagull) contain proteins that 
cross-react with allergens in hen’s egg white. Several proteins that cross-react with allergens 
in hen’s egg white are also detected in egg yolk, hen sera, and meat (Bernstein IL et al., 
2006). 
The major allergen in seafood and shellfish is tropomyosin, a heat-stable muscle protein,  
with highly homologous proteins being found in the commonly edible crustaceans. These 
homologies cause the cross-reactive allergies observed between various types of seafood 
including shrimps, lobsters, crab, squid and abalone, and inhalant insect allergens, such as 
those from cockroaches. Two main linear IgE-binding sites have been identified in the shrimp 
allergen, Pen i 1, in the N- and C-terminal regions. The first two residues of the C-terminal 
epitope appear to be crucial for IgE binding and are not found in vertebrate tropomyosin 
(Mills et al., 2005). There is no IgE crossreactivity between crustacean and animal muscle 
tropomyosins since the lack of homology in the IgE epitopes. In addition to being found in 
cooked meat, the allergen also leaches into cooking water (Lehrer et al., 2003).  
 
1.1.2 Allergenic foods of plant origin 
Soy and peanut are the major allergenic legumes. Major allergens include the 7S (Ara h 1 for 
peanut, h-conglycinin for soy) and 11S seed storage globulins (Ara h 3 in peanut, glycinin in 
soy) (Mills et al., 2005). Peanut and soybean are members of the legume family and share 
several common antigenic fractions. Patients allergic to one of these foods have serum IgE 
antibodies that immunologically cross-react with other legumes(Bernstein IL et al., 2006). 
Wheat and the related cereals, barley and rye, contain a range of allergens including the 
prolamins (alcohol soluble storage proteins) which are responsible for food dependent 
exercise induced anaphylaxis and atopic dermatitis. Inhibitors of proteases and a-amylases of 
cereals have also been described as both inhalant (e.g. Baker’s asthma) and food allergens. 
The 2S albumins and the 7S and 11/12S globulins are the major allergens of seeds and nuts. 
In addition to storage protein allergens, chestnut contains an endochitinase allergen Cas s 1 
involved in the latex-fruit allergy syndrome (Mills et al., 2005).   
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Although IgE-mediated reactions to fruits and vegetables are commonly reported, clinically 
relevant cross-reactivity resulting in severe reactions is uncommon. The latex-fruit syndrome 
is the result of cross-reactivity between natural rubber latex proteins and fruit proteins. The 
most commonly reported cross-reactive foods include banana, avocado, kiwi, and chestnut, 
but many other fruits and some nuts have been identified in cross-reactivity studies. Reactions 
are typically midl and related to initial sensitization to pollens that share homologous proteins 
with the implicated fruits and vegetables; this is known as the pollen-food syndrome or oral 
allergy syndrome (Bernstein IL et al., 2006). 
 
1.1.3 Food allergies and the relevance for industrial proteins 
The 8 types of foods originally identified by Bush (Bush et al.,1996) as responsible for the 
majority of allergies represent important sources of industrial proteins. They could be 
involved in the production of foods but also in other products such as cosmetics. For this 
reason in the industrialized countries, the necessisty to regulate the diffusion of products 
containing allergenic proteins is born, particularly in the wake of recent legislation regarding 
labelling of allergens in foods.  
Following on from the FAO–WHO Codex Alimentarius Commission amendment to the 
Codex General Standard for the Labelling of Prepackaged  Foods, the European Union, the 
USA and other countries have been developing the necessary regulations to ensure that 
allergenic foods, or ingredients, are labelled on prepackaged foods (Mills et al., 2004)..  
There are also associated concerns about so-called cross-contact allergens which may arise 
from use of common or adjacent processing lines to prepare foods that do and do not contain 
any allergenic ingredients. Given that a kiss from a person eating peanuts given to a severely 
peanut allergic child can be enough to trigger a severe reaction, this represents a considerable 
hazard for allergic consumers which is frequently “hidden”. Whilst manufacturers may 
protect themselves by placing “may contain” labels to deal with cross-contact allergens in 
foods, such a strategy runs the risk of devaluing labels and undermining consumers trust in 
food manufacturers. The lack of knowledge on how much of an allergen causes a problem, 
and the development of associated analytical methodology with appropriate performance 
criteria and reference materials are also issues that will have to be met in the coming years. 
Awareness of the problems facing allergic consumers, good manufacturing practices to 
manage allergenic ingredients coupled with an effective dialogue with allergy sufferers, 
including good quality information on products, will undoubtedly help in managing the 
apparently rising tide of food allergies we are faced with.  
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The number of additives used by the food industry is extensive. Only a small number of 
additives have been implicated in IgE-mediated or other (immunologic or nonimmunologic) 
adverse reactions. Adverse reactions to food additives, therefore, are rare (Bernstein IL et al., 
2006). 
 
Major allergenic foods listed in annex IIIa of the EU directive on labelling of foods 
Cereals containing gluten (i.e. wheat, rye, barley, oats, spelt or their hybridized strains), 
and products thereof 
Crustaceans and products thereof 
Eggs and products thereof 
Fish and products thereof 
Peanuts and products thereof 
Soybeans and products thereof 
Milk and products thereof (including lactose) 
Nuts i.e. Almond, Hazelnut, Walnut, Cashew, Pecan nut, Brazil nut, Pistachio nut, 
Macadamia nut and Queensland nut and products thereof 
Celery and products thereof 
Mustard and products thereof 
Sesame seeds and products thereof 
Sulphur dioxide and sulphites at concentrations of more than 10 mg/kg or 10 mg/l 
expressed as SO2 
 
Tab. 1.1 List of the allergenic foods (or derived ingredients) which will have to be labelled as allergens in 
accordance with the EU directive (Mills et al., 2005). 
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1.2 STRUCTURAL BIOLOGY OF ALLERGENS 
Immunogenicity and cross-reactivity are the two aspects which have to be distinguished in 
predicting the allergenic potential of a protein, particularly in novel foods. Immunogenicity 
represents the potential of a protein to induce IgE antibodies, while cross-reactivity is the 
reactivity of (usually preexisting) IgE antibodies with the target protein. Moreover, the 
relation between IgE-binding potential and clinical symptoms is of interest and is influenced 
by physical properties (eg, stability and size) and immunologic properties (affinity and 
epitope valence). Discussions on immunogenicity and cross-reactivity of allergens rely on the 
establishment of structural similarities and differences among allergens and between allergens 
and non allergens (Aalberse RC, 2000). 
 
1.2.1 Determinants of allergenicity 
The solubility, stability, size, and the compactness of the overall fold are relevant aspects of 
protein structure for its allergenicity. These aspects reflect dependency of allergenicity on 
transport over mucosal barriers and susceptibility to proteases. Size and solubility of the intact 
protein would be relevant factors for airborne allergens more than for food allergens (for 
which limited proteolysis might enhance mucosal transport and hence allergenicity) or 
parenteral antigens, such as insect venoms, insect salivary allergens, invasive organisms 
(helminths and fungi), vaccines, or therapeutic proteins.  
The allergenicity can be affected by post-translational modification in different ways. A post-
translational modification may influence solubility, stability, size, and susceptibility toward 
proteases and it may induce new epitopes. Moreover, uptake and processing by antigen-
presenting cells are also known to be markedly influenced. Although glycosylation affects 
many of these processes, it is not a critical factor for allergenicity in general. Many allergens 
are not glycosylated, whereas some important allergens (eg, Gal d 1 ovomucoid) are heavily 
glycosylated. It will become clear from this overview that few, if any, structural features are 
currently known to be common for allergens in general, even though most allergens can be 
grouped into a small number of structural classes. Some of these classes have been suggested 
to be intrinsically more allergenic, for example, 2S albumin from seeds and  lipocalin. It is, 
however, likely that features other than structure are more relevant for allergenicity. In 
addition, the search for common structural features relevant for allergenicity will become 
more relevant. It is not realistic to assume that the requirements for sensitization to food 
allergens in early childhood are very similar to those for late-onset sensitization to airborne 
occupational allergens (Aalberse RC, 2000).  
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1.2.2 Determinants of cross-reactivity 
Cross-reactivity is largely determined by structural aspects: two proteins are crossreactive 
only (almost) if they share structural features, in contrast to allergenicity.  
There are some exceptions to this rule. Antibody affinity is an important consideration: low 
affinity antibodies (particularly of the IgM class) have been found to be reactive with antigens 
with very little structural similarity. However, IgE-producing plasma cells evolved from a 
strongly T cell–dependent immune reaction in which only high-affinity B cells survive. 
Moreover, IgE-mediated cellular reactions are triggered by trace amounts of allergens. 
However, that information on the threshold of the affinity required for triggering allergic 
reactions by using cross-reactive allergens is still lacking. Another apparent exception is the 
cross-reactivity between glycoprotein allergens with unrelated protein structures (Aalberse et 
al., 1997). In this situation cross-reactivity is due to shared glycans and thus similarity in 
structure. Apart from these exceptions, all IgE cross-reactions described so far have been 
found to reflect shared features on the level of both primary and tertiary structure of the cross-
reactive proteins. Whereas all cross-reactive proteins have a similar fold, the reverse is not 
true: proteins with a similar fold are not necessarily cross-reactive. This is partially due to 
immunologic tolerance induced by autologous proteins with a similar fold. More importantly, 
protein folding is liberal with respect to single amino acid substitutions for many positions in 
the sequence. Such substitutions may markedly affect the outer protein surface and thus 
reduce antibody reactivity. 
Similar protein folds are found with as little as 25% amino acid identity, whereas cross-
reactivity is rare below 50% identity. In most situations cross-reactivity requires more than 
70% identity. 
The likelihood of cross-reactivity depends not only on the similarity between the primary 
sequences of the two antigens. If a human homologue exists and is available to the immune 
system, this is likely to induce immune tolerance to the common epitopes. In some instances 
tolerance to the human protein appears to be absent, resulting in autoreactive IgE antibodies. 
The first description of such an autoreactive IgE antibody presumably induced by contact with 
a cross-reactive environmental allergen was the autoreactivity described for human profilin in 
patients with pollinosis (Bettelheim P et al., 1991). Another striking example is the reactivity 
of IgE antibodies induced by the fungal allergen Asp f 6 (manganese-dependent superoxide 
dismutase [MnSOD]). The recombinant human protein was found to give strongly positive 
skin reactions in subjects with reactivity to the Aspergillus protein.  
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To predict potential cross-reactivity of a new allergen (eg, an engineered food protein), it is 
informative to compare protein folds. In the absence of similarity in folding with allergens, 
protein cross-reactivity is virtually excluded (apart from the above-mentioned exceptions). 
If similarity in folding is observed, cross-reactivity needs to be investigated. The knowledge 
of the folding family allows a search restricted to subjects with sensitization to allergens with 
that particular protein fold. However, antibodies are highly idiotypical. Therefore absence of  
crossreactivity of one antibody (or even many antibodies) does not exclude cross-reactivity of 
another antibody, even with the same epitope specificity. As with all risk assessments, 
statistical evaluation on the basis of a sufficiently large number of cases is important. 
 
1.2.3 Protein structure 
Protein structure can be described at different levels: primary structure (ie, the amino acid 
sequence), protein fold, domain structure, and surface structure. The surface structure is the 
most relevant for antibody binding, particularly the epitope, which is that part of the surface 
that on an atomic level interacts with the antibody. The surface structure was given by the 
protein fold that is the results of the interaction of the secondary structure elements.  
The primary structure of a segment of a polypeptide chain or of a protein is the amino-acid 
sequence of the polypeptide chain(s), without regard to spatial arrangement (apart from 
configuration at the alpha-carbon atom). The commonly occurring amino acids are of 20 
different kinds which contain the same dipolar ion group H3N
+.CH.COO
-. They all have in 
common a central carbon atom to which are attached a hydrogen atom, an amino group (NH2) 
and a carboxyl group (COOH). The central carbon atom is called the Calpha-atom and is a 
chiral centre. All amino acids found in proteins encoded by the genome have the L-
configuration at this chiral centre.  
There are 20 side chains found in proteins encoded by the genetic machinery of the cell. The 
side chains confer important properties on a protein such as the ability to bind ligands and 
catalyse biochemical reactions. They also direct the folding of the nascent polypeptide and 
stabilise its final conformation. Amino acids in proteins (or polypeptides) are joined together 
by peptide bonds. The sequence of R-groups along the chain is called the primary structure. 
The C-N bond length of the peptide is 10% shorter than that found in usual C-N amine bonds. 
This is because the peptide bond has some double bond character (40%) due to resonance 
which occurs with amides. The two canonical structures are showed below.  
As a consequence of this resonance all peptide bonds in protein structures are found to be 
almost planar, i.e. atoms Calpha, C, O, N and Calpha+1 are approximately co-planar.  
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This rigidity of the peptide bond reduces the degrees of freedom of the polypeptide during 
folding. The peptide bond nearly always has the trans configuration since it is more 
favourable than cis, which is sometimes found to occur with proline (Pro) residues (Schirmer 
et al., 1990). Steric hindrance between the functional groups attached to the Calpha atoms will 
be greater in the cis configuration. However, for proline residues, the cyclic nature of the side 
chain means that both cis and trans configurations have more equivalent energies. Thus 
proline is found in the cis configuration more frequently than the other amino acids. The 
sequence and properties of side chains determine all that is unique about a particular protein, 
including its biological function and its specific three-dimensional structure. 
The rotation around bounds N–Cα e Cα–Co is permitted. The rotation angles φ (phi) and ψ 
(psi) can assume values from -180° to +180°, but many of these can’t be formed for the steric 
interactions between atoms of the polypeptidic and lateral chains. For this reason the 
conformation’s value zero of φ and ψ is forbidden, but it is used like a reference point only. 
Every possible secondary structure is completely described by φ e ψ angles (Lehninger et al., 
1994). The permitted values of φ and ψ are indicated on a two-dimensional map of the φ - ψ 
plane. 
 
 
 
Fig.1.1 Representation of the possible rotation movements in the polypeptidic chain. The C-N bonds of the 
planar peptidic groups aren’t free to rotate. The possible obstacled rotation of the other skeleton’s single bonds 
depends on the charge and dimension of R groups (Lehninger et al., 1994). 
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The secondary structure of a segment of polypeptide chain is the local spatial arrangement 
of its main-chain atoms without regard to the conformation of its side chains or to its 
relationship with other segments. There are three common secondary structures in proteins: 
alpha helices, beta sheets and turns. Regular secondary structure conformations in segments 
of a polypeptide chain occur when all the φ bond angles in that polypeptide segment are equal 
to each other, and all the ψ bond angles are equal.  
The alpha-helix and beta-structure conformations for polypeptide chains are generally the 
most thermodynamically stable of the regular secondary structures. However, particular 
amino acid sequences of a primary structure in a protein may support regular conformations 
of the polypeptide chain other than alpha-helical or beta-structure. Thus, whereas alpha-
helical or beta-structure are found most commonly, the actual conformation is dependent on 
the particular physical properties generated by the sequence present in the polypeptide chain 
and the solution conditions in which the protein is dissolved. In addition, in most proteins 
there are significant regions of unordered structure in which the φ and ψ angles are not equal. 
A large proportion of (85%) of helices are distorted in some way i.e. radius of curvature 
greater than 90Å and deviation of axis from straight line is equal to or greater than 0.25Å. 
These may be due to a number of reasons:  
•  CO groups form hydrogen bonds with NH groups 3 residues along the chain forming a 
310 helix. A substantial amount of all 310 helices occur at the ends of alpha-helices. 
They are called 310 because there are 3 residues per turn and 10 atoms enclosed in a 
ring formed by each hydrogen bond. Dipoles are not aligned as in a normal right-
handed alpha-helix.  
•  Packing of buried helices against other secondary structural elements in the core of a 
protein can lead to distortions since the side chains are on the surface of helices.  
•  Proline residues induce distortions of around 20deg in the direction of a helix. This is 
because proline cannot form a regular alpha-helix due to steric hindrance arising from 
its cyclic sidechain which blocks the main chain NH group. Proline causes 2 hydrogen 
bonds in the helix to be broken. Helices containing proline are usually long because 
shorter helices would be destabilized.  
•  Exposed helices are often bent away from the solvent. This is because the exposed 
C=O groups tend to point towards solvent to maximize their hydrogen bonding 
capacity i.e tend to form hydrogen-bonds to solvent as well as N-H groups. This gives 
rise to a bend in the helix axis.   
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•  The pi helix is an extremely rare secondary structural element in proteins. Like the 310 
helix, one turn of pi helix is sometimes found at the ends of regular alpha helices. The 
infrequency of this particular form of secondary structure stems from the following 
properties: (i) the phi and psi angles of the pure pi helix (-57.1, -69.7) lie at the very 
edge of an allowed minimum energy region of the Ramachandran map, (ii) the pi helix 
requires that the angle tau (N-Calpha-C') be larger (114.9) than the standard tetrahedral 
angle of 109.5degrees, (iii) the large radius of the pi helix means the polypeptide 
backbone is no longer in van der Waals contact across the helical axis forming an axial 
hole too small for solvent water to fill, and (iv) side chains are more staggered than the 
ideal 310 helix but not as well as the alpha helix (Schirmer et al., 1990). 
 
Fig.1.2 Representation of alpha-helix one of the structural element of the regular secondary structures in globular 
proteins.  
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Besides the alpha-helix, beta-sheets are another major structural element in globular proteins 
containing 20-28% of all residues. The basic unit of a beta-sheet is a beta strand (which can 
be thought of as a helix with n=2 residues/turn) with approximate backbone dihedral angles 
phi = -120 and psi = +120 producing a translation of 3.2 to 3.4 Å / residue for residues in 
antiparallel and parallel strands, respectively. The beta strand is then like the alpha-helix, a 
repeating secondary structure. However, since there are no intra-segment hydrogen bonds and 
van der Waals interactions between atoms of neighbouring residues are not significant due to 
the extended nature of the chain, this extended conformation is only stable as part of a beta-
sheet where contributions from hydrogen bonds and van der Waals interactions between 
aligned strands exert a stabilizing influence. The beta-sheet is sometimes called the beta 
pleated sheet since sequential neighbouring Calpha atoms are alternately above and below the 
plane of the sheet giving a pleated appearance. beta-sheets are found in two forms designated 
as "Antiparallel" or "Parallel" based on the relative directions of two interacting beta strand as 
showed in figure 1.3.  
 
Fig.1.3 Rapresentation of hydrogen bond patterns in Antiparallel (red lines) or Parallel (blue lines) beta-sheets. 
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Hydrogen bond patterns in beta-sheets. A four-stranded beta-sheet is drawn schematically 
which contains three antiparallel and one parallel strand. Hydrogen bonds are indicated with 
red lines (antiparallel strands) and blue lines (parallel strands) connecting the hydrogen and 
receptor oxygen. Like alpha-helices, beta-sheets have the potential for amphiphilicity with 
one face polar and the other apolar. However, unlike alpha-helices which are composed of 
residues from a continuous polypeptide segment, beta-sheets are formed from strands that are 
very often from distant portions of the polypeptide sequence. Hydrogen bonds in beta-sheets 
are on average 0.1 Å shorter than those found in alpha-helices (Baker and Hubbard, 1984). 
The classical beta-sheets originally proposed are planar but most sheets observed in globular 
proteins are twisted (0 to 30 degrees per residue).  
Antiparallel beta-sheets are more often twisted than parallel sheets. Another irregularity found 
in antiparallel beta-sheets is the hydrogen-bonding of two residues from one strand with one 
residue from another called a beta bulge (as shown above).  
 
Fig.1.4 Atomistic illustration of two beta strands in an antiparallel beta hairpin motif. A very simple structural 
motif involving β sheets is the β hairpin, in which two antiparallel strands are linked by a short loop of two to 
five residues, of which one is frequently a glycine or a proline, both of which can assume the unusual dihedral-
angle conformations required for a tight turn. However, individual strands can also be linked in more elaborate 
ways with long loops that may contain alpha helices or even entire protein domains. 
 
Turns are the third of the three "classical" secondary structures that serve to reverse the 
direction of the polypeptide chain. They are located primarily on the protein surface and 
accordingly contain polar and charged residues. Turns may be viewed as a weak link in the 
polypeptide chain, allowing the other secondary structures (helix and sheet) to determine the 
conformational outcome. There were structural components comprising a few alpha-helices or 
beta-strands which were frequently repeated within structures, called "supersecondary 
structures" (being intermediate to secondary and tertiary structure) and suggested that these 
structures might be due to convergence. A variety of recurring structures were subsequently 
recognised such as the "Greek key" (Richardson, 1977). Some of these structural motifs can  
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be associated with a particular function whilst others have no specific biological function 
alone but are part of larger structural and functional assemblies. proteins containing mostly 
alpha-helix. The simplest motif with a specific function consists of two alpha-helices joined 
by a loop region. Two such motifs are (i) a motif specific for DNA binding and (ii) a motif 
specific for calcium binding and is present in parvalbumin, calmodulin, troponin-C, and other 
proteins that bind calcium and thereby regulate cellular activities.  
The tertiary structure of a protein molecule, or of a subunit of a protein molecule, is the 
arrangement of all its atoms in space, without regard to its relationship with neighbouring 
molecules or subunits. As an example of a protein's tertiary structure, the structure of 
lysozyme is shown below. The quaternary structure of a protein molecule is the 
arrangement of its subunits in space and the ensemble of its inter-subunit contacts and 
interactions, without regard to the internal geometry of the subunits. The subunits in a 
quaternary structure must be in no-covalent association. Haemoglobin contains four 
polypeptide chains (alpha2b2) held together no-covalently in a specific conformation as 
required for its function. To be biologically active, proteins must adopt specific folded three-
dimensional, tertiary structures. Yet the genetic information for the protein specifies only the 
primary structure, that is the linear sequence of amino acids in the polypeptide backbone. 
Many purified proteins can spontaneously refold in vitro after being completely unfolded, so 
the three-dimensional structure must be determined by the primary structure (Anfinsen, 1973). 
Different conformations of a protein differ only in the angle of rotation about the bonds of the 
backbone and amino acid side-chains. It may therefore, appear surprising that a protein folds 
into a single unique conformation from all the possible rotational conformations available 
around single bonds in the primary structure of a protein. The question arises as to when a 
protein folds up to its native conformation, does this structure represent a local or a global 
energy minimum? When a protein folds it samples a number of conformations. Does the 
structure which results from the folding depend on its stability or on the energy barriers 
encountered by the polypeptide? The polypeptide whilst folding may become trapped in the 
local energy well and cannot fold to the global energy minimum (Wetlaufer DB, 1973).  
The amino acid sequence deduced from the nucleotide sequence is usually not the complete 
and final primary structure because cotranslational and posttranslational modifications are 
common. Most allergens are extracellular proteins. Secretion of a protein by a cell requires 
the presence of an N-terminal leader peptide for transport of the protein through the 
membrane of the endoplasmic reticulum (ER). After in vitro unfolding, most proteins will 
fold at least partially back into their native structure. Therefore the primary sequence contains  
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all the clues for the 3-dimensional structure, and we should be able to predict the 3-
dimensional structure of the protein. Homology modeling proves to be reliable for sequences 
that can be aligned well. With sequence homology as low as 25%, overall backbone folds can 
be predicted often with high accuracy, with the exception of some of the more complicated 
loops. Configurations of solvent-exposed side chains are far more difficult to predict, and 
therefore even if the 3-dimensional structure of two proteins with similar folds is known, 
prediction of cross-reactivity is not yet possible. Fold recognition is, however, an important 
help in the search for potential cross-reactivity. Fold recognition on the basis of the primary 
sequence is dependent on the classification of folds, which can be automated to a certain 
extent, but remains to some degree a subjective process (Aalberse RC, 2000). 
 
1.2.4 Linear and conformational epitopes 
The part of the surface of the allergen that interacts with the Fab fragment of the antibody (ie, 
the epitope) is of particular interest. The atomic details of the interaction between antibody 
and antigen are known for more than 30 antibody-antigen combinations. The interaction 
between two proteins is usually described in terms of buried surface (ie, the surface area that 
becomes inaccessible to water molecules as a consequence of the formation of the immune 
complex). This value is calculated from crystallographic data by using a spherical probe the 
size of a water molecule. The review by Padlan (Padlan EA, 1996) gives a range of 54.0 to 
89.0 nm2 for the immune complexes with intact protein antigens (as opposed to peptides or 
haptens) that were available at that time. For a typical globular 20-kd allergen, the radius is 
approximately 2.0 nm, with a spherical surface area of 500.0 nm2. The water-accessible 
surface area varies depending on the compactness of the folded structure structure but will 
usually be approximately twice this value or 1000.0 nm2 in this example. Thus the interaction 
with a Fab fragment of an antibody will bury approximately 5% to 10% of the surface of such 
a 20-kd allergen. The surface area that is accessible to a water molecule is obviously larger 
than the surface area accessible to a Fab fragment (and even more so for a complete 
antibody). It is therefore likely that a single allergen of this size cannot accommodate more 
than 5 to 10 antibodies at the same time. Before crystallographic information was available, 
information on the structure of epitopes was derived, among others, from the reactivity of the 
antibody with peptides derived from the linear sequence of the allergen or with the unfolded 
allergen on an immunoblot. On the basis of this type of information, epitopes were classified 
as either linear or conformational. An antibody was assumed to react with a linear epitope if it 
was reactive with a small peptide (usually 8-15 amino acids) derived from the linear sequence  
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or if it was reactive (in an immunoblot) after the allergen had been unfolded by boiling in 
SDS in the presence of a reducing agent. However, from the crystallographic studies, a 
general picture emerges that does not support the dichotomy of linear versus conformational 
epitopes: all protein epitopes are conformational. In all examples studied this buried surface 
area involves amino acids from different parts of the linear sequence; that is, all these epitopes 
are conformational to some extent. Figure 1.5 shows the epitope of lysozyme for mAb D1.3 
(Bentley GA, et al., 1991). 
How can this observation be reconciled with the observation that many antibodies react with 
small peptides derived from the linear sequence of the antigen? The main factor is the huge 
difference in affinity. On a molar basis, the peptides are very inefficient compared with the 
intact antigen, inhibiting the interaction between antigen and antibody. The peptide represents 
a fraction of the epitope, and the strength of the interaction with the antibody is a fraction of 
the strength with the complete antigen. The strength of interaction with the peptide is usually 
decreased even more because of the higher flexibility of the free peptide compared with the 
peptide in the complete antigen, resulting in a larger loss of entropy on binding (Aalberse RC, 
2000). 
 
 
 
Fig. 1.5 The epitope of egg white lysozyme as recognized by mAb D1.3 (PDB code 1FDL).31 The amino acids 
that contribute to the N-terminal part of the epitope (18, 19, 22, 23, 24, and 27) are indicated in blue. The amino 
acids that contribute to the C-terminal part of the epitope (116-121, 124, and 125) are indicated in red (Bentley 
GA, et al., 1991). 
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1.3 CALCIUM-BINDING ALLERGENS 
1.3.1 Calcium binding proteins 
Calcium is an essential component of bone. It is also required for many intracellular 
functions. Maintenance of calcium homeostasis is a dynamic process involving calcium 
absorption and excretion in the intestine, filtration and reabsorption in the kidney, and storage 
and mobilization in the skeleton. Nearly all of the body calcium (98%) is stored in slowly 
exchangeable skeletal hydroxyapatite crystals. It is the rapidly exchangeable calcium in 
recently deposited bone and in the extracellular, intracellular, and vascular spaces (2% of 
body calcium) that plays a critical role in intracellular communication, synthesis and release 
of neurotransmitters and hormones, muscle contraction, development, and differentiation, as 
well as aging and apoptosis. Therefore it is not surprising that a number of diseases in 
children and adults are associated with altered Ca
2+-homeostasis. 
Ca
2+-levels are controlled by release into, and removal from, the cytoplasm (Figure 1.6). Ca
2+-
pumps in the plasma membrane and endoplasmic reticulum (ER; the Ca
2+-store in a cell) keep 
cytoplasmic Ca
2+-levels low (about 0.1 mmol/L in resting cells) and generate a 10,000-fold 
concentration gradient across membranes (because extracellular Ca
2+ is in the millimolar 
range). On stimulation Ca
2+ enters the cytosol of the cell via Ca
2+-channels (plasma 
membrane) or via Ca
2+-channels in the ER, leading to the activation of a great variety of Ca
2+-
dependent processes in the cell. 
A large group of diseases is associated with defects in Ca
2+-channels. After entering the cell, 
Ca
2+ is reversibly complexed to specific Ca
2+-binding proteins that fulfill multiple functions, 
including Ca
2+-buffering and transport, activation of enzymes, regulation of contraction, 
secretion, and proliferation (Figure 1.6) (Heizmann CW, 2005). 
The majority of proteins involved in transducing intracellular Ca
2+ signals are characterized 
by a common helix-loop-helix structural motif in their Ca
2+-binding sites, termed the EF-hand 
(Chazin WJ et al, 1998). 
A large family of Ca-binding proteins is characterized by a common structural element, the 
EF-hand motif (Figure 1.7). These proteins decipher the information carried by Ca
2+ and pass 
it on to various targets regulating biological functions (Heizmann CW, 2005). 
The canonical EF-hand consists of a 29 residue contiguous polypeptide containing helix I 
(helix E), a loop around the calcium ion, and helix II (helix F). Residues 1, 3, 5, 7, 9 and 12 of 
the canonical binding loop chelate the Ca
2+ ion, forming a pentagonal bipyramidal array of 
seven oxygen ligands. Residues 1, 3 and 5 provide monodentate oxygen ligands via sidechain 
oxygens, usually aspartate carboxylates. Residue 12 is a bidentate oxygen ligand, and is  
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almost always a glutamate residue, which ligates calcium via both sidechain carboxlyate 
oxygens. Residue 7 directly coordinates Ca
2+ via its mainchain oxygen. Residue 9 hydrogen 
bonds to a water molecule that provides the remaining Ca
2+ ligand. Most EF-hand proteins 
use this canonical motif. However, members of the S100 subfamily of CaBPs have a two 
residue insertion and a modified coordination scheme in the first binding loop, creating a 
motif termed the pseudo EF-hand (Chazin WJ et al, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6 Pathways of Ca
2+ release and uptake. Three types of Ca
2+-channels (gated by ligands, voltage, emptying 
of Ca21-stores) mediate Ca
2+-entry into cells and 2 Ca
2+-pumps of plasma membrane and of endoplasmic 
reticulum remove ion from cytoplasm. Ca
2+-signal is mediated by EF-hand Ca
2+- binding proteins (including 
S100 protein family), which has intra- and extracellular cytokine-like functions (Heizmann CW, 2005). 
 
Proteins of this family are closely associated with a number of human diseases such as 
cardiomyopathy, diabetes, brain disorders, inflammation, and cancer. They have also been 
proven to be valuable in the diagnosis of these diseases and as predictive markers of 
improving clinical management, outcome, and survival of patients. They are considered as 
having potential as drug targets to improve therapies.   
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Fig. 1.7 a The EF-hand proteins are based on a motif characterized by a helix–loop–helix structure, with a 12 or 
14 amino acid long interhelical loop able to bind a calcium ion. The motif’s name is derived from the E and F 
helices, in the Ca2+ binding site of parvalbumin, resembling the thumb and the forefinger pair of the hand .b The 
minimal structural and functional unit of EF-hand proteins is a domain composed of a pair of EF-hand motifs 
tethered together by a linker of variable length. Helices are numbered from the N-terminal to the C-terminal of 
the domain (Capozzi et al., 2006). 
 
 
A prominent member is troponin (subunits TN-T, TN-I, TN-C), a regulator of striated muscle 
contraction. Measurements of troponin I levels are routinely used in the diagnosis of 
myocardial infarction. In addition, mutations in the troponin I subunit are associated with 
familial hypertrophic cardiomyopathy. 
Parvalbumin has been found to be a major fish allergen in human beings. Approximately 70% 
of fish allergies, mediated by parvalbumin IgE antibodies, lead to respiratory and 
gastrointestinal symptoms. Parvalbumin also became of interest because of its potential use in 
gene therapy to correct cardiomyopathy (Heizmann CW, 2005). 
 
1.3.2 Calcium binding allergens 
In the last decade, the number of available allergen sequences has rapidly increased due to the 
introduction of molecular biology techniques for allergen characterization. Sequence analysis 
of allergen-encoding cDNAs revealed the presence of typical calcium-binding motifs, termed 
EF-hands, within allergens from various sources. Parvalbumin represented the first calcium-
binding allergen described. It represents the major allergen in fish and belongs to a subfamily 
of closely related calcium-binding proteins that contain two functional and one silent EF-hand 
motif. In countries with high fish consumption almost 1 per 1000 of the population is allergic 
to fish with most of the IgE antibodies directed against parvalbumin. Because of sequence and 
structural similarities among parvalbumins, fish allergic individuals exhibit allergic reactions 
after contact and/or consumption of various fish species. Next after parvalbumin, EF-hand 
E
F  
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domains were identified in the deduced amino acid sequences of two birch pollen allergens 
and the allergens were subsequently identified as a three and a two EF-hand allergen 
designated, Bet v 3 and Bet v 4, respectively. It was found that IgE recognition of Bet v 3 was 
strongly influenced by the presence or absence of protein-bound calcium, a property which 
was shared by most of the other calcium-binding allergens described later on. Table 1 
provides an overview of the calcium-binding allergens described so far. The allergens were 
grouped according to the number of calcium-binding domains. Allergen sources, molecular 
weights, accession numbers for the sequences and references are also displayed. As is evident 
from Table 1, pollens from various plant species turned out to be major sources of calcium-
binding allergens. The latter may be related to the fact that calcium ions are important for 
pollen tube growth and perhaps for the self-incompatibility response in plants.  
Many calcium-binding allergens are therefore abundantly expressed in pollen tissue and, due 
to the fact that pollen from wind pollinated plants becomes airborn in large amounts, can 
sensitize patients via the respiratory mucosa. In this context it is noteworthy that calcium-
binding allergens, although representing intracellular proteins, are rapidly eluted when pollen 
becomes hydrated as it happens after contact with the mucosa of patient). Bet v 3 from birch 
pollen was the first described calcium-binding pollen allergen. It was isolated by 
immunoscreening of a birch pollen cDNA library using serum IgE from a pollen allergic 
patient. Within its sequence, Bet v 3 contains three typical calcium-binding motifs and was 
found to be highly expressed in mature pollen. Another family of calcium binding allergens 
representing two EF-hand proteins of 8-9 kDa was identified in tree-, weed-, and grass pollens 
(Table 1.2). Jun o 2 and Ole e 8 represent four EF-hand calcium-binding allergens which were 
isolated from cypress and olive (Valenta R et al., 2000). 
Calcium-binding allergens were however also described in parasites, which are potent 
inducers of IgE responses, and in animal hair/dander. Recently even a calcium-binding 
autoallergen was isolated using serum IgE from atopic dermatitis patients for screening of a 
human epithelial expression cDNA library. 
 
 
No Allergen Species - 
Scientific Name 
Species - 
Common Name  Allergen Type  Allergen 
Description  Class 
1  Aln g 4   Alnus glutinosa  alder   tree Fagales      non-IUIS 
2  Bet v 3   Betula 
verrucosa   birch   tree Fagales      IUIS 
3  Bet v 4   Betula  birch   tree Fagales      IUIS  
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verrucosa  
4  Bos d 3   Bos domesticus  domestic cattle   animals    Ca-binding 
S100 homolog   IUIS 
5  Bra n 1   Brassica napus   rapeseed   foods    2S albumin   IUIS 
6  Bra n 2   Brassica napus   rapeseed   foods       non-IUIS 
7  Bra r 1   Brassica rapa   turnip   foods    2S albumin   IUIS 
8  Che a 3   Chenopodium 
album  
lamb's-quarters, 
pigweed, white 
goosefoo  
weed 
Caryophyllales  polcalcin   IUIS 
9  Cyn d 7   Cynodon 
dactylon   Bermuda grass   grass Poales      IUIS 
10 Cyp c 
1.01   Cyprinus carpio  common carp   foods    parvalbumin   non-IUIS 
11 Cyp c 
1.02   Cyprinus carpio  common carp   foods    parvalbumin   non-IUIS 
12 Gad c 1   Gadus callarias  cod   foods   
allergen M, 
parvalbumin 
beta  
IUIS 
13 Gad m 1  Gadus morhua   Atlantic cod   foods    parvalbumin 
beta   non-IUIS 
14 Hom s 4  Homo sapiens   human 
autoallergens   others       IUIS 
15 Jun o 4   Juniperus 
oxycedrus   prickly juniper   tree Pinales  
homolog: 
calmodulin; old 
name: Jun o 2  
IUIS 
16 Ole e 3   Olea europea   olive   tree Lamiales 
Oleaceae      IUIS 
17 Ole e 8   Olea europea   olive   tree Lamiales 
Oleaceae  
Ca2+-binding 
protein   IUIS 
18 Phl p 7   Phleum pratense timothy   grass Poales      non-IUIS 
19 Ran e 1   Rana esculenta   edible frog   foods    parvalbumin 
alpha   IUIS 
20 Ran e 2   Rana esculenta   edible frog   foods    parvalbumin 
beta   IUIS 
21 Sal s 1   Salmo salar   Atlantic salmon   foods    parvalbumin   IUIS 
22 Sco j 1   Scomber 
japonicus   chub mackerel   foods    parvalbumin   non-IUIS 
23 Syr v 3   Syringa vulgaris lilac   tree Lamiales 
Oleaceae      non-IUIS 
24 The c 1   Theragra 
chalcogramma   Alaska pollock   foods    parvalbumin 
beta   non-IUIS 
Tab. 1.2 Calcium-binding allergens from the Pfam A Family PF00036 (http://fermi.utmb.edu/cgi-
bin/SDAP/sdap_07?dB_Type=0&Code=3&Pfam=PF00036). 
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1.3.3  Calcium-binding proteins as cross-reactive allergens 
The classical EF-hand domain found also in calcium-binding allergens consists of an a-helix, 
a loop coordinating the Ca
2+  ion and a second a-helix. In the EF-hand, calcium ions are 
usually bound through four carboxylate or carboxamide groups and a single backbone 
carbonyl oxygen placed in the loop with a specific spacing. Although EF-hand domains 
represent highly conserved sequence motifs also in calcium-binding allergens, it seems that 
crossreactivity of IgE antibodies from allergic patients who are sensitized against a particular 
calcium-binding allergen is rather limited to closely related proteins. There is extensive IgE 
crossreactivity of fish allergic individuals with parvalbumins from various fish species which 
explains why parvalbumin-sensitized individuals exhibit allergic symptoms after ingestion of 
various fish species (Table 1.2). Likewise, there is strong crossreactivity among the members 
of the two-EF-hand pollen allergens. Patients who are sensitized to the two-EF hand allergen 
from birch always exhibit IgE crossreactivity with the homologous proteins in weed and 
grasspollens and therefore constitute a group of allergic patients who can exhibit allergic 
reactions after contact with pollens from many, even unrelated plant species. While there is 
extensive crossreactivity to calcium-binding allergens within certain allergen families 
(parvalbumins, 2 EF-hand pollen allergens) there seems to be little or no crossreactivity 
among the various families of calcium-binding allergens in general. The latter fact indicates 
that the less conserved sequence motifs and, perhaps conformational epitopes which are 
unique to a given protein family, play an important role for IgE recognition. 
Crossreactivities of IgE antibodies within certain families of calciumbinding proteins may 
have important implications for diagnosis as well as for therapy. If an allergic patient contains 
for instance IgE antibodies against a particular 2 EF-hand pollen allergen (e.g., birch: Bet v 4) 
these IgE antibodies will crossreact with 2 EF-hand allergens in grass-, weed- and other tree 
pollens leading to allergic reaction against most plant pollens. Calcium-binding allergens can 
thus be used as marker allergens which when used for diagnostic testing allow to predict 
broad sensitization of a given patient. On the other hand it seems possible to treat sensitized 
patients by specific immunotherapy only with a few representative members containing the 
crossreactive epitopes in order to cover the complete familyof crossreactive calcium-binding 
allergens (Valenta R et al., 2000). 
 
1.3.4 Conformation-dependent IgE recognition of calcium-binding allergens 
It is well established that calcium-binding proteins can undergo dramatic open-closed 
conformational changes depending on the presence or absence of protein-bound calcium. It is  
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also well established that these conformational changes can strongly affect the physochemical 
properties of calcium-binding proteins. E.g., it is known that the calcium-bound (open 
conformations) are more stable than the apoforms (closed conformations) and that the 
calcium-bound (open conformations) forms can expose hydrophobic surfaces which are not 
available in the closed conformation (Figure 1.8). Calcium can thus strongly influence the 
ability of calcium-binding proteins to interact with other ligands and thereby represents a 
physiological calcium-dependent regulation mechanism for ligand interactions. 
Likewise it was discovered that the IgE-binding capacity of calcium-binding allergens is 
affected by calcium. A calcium-dependent modulation of the IgE-binding capacity was 
reported for calcium-binding birch pollen allergens, Bet v 3 and Bet v 4, as well as for other 
calcium-binding pollen allergens and the major fish allergen, parvalbumin. Loss of the 
protein-bound calcium triggers a large change in conformation and an associated loss of 
conformation-dependent IgE epitopes (Breiteneder H et al, 2005). 
Most sensitized patients contain IgE antibodies which recognize preferentially the calcium-
bound form and exhibit strongly reduced IgE binding to the calcium-free apoform. This 
observation indicates that patients who are allergic against calcium-binding allergens were 
preferentially sensitized against the calcium-bound forms which are also more stable than the 
apoforms (Valenta R et al., 2000). 
 
 
 
Fig. 1.8 Surface representation of the N-terminal domain of CaM, a calcium sensor protein, in the apo (a, 1CMF) 
and calciumbound (b, 1CMG) forms. The surface is colored according to the physicochemical properties of the 
underlying amino acids: red acidic, blue basic, yellow hydrophilic, and gray hydrophobic. Calcium binding to 
CaM leads to a transition from a closed to an open state, with resulting exposure of a large hydrophobic surface, 
allowing the protein to interact with targets to accomplish regulatory functions (Capozzi et al., 2006). 
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1.3.5 Conversion of calcium-binding allergens into hypoallergenic  molecules for 
vaccination  against allergy 
 
A major disadvantage of allergen-specific immunotherapy is that administration of allergens 
to patients can cause anaphylactic side effects. Therefore attempts are made to convert active 
allergens into molecules with reduced allergenic activity for immunotherapy with reduced rate 
of anaphylactic side effects. The finding that IgE recognition of calcium-binding allergens 
depends on protein-bound calcium has stimulated ideas to convert these allergens into 
allergen variants with reduced IgE binding capacity by mutation of the calcium-binding sites. 
It was demonstrated that mutated versions of the birch pollen allergen Bet v 4 and the 2 EF-
hand allergens from rape containing amino acid exchanges within the calcium-binding 
domains lost their calcium-binding properties and exhibited a strongly reduced IgE-binding 
capacity. It was also demonstrated that deletion variants and fragments of calcium-binding 
allergens exhibited reduced IgE binding capacity. This opens now possibilities to produce by 
genetic engineering hypoallergenic versions of calcium-binding allergens which may be used 
for allergen-specific immunotherapy with reduced risk of anaphylactic side effects (Valenta R 
et al., 2000). 
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1.4 EuroPREVALL - THE PREVALENCE, COST AND BASIS OF FOOD ALLERGY 
ACROSS EUROPE 
EuroPrevall is a multidisciplinary integrated project (IP) involving 15 European member-
states, Bulgaria (a candidate country), Switzerland and Iceland, and Ghana. Of the 53 
partners, there are 17 clinical organisations and 11 small-medium sized enterprises (SMEs). 
Its aim is to deliver the information and tools necessary for policy makers, regulators and the 
food industry to effectively manage food allergies across Europe and hence deliver an 
improved quality of life to food allergic consumers. Improved quality of life, including 
reduced risk, will be delivered by integrating information and developing tools for use by 
European food allergy scientists, health professionals, food and biotech industries, and 
consumers – those who are food allergic and those who are not. Much of these benefits will 
be realised through exploitation of research results by SME industries.  
More specifically, EuroPREVALL will: 
¾  Provide a  library (collection) of highly characterized , well defined  food allergens which 
will allow the development of component resolved diagnosis, to developed novel methods 
with improved diagnostic power for food allergy  including allergen chips and measures 
of IgE-cross linking as an alternative skin test in vitro.  
¾  Carry out epidemiological studies to establish the true occurrence, prevalence and 
distribution of food allergy and hypersensitivity in children and adults as well as 
influences during pregnancy and early-years, involving a birth cohort of 10,000 babies, 
yet to be born across Spain, Germany, Iceland, Greece, Poland and the UK.  
¾  Investigate the role of diet, environment and infections in determining patterns of food 
allergy by mapping patterns of food allergy against other environmental allergies and 
patterns of food consumption. Determine the role of infections in allergy as well as the 
effectiveness of genetic markers.  
¾  Measure the socioeconomic impact of food allergy, the cost to society and the effect on 
food allergic individuals and their families by questionnaires. Develop tools to assess the 
economic impact on individuals and their households, as well as the agro-food industry.  
¾  Use the battery of existing methods, and those newly developed in EuroPrevall, to predict 
the outcome of exposure of susceptible individuals to allergens in real foods and in model 
systems.   
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¾  Capitalise on existing freely-available evidence-based information, developed in 
conjunction with allergic patient groups for the benefit of patients and the scientific 
community.  
¾  Create training materials for patient groups, health professionals and the food industry. 
¾  Train a new generation of food allergy scientists in a consensus approach. 
Italy is one of the country involved in the project. The participation concerns on the 
assembling of a new library of natural and recombinant allergens. Allergens will be 
characterised with regards structure (primary to quaternary), using NMR and X-ray 
crystallography, and post-translational  modification and the presence of different isoforms 
(EuroPREVALL, 2005).  
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1.5 HIGH THROUGHPUT PRODUCTION OF RECOMBINANT PROTEINS 
The discovery of thousands of novel protein-coding sequences and the increased availability 
of large cDNA collections provide the opportunity to investigate protein function in a 
systematic manner and at an unprecedented scale. This opportunity highlights the need for 
development of high throughput (HT) methods for protein isolation. 
Purified proteins are a key reagent for numerous assays that address fundamental questions 
about their structure, function and regulation. 
For applications that require large amounts of purified proteins (mg) HT methods for protein 
isolation can be used to efficiently screen many different constructs (orthologues, tags etc.) to 
identify those that produce a high yield of soluble protein. For microscale applications HT 
protein purification provides the front end to produce proteins for various applications that 
require limited amount of protein per sample. 
Over the past few decades several protein expression systems have been developed for 
recombinant protein expression. Different expression hosts (e.g., Escherichia coli, 
Saccharomyces cerevisiae,  Pichia pastoris, insect and mammalian cell lines) have been 
developed to express heterologous proteins.  Additionally, genomic approaches are being 
pursued to solve the structure of numerous proteins. 
Each of these systems has its strengths and weaknesses concerning yield, proper folding, post-
translational modification (PTM), cost, speed and ease of use. With respect to HT application, 
it is also useful to consider the ‘success rate’ – the fraction of proteins that can be produced in 
practical yields. 
Escherichia coli is the simplest and by far the most widely used organism for protein   
expression. The most appreciated advantages of this system are its speed, ease of use and low 
cost. These advantages are sometimes offset by the lack of eukaryotic post-translational 
modification  PTMs and the low solubility of some proteins. 
Interest in Saccharomyces cerevisiae as a protein expression system has increased recently 
because this organism combines the advantages of an inexpensive, fast growing unicellular 
organism with the physiological properties of a eukaryotic cell. 
Protein production in insect cells is commonly performed using the baculovirus system. This 
protein expression system is popular for large scale protein expression. Appreciated 
advantages of insect cells are the robust and relatively inexpensive cell culture and the fact 
that most eukaryotic PTMs are executed properly. 
Cell-free expression systems are particularly attractive for HT applications because the 
absence of a cell membrane eliminates the harsh process steps associated with introducing  
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DNA into cells, lysing cells and clearing lysate. Expression systems from eukaryotic cell 
lysates have the additional benefit that most PTMs are executed properly. The most widely 
used open expression systems are bacterial, wheat germ and reticulocyte lysates, although 
lysates from other cell types have also been made (Pascal B et al., 2003). 
 
High-throughput protein purification depends on affinity tags to provide a generic 
purification strategy. The use of affinity tags enables different proteins to be purified using a 
common method as opposed to highly customized procedures used in conventional 
chromatographic purification.  
Introducing an affinity tag may have a positive effect in the biochemical properties of the 
target protein, especially in bacterial protein expression. Affinity tags have been observed to:  
¾  improve protein yield, 
¾  prevent proteolysis,  
¾  facilitate protein refolding,  
¾  protect the antigenicity of the fusion protein, and 
¾  increase solubility. 
 
On the other hand, although the advantages it is important to consider any tag can potentially 
negatively affect the target protein resulting in: 
¾  a change in protein conformation,  
¾  lower protein yields, 
¾  inhibition of enzyme activity, 
¾  alteration in biological activity,  
¾  undesired flexibility in structural studies  
¾  toxicity  
 
Due to the somehow unpredictable changes that adding a tag may introduce in a protein and 
its behaviour, it is usually desirable to remove the tag. This reflects on the design of the 
protein fusion. Importantly, removal of the tag needs to be considered when designing a 
process for the production of a recombinant protein that is intended for human use to enable 
production of a ‘native’ (i.e., tagless) protein. And consequently, both the enzyme(s) used to 
cleave the tag and the cleaved fusion partner need to be removed from the purified protein. 
Affinity tags can be defined as exogenous amino acid (aa) sequences with a high affinity for a 
specific biological or chemical ligand. A major group of affinity tags consists of a peptide or 
protein that binds a small ligand linked on a solid support (e.g., his-tags bind to immobilized 
metals). Another group includes tags that bind to an immobilized protein partner such as an 
antibody or antibody purification using protein A affinity chromatography.   
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In Table 1 the main tags available are reported with the respective dimension (aa). Although 
the number of different tags available may reflect the different biochemical properties of 
proteins and the host cells, it is possible to discriminate tags needed for purification (e.g., his-
tag) from those developed to aid, e.g., solubility and folding like maltose-binding protein 
(MBP),  glutathione S-transferase (GST) or small ubiquitin modifying protein (SUMO), 
among others (Arnau J et al., 2006). 
 
Tag  Size (aa)  Comments 
His-tag  
FLAG  
Streptag II  
HA-tag  
Softag1, Softag 3  
c-myc  
T7-tag  
S-tag  
Elastin-like peptides  
Chitin-binding  
Thioredoxin  
Xylanase  
Glutathione S-transferase  
Maltose binding protein  
NusA  
5-15 
8 
8 
9 
13-8 
10 
11-16 
15 
18-320 
52 
109 
163 
201 
396 
495 
 
Purification under native or denaturing conditions  
Calcium-dependent, mAb-based purification 
Modified streptavidin, elution with biotin analog 
InXuenza virus hemagglutinin tag, Ab-based purification  
Recognized by polyol-responsive mAb  
mAb-based purification  
mAb-based purification  
S-protein resin affnity purification  
Protein aggregation by temperature shift, intein used to remove tag  
Binds only insoluble chitin  
Affnity purification with modified resin  
Cellulose based capture, elution with glucose  
Glutathione or GST-Ab affnity  
Amylose affnity purification  
Increased solubility in E. coli. Affnity tag needed for purification  
 
Tab. 1.3. Affinity and solubility tags for recombinant proteins (Arnau J et al., 2006). 
 
It is often reasonably assumed, although rarely formally demonstrated, that small tags, such as 
the His6-tag, bear a smaller risk of steric interference than larger tags, such as glutathione-S-
transferase (GST) or maltose binding protein (MBP). 
The His6-tag is a popular purification tag because of its small size, its relatively strong 
reversible binding and because it functions under denaturing conditions. These advantages 
have led many structural proteomics groups to use the His6-tag almost exclusively for their 
initial studies. 
For prokaryotic proteins the success rate is typically, 50%, which most likely reflects the 
close phylogenetic relationship between the target organisms and the expression system. 
For eukaryotic proteins, the success rates are significantly lower. Proteins become 
progressively more difficult to purify as their molecular weight increases. 
Given the poor performance of the His6-tag for higher eukaryotic proteins, many alternative 
purification tags have been developed, many of which increase the solubility of the 
recombinant proteins. Several studies systematically examined the success rates obtained with 
different tags in HT purifications (Pascal B et al., 2003).  
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1.6 NMR IN STUCTURAL PROTEOMICS OF SMALL PROTEINS 
The Magnetic Nuclear Resonance (NMR) is advised, to good reason, the prince technique for 
the structural determination of the biomolecules in solution, that is flanked to the already 
consolidated and well exploited X rays solid state crystallography. The NMR notional 
principles are largely treated in specialized books and, for the present work of thesis, they will 
be only illustrated with a distinctive attention turned to depict the type of information that it 
could be obtained from the spectrum of a protein in solution. 
The result of a NMR experiment on a very simple molecule, e.g. the the water, takes the name 
of FID (Free Induction Decay). 
 
Fig. 1.9 Representation of the water signal (FID) caused from only one type of hydrogen atom. 
 
It consists of a signal with fluctuating intensity in the time (defined time of acquisition) with 
an exponential decadence trend. For the water molecule, that contains only one type of 
hydrogen atom, the resultant FID contains three information: 1) the frequency of resonance, 
dependent from the chemical characteristics of the molecule; 2) the exponential decay time, 
defined as the time of laxness, that depends on different factors, first of all the rotation speed 
of the molecule around to his own axis; 3) the signal intensity, proportional to the observed 
nucleus concentration, in the sample.  
The more complex molecules have more difficult to comprise FID and, for this Fourier’s 
transform allows the conversion in a more comprehensible spectrum that contains the same 
original information.  
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Fig. 1.10 Fourier’s transform of the water FID. 
 
The axis of the abscissas shows the frequency of resonance of the observed nucleus (in this 
case the atoms of the equivalent hydrogen of the water) that is different for each type of  
magnetically active nuclei. The position of the signal in the spectrum is commonly expressed 
with the term "chemical shift", that indicates the difference between resonance frequency of 
the observed signal and the frequency of a reference molecule. The value is generally 
comprised between 0 and 10 ppm, although, in many substances, could be observed values 
distant from these limits. For any proteins it’s possible to acquire hydrogen spectra but also 
those relative to other atoms, for example carbon-13 and nitrogen-15: each of them resonating 
at completely different frequencies from the other one. The concentration of the nucleus in the 
sample (equal to that of the molecule multiplied for the number of identical nucleus for 
molecule) is proportional to the area of the signal. 
The other information, concerning the transversal relaxation time (T2), is contained in the 
width, to half height, of the transformed signal (∆ν): 
∆ν = 1/ (π T2) 
In a protein that doesn't contain prosthetic paramagnetic groups, the T2 is inversely 
proportional respect to the rotation time around to the rotation axle of the molecule (τR),  
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unless other local movements intervene to alter, also transitorily, the chemical environment of 
the nucleus in observation. However, in the more general case: 
T2= c / τR 
According to the relation of Stokes-Einstein: 
τR = 4πηa
3 / (3κT) 
the rotation time is inversely proportional with respect to the kinetic energy of the molecule 
and directly proportional with respect to the solution viscosity (η) and to the volume of the 
molecule (proportional to the cube of the ray of the molecule, a, considered globular). 
This indicator is, in approximation, directly proportional to the molecular molar mass. This 
explains the reason for which the NMR is applicable to molecules with molar mass under 30 
kDa. That is the same to say that proteins (or aggregates of them), with a number of 270 
amino acids, could not be studied (considering a middle molar mass for each amino acid of 
110 Da). For bigger molecules, each NMR signal would be so large to result flat: its height 
would be equivalent to ground noise, since the signal’s area has to remain constant. Large and 
few intense signals are absolutely to be avoid in NMR, like in any other technique, ever since 
the  spectrum could show completely superposed signals and, then, not unequivocally 
identifiable. 
The spectrum of the glycine, the natural smaller amino acid, dissolved in water, presents two 
signals: one relative to the hydrogen atoms in α position (that are two equivalent) and the 
other one referred to the solvent-water added to it. 
H2N-CH2-COOH 
The signals of the aminic hydrogen atoms and those of the carboxylic groups result instead 
grouped in those of the solvent, since they exchange chemically with it, and so they result 
invisible. Since the concentration of the solvent is, commonly, three orders of greatness 
superior than that one of the solute, its signal would be hugely predominant in the spectrum 
and, for reasons that won't be discussed for brevity, it could obscure the presence of the less 
intense signals than which of the dissolved molecules. For this reason, it is opportune to use 
deuterated water (D2O) as solvent, which is spectroscopically silent. The result is still a 
spectrum containing a single signal (except for a residual hydrogen signal due to traces of 
HOD formed for chemical exchange of the aminic protons with the carboxylic one and the 
solvent). 
The spectrum of the dissolved polypeptide poliglycin in D2O, presents a number of signals 
equal to the double of that of the amino acids that constitute it, instead that the same number.  
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H2N-CH2-CO-(NH-CH2-CO)n-NH-CH2-COOH 
This because the molecule assumes a low energy conformation that loses every symmetry; so 
that all the hydrogen atoms, also those bound to the same atom of carbon, get a different 
chemical environment and becoming inequivalent. Each of these signals is characterized by a 
resonance frequency, and then a chemical shift very similar, determining a very crowded 
spectrum in the region around 3.5 ppm. For a protein with mean dimensions (10-15 kDa), in 
which all the natural amino acids are present, the 
1H-NMR spectrum results to be very 
complex in all its regions (from 0 to 10 ppm), resulting by the overlap of 500-800 signals 
derived from hydrogen atoms with different chemical characteristics. 
 
 
 
Fig. 1.11 
1H-NMR spectrum of a protein with medium dimension (10-15 kDa) in which all the natural amino 
acids are present. 
 
Although distinguished signals aren’t visible, it’s however possible divide the spectrum in 
characteristic regions where the different chemical types of hydrogen atoms resound. 
Proceeding from left (defined as downfield spectrum part) to right (upfield), the spectrum can 
be divided into the following regions: 
a) amidic region (11-7.5 ppm): signals of amidic protons that don't exchange (not exchanging) 
with the solvent. This region is indicative of a molecular compact structure (protein folding) 
as only the internal amidic groups are inaccessible to the solvent and don't exchange protons 
with it;  
b) aromatic region (7.5-6.5 ppm) is relative to the lateral chains of amino acids like 
phenylalanine, tyrosine and tryptophan, commonly collected in the hydrophobic "core" of the 
protein; 
c) alfa-protonic region (4.8-3.5 ppm): it is the region where the signals of hydrogen of every 
amino acid in α position (αCH) resound; this area of the spectrum is diagnostic for the 
secondary protein structure: as more the signals are dispersed in this region as more the 
polypeptidic skeleton is rigid;  
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d) aliphatic region (3.0-1.0 ppm): here there are the hydrogen atoms signals of all the lateral 
chains. Being the more crowded region it’s not able to give specific information in the 
analysis of a mono-dimensional spectrum; 
e) methyl region (1.0-0.0 ppm): all the methyl protons signals of alanine, methionine, 
threonine, valine, leucine and isoleucine resound in this region. The presence of isolated 
signals under 0.5 ppm is indicative of stable hydrophobic interactions, and then of a rigid 
tertiary structure. 
Besides the above-mentioned indications obtained from the analysis of a mono-dimensional 
spectrum (1D-NMR), the NMR spectroscopy is able to give information on the spatial 
relations of the protein molecule, allowing an indirect measure of the distances between the 
atoms constituting it. For this purpose it’s necessary to acquire a bi-dimensional spectrum 
(2D-NMR), resultant from an experiment known as NOESY (acronym of Nuclear Overhauser 
Effect SpectroscopY). In defining the number of spectrum dimension, it needs to accentuate 
that it is relative to the only domain of the frequencies. For this, while the 1D-NMR  spectrum 
is characterized by a graphic that reports on the abscissas the domain of frequencies and on 
the ordinates the signals intensity, the 2D-NMR spectrum is constituted by frequencies 
domain both in abscissas and in ordinates, since the signals intensity dimension is expressed 
like the level curves analogous to isohypse of a geographical map. In figure 1.12 a schematic 
representation of a 2D-NMR spectrum is showed. The molecule is characterized by six 
signals: three amidic not exchanging with the solvent and three αCH. The diagonal of a 2D-
NMR spectrum coincides with the 1D-NMR spectrum, while out of the diagonal three 
correlation signals are present, so called as they correlate two signals staying on the diagonal. 
From the analysis of correlation signals it is possible to acquire two information: a) the exact 
chemical shift of each signals, one correspondent to the abscissas and the other one to the 
ordinates of the bi-dimensional graphic; b) the distance of the atoms corresponding to the 
signals, since the correlation peak volume is proportional to r
-6, where r is the distance. The 
decisive passage to obtain the three-dimensional molecule structure is the signals assignment, 
that is the attribution to each hydrogen atom of the molecule a precise position in the 1D-
NMR spectrum. 
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Fig. 1.12 Schematic representation of a 2D-NMR spectrum of a molecule characterized from six signals. 
 
 
The 2D-NMR spectrum analysis provides important information, also without arriving to 
molecule structure determination involving a complex work. The form and the dispersion of 
correlation peaks allows to establish if the molecule forms aggregation state or if it has a rigid 
structure, sign of a correct tertiary structure. This information is very important in proteomic 
research projects aiming to the study of the relations between protein sequence, structure and 
function. 
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2 MATERIALS 
 
2.1 EQUIPMENT 
 
Analytical balance (SBC 21, Scaltec). 
Centrifuge tubes (Beckman Coulter). 
Chromatographic columns:  
-  metal chelate affinity chromatography (nickel chelate HiTrap, Amersham 
Biosciences);  
-  GST affinity chromatography (GSTrap, Amersham-Biosciences);  
-  size exclusion chromatography (Superdex 75 Hiload 16/60 column, Pharmacia 
Biotech);  
-  anion exchange chromatography (diethylaminoethyl, DEAE column, Whatman) or 
cation  exchange chromatography (Macro Prep S supports SO3
-, BIORAD) 
Dialysis membrane (MWCO, 4000-6000) con relativi fermi (CELLU.SEP T1, NFPI). 
Eectrorophoresis apparatus (Mini-Protean II, Biorad). 
Franch Pressure Cells Pmax 40000 psi (SIM-AMINCO Spectronic Instrument). 
HPLC (Amersham Pharmacia Biotech). 
Kier (Vapor Matic 770, Asal). 
Refrigerator (FTO 220). 
Regulated power supply (E-C 105, E-C Apparatus Corporation). 
Shaker (Universal table Shaker 709, Asal srl). 
Thermostated agitator: (Climatic Hood 810, Asal srl). 
Thermostated centrifuge  with rotors: JA 10 RPM max 10000, JA 14 RPMmax. 14000, JA    
25.50 RPMmax 25000 (Avanti J-25, Beckman Coulter). 
Thermostated magnetic agitator (Tmax 300 °C, RPM max  9, FALC). 
Microcentrifuge, RPMmax 14000 (Beckman Coulter). 
Micropipets  P2, P10, P20, P100, P150, P200, P1000 (Gilson). 
pH meter Basic 20 (CRISON). 
Plates (Sterilin). 
Ultrafiltration cells, 10-50 ml (8010, 8050 Amicon) 
Ultrafiltration regenerated cellulose membrane MW>5000 (PLCC, MILLEPORE). 
Vortex. 
  
38 
2.2 REAGENTS 
Acetic acid, glacial (C.E., 99% purity) 
Acrylamide (Fluka) 
Agar 
Ampicillin (Fluka) 
Bromophenol Blue (Merk-Darmastad) 
Calcium carbonate (Rectapur, 99.9% purity) 
Commassie Blue (Fluka) 
EDTA (C.E., 100% purity) 
Ethanol (C.E., 99.9% purity) 
Ethanol, 70%  (C.E., 69% purity) 
Ethidium bromide  
Ferrous sulfate epta-hydrate (C.E., 99.5% purity) 
Glycerol 
Glycin (C.E., 99% purity) 
Guanidine hydrochloride (Sigma, 99% purity) 
Hydrochloric acid, 37% (C.E., 36.5% purity) 
Imidazole (Fluka, 69% purity) 
IPTG (Sigma) 
Methyl alcohol (C.E., 69% purity) 
Magnesium chloride (C.E., 99.5% purity) 
Manganous sulfate epta-hydrate (C.E., 99.5% purity) 
β-mercaptoethanol (Sigma, 98% purity) 
Nichel chloride (C.E., 99.5% purity) 
Phosphoric acid (C.E., 99.9% purity) 
PMSF (Sigma) 
Potassium chloride (C.E., 99.5% purity) 
Potassium phosphate bibasic (Carlo Erba) 
Protein Molecular Weight marker (Biorad) 
SDS-PAGE standard, Low range (Biorad)  
Sodium acetate (C.E., 99.9% purity)  
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Sodium chloride (C.E., 99.5% purity) 
Sodio dodecil-solfato (Boehringer Mannheim) 
Sodium hydroxide (C.E., 97.5% purity) 
Temed (Sigma) 
Thiamine (Sigma) 
Tryptone (Difco) 
Tris-base (C.E., 99% purity) 
Urea (Carlo Erba) 
Yeast extract (Difco) 
 
2.3 ENZYME 
Actev protease (Invitrogen) 
DNasi liofilizzata (Boehinger Mannhein) 
BR Clonase enzime (Invitrogen) 
FactorXa (Amersham) 
LR Clonase enzime (Invitrogen) 
Proteinase K (Invitrogen) 
Trombin  
 
2.4 SOLUTIONS 
1 M solutions were prepared by dissolving 1 mole of substance in distilled water. To adjust 
the pH at a specific value, the acid or the base was added under agitation. The final volume of 
1 liter was adjusted in a volumetric cylinder. The 1M solution utilized along the thesis work 
are the following (the adopted molar masses are reported in parenthesis): 
1 M calcium chloride (111 g/mol) 
1 M nichel chloride (237.7 g/mol)  
1 M potassium chloride  (74.55 g/mol) 
1 M sodium chloride (58.44 g/mol) 
1 M IPTG (200g/mol) 
1 M Sodium hydroxide (40g/mol) 
1 M Imidazol (68.08 g/mol)  
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1 M Tris-HCl pH 6.8, 7.5, 8.0, 8.5 (748.6 g/mol) 
 
2.5 LIQUID MEDIA 
LB medium was prepared dissolving 10 g of tryptone, 5 g of yeast extract and 10 g of sodium 
chloride in  800 ml of water. The final volume was adjusted at 1 litre in a volumetric cylinder. 
The solution was transferred in flasks and autoclaved at 121 °C for 20 minutes. At 60 °C the 
specific antibiotic was added to the solution. 
2xY medium was prepared dissolving 16 g of tryptone, 10g of yeast extract and 5 g of sodium 
chloride in  800 ml of water. The final volume was adjusted at 1 litre in a volumetric cylinder. 
The solution was transferred in flasks and autoclaved at 121 °C for 20 minutes. At 60 °C the 
specific antibiotic was added to the solution. 
 
2.6 SOLID MEDIA 
For the growths on plates LB and 2xY medium were used. The media were prepared using the 
same reagents for the liquid media and 2% agar. The solution was transferred in flasks and 
autoclaved at 121 °C for 20 minutes. At 60 °C the specific antibiotic was added to the 
solution. Before the polymerization, the solution was poured in the plates leaved to cool. The 
plates were stored at 4 ºC until needed. 
 
2.7 SELECTABLE MARKER  
The antibiotic Ampicillin was used as selectable marker during the bacterial growths. To 
prepare an ampicillin stock solution 100 mg/ml (1000x), the below reported procedure was 
followed. 
1 g of ampicillin was dissolved in 8 ml of distilled water. The pH was adjusted at 9 by adding 
2N Sodium hydroxide under agitation. The final volume was adjusted at 10 ml in a volumetric 
cylinder. The solution was stored as 1 ml aliquots at -20ºC. 
The antibiotic was added to the media as over described, using a dilution ratio of  1:1000. 
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3  METHODS 
 
3.1 GATEWAY TECHNOLOGY 
The Gateway technology is a universal cloning method based on the site-specific 
recombination proprieties of bacteriophage lambda that provides a rapid and highly efficient 
way to move DNA sequences into multiple vector systems for functional analysis and protein 
expression. This method allows using multiple types of DNA sequences (PCR products, 
cDNA clones, restriction fragments) and multiple destination vectors. Moreover, Gateway 
technology is suitable for adaptation to high-throughput formats giving the opportunity to 
investigate the more effective methods to isolate protein targets, in a systemic way. In 
particular, this technology permits to test rapidly more vector-host combinations to increase 
the successful probabilities in protein expression strategies (Figure 3.1). 
 
 
 
Fig. 3.1 The Gateway technology provides a rapid and highly efficient way to move DNA sequences into 
multiple vector systems for functional analysis and protein expression. 
 
 
3.1.1 Recombination reactions  
 
A recombination reaction consists of a DNA fragment transfer from a donor to a receiver 
vector. This reaction is catalyzed by a mixture of restriction enzymes that bind to specific 
nucleotidic attachment sequences (att sites), bring together the target sites, cleave them, and 
covalently attach the DNA. The Gateway technology is based on the bacteriophage lambda  
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site-specific recombination system which facilitates the integration of lambda into the E. coli 
chromosome. The integration occurs via intermolecular DNA that involves two major 
components: the DNA recombination sequences (att sites) and the Clonase enzyme mix, a 
mixture of lambda and E. coli encoded recombination proteins.  The att sites serve as the 
binding sites for recombination proteins and have been well-characterized: attB on the E. coli 
chromosome and attP on the lambda chromosome. The λ integration occurs between attB and 
attP sites to give rise to attL and attR sites. Two recombination reactions constitute the basis 
of the Gateway technology: 
 
•  BP reaction catalyzed by BP Clonase enzyme mix, facilitates recombination of an attB-
substrate (ex. attB-PCR product) with an attP substrate (donor vector) to create an attL entry 
clone (Figure 3.2). 
 
 
 
 
Fig. 3.2: The DONOR vector (pDONOR) contains attP sites compatible with the PCR product extremities (attB 
sites). The PCR product attach occurs in these nucleotidic sequences (att sites). The entry clone attL sites are 
composed of sequences from attB sites of PCR product and attP sites from donor vector.  
 
 
 
•  LR reaction catalyzed by LR Clonase enzyme mix, facilitates recombination of an attL- 
entry clone with an attR substrate (destination vector) to create an attB expression clone 
(Figure 3.2). 
 
 
 
Fig. 3.3: The Entry clone (pENTR) contains attL sites compatible with the attR sites of the destination vector. 
The gene attach occurs in these compatible nucleotidic sequences (att sites). The expression clone attB sites are 
composed of sequences from attL sites of the entry clone and attR sites from destination vector. The destination 
vector contains elements necessary to express the gene of interest in appropriate system (i.e. E.coli, mammalian, 
yeast, insect). 
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3.2 AMPLIFICATION OF THE GENES BY PCR  
The nucleotide sequences coding for the selected proteins were amplified from cDNA by 
PCR, using the specific primers, reported in annex 1. In a 0.5 ml microcentrifuge tube, the 
following 50 µl PCR reaction mixture were prepared: 
 
 
  
 
 
 
 
 
The amplification was performed using the following cycling parameters: 
 
Step Time  Temperature  Cycles 
Initial Denaturation  5 minutes  94 °C  1x 
Denaturation 1  minutes  94  °C 
Annealing 1  minutes  54°C 
Extension 2  minutes  72°C 
35x 
 10  minutes  72°C  1x 
 
The  PCR products were analysed by agarose gel electrophoresis as described at paragraph 
3.10. 
 
 
3.3 BP RECOMBINATION REACTION 
According to Gateway technology (Invitrogene, 22 September 2003), the  ENTRY CLONES 
were constructed using the PCR products. The reaction mixtures were incubated 1 hour at 
25°C with BP Clonase enzyme mix and the specific BP Clonase Reaction Buffer 
(Invitrogene). Each reaction mixture was composed as follows showed: 
 
5X BP Clonase reaction buffer                        4  µl 
attB-PCR product                                          300 ng 
pDONR vector                                              300 ng 
TE buffer  pH 8.0                                       to 16  µl 
LR Clonase                                                       4  µl 
 
cDNA template (5ng/µl)  5 µl
dNTP mix (10mM)  1 µl
Primer Forward (10pmol/µl)  10 µl
Primer Reverse (10pmol/µl)  10 µl
Pfu DNA Polymerase  1 µl
Pfu Buffer 10x  5 µl
H20 18  µl
Final volume  50 µl 
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After incubation, 2 µl of Proteinase K solution (2µg/µl) was added to the mixture and 
incubated at 37°C for 10minutes. Each reaction mixture was used to transform competent 
TOPO10  E.coli host strain as described in paragraph 3.4  and the entry clones obtained were 
selected on plates using Kanamycin 50µg/ml LB medium. 
 
3.4 TRANSFORMING COMPETENT CELLS 
To transform competent cells the following protocol was used. For each transformation, 2 µl 
of the BP recombinant reaction were added into 1.5 ml microcentrifuge tube containing 50 µl 
of competent TOPO10 E.coli cells. After a gentle shaking, the mixture was incubated on ice 
for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, without shaking. 
Immediately the tubes were transferred to ice. 450 µl of room temperature S.O.C. medium 
were added to the cells and the tubes were shaken horizontally at 37°C for 1hour. 20µl, 50µl  
and 100µl of the mixture were spread on pre-warmed selective plates (Kanamycin 50µg/ml) 
and incubated overnight at 37°C. 
 
3.5 ENTRY CLONES SEQUENCING 
The entry clones (pENTR/D-TOPO)  generated by BP recombinations were sequenced to 
confirm the DNA sequences. The plasmid were extracted from 3 ml of growth culture using 
the Quantum prep Plasmid Mini Prep Kit (BIORAD). The sequencing was performed by 
PRIMM (Centro Servizi Sequenzaimento DNA, Milano) using the M13 Sequencing Primers 
whose sequence is here reported: 
 
M13 [forward]  5’-GTAAAACGACGGCCAG- 3’ 
M13[reverse]  5’-CAGGAAACAGCTATGAC- 3’ 
 
The sequencing results were compared  with the actual sequences of the gene fragments. 
 
3.6 LR RECOMBINATION REACTIONS.  
To produce expression clones, a recombinational cloning of genes with destination vectors 
was performed. To obtain every gene cloned into different expression systems, all the 
pENTR/D-TOPO (Invitrogen), containing the specific gene, were recombined with an 
equimolar mixture of destination vectors, carrying five different specific tags, described at 
paragraph 4.4: (His)6-tag for pDEST17, GST for pDEST15, Trx+(His)6-tag for pDEST20A, 
GST+(His)6-tag for pDEST30A, NusA+(His)6-tag for pDEST60A. The reaction mixtures  
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were incubated for 1 hour at 25°C with LR Clonase enzyme and the specific LR Clonase 
Reaction Buffer (Invitrogen). Each reaction mixture was composed as follows: 
 
5X LR Clonase reaction buffer                        4  µl 
Destination vector mix                                  300 ng 
Entry clone pENTER/D-TOPO (gene)         300 ng 
TE buffer  pH 8.0                                       to 16  µl 
LR Clonase                                                       4  µl 
 
After incubation, 2 µl of Proteinase K solution (2 µg/µl) were added to the mixture and 
incubated at 37°C for 10 minutes. Each reaction mixture was used to transform three 
competent E.coli host strains (BL21 Gold, Codon plus, Plys), to obtain for each strain at least 
one colony (CFU) for every destination vector.  
To transform 50 µl of competent cells 2 µl of LR reaction mixture were used as described at 
the paragraph 3.4. The transformed cells were isolated on plates with LB medium using 
Ampicillin (100µg/ml) as selectable marker.  
 
3.7 PROTEIN EXPRESSION SCREENING 
After transformation, the isolated colonies were grown in 5 ml of 2xYT medium and 
Ampicillin (100µg/ml) at 37°C with continuous shaking at 210 rpm. To induce protein 
expression, Isopropyl β-thiogalactopyranoside (IPTG) was added to the culture when the 
absorbance at 600 nm reached the value 0.5. Cells were harvested after 20 hours from 
induction and protein expression was checked by SDS-page described at paragraph  
 
3.8 PROTEIN SOLUBILITY SCREENING 
The cells of the samples found positive to expression, were harvested from 2.5 ml of culture. 
The cells were broken with liquid nitrogen and the cellular debris were centrifuged. The 
proteins solubility was checked by loading on SDS-page both the soluble fractions and the 
inclusion bodies obtained by centrifugation.  
 
3.9 EXPRESSION CLONES SEQUENCING 
Every destination vector allows to express the protein with a different peptide or fusion 
protein (tags), encoded from a different nucleotidic sequence with specific dimension (bp). To 
confirm that the DNA sequences were correct, the expression clones generated by LR 
recombinations and showing a high expression yield were sequenced. The plasmid were  
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extracted from 3 ml of growth culture using the Quantum prep Plasmid Mini Prep Kit 
(BIORAD). The sequencing was performed by PRIMM (Centro Servizi Sequenzaimento 
DNA, Milano) using the T7 Sequencing Primers whose sequence is here reported: 
 
T7[forward]  5’-TAATACGACTCACTATAGGG- 3’ 
T7[reverse]  5’-GCTAGTTATTGCTCAGCGG - 3’ 
 
The sequencing results were compared  with the actual sequences of the gene fragments. 
 
 
3.10 AGOROSE AND SDS-PAGE ELECTROPHORESIS 
Electrophoresis is the migration of charged molecules in solution in response to an electric 
field. Their rate of migration depends on the strength of the field, on the net charge, size and 
shape of the molecules and also on the ionic strength, viscosity and temperature of the 
medium in which the molecules are moving. As an analytical tool, electrophoresis is simple, 
rapid and highly sensitive. It is used analytically to study the properties of a single charged 
species, and as a separation technique. 
Generally the sample is run in a support matrix such as paper, cellulose acetate, starch gel, 
agarose or polyacrylamide gel. The matrix inhibits convective mixing caused by heating and 
provides a record of the electrophoretic run: at the end of the run, the matrix can be stained 
and used for scanning, autoradiography or storage. In addition, the most commonly used 
support matrices - agarose and polyacrylamide - provide a means of separating molecules by 
size, in that they are porous gels. A porous gel may act as a sieve by retarding, or in some 
cases completely obstructing, the movement of large macromolecules while allowing smaller 
molecules to migrate freely. Because diluted agarose gels are generally more rigid and easy to 
handle than polyacrylamide of the same concentration, agarose is used to separate larger 
macromolecules such as nucleic acids, large proteins and protein complexes. Polyacrylamide, 
which is easy to handle and to make at higher concentrations, is used to separate most proteins 
and small oligonucleotides that require a small gel pore size for retardation. 
Proteins are amphoteric compounds; their net charge therefore is determined by the pH of the 
medium in which they are suspended. In a solution with a pH above its isoelectric point, a 
protein has a net negative charge and migrates towards the anode in an electrical field. Below 
its isoelectric point, the protein is positively charged and migrates towards the cathode. The 
net charge carried by a protein is in addition independent of its size - ie: the charge carried per 
unit mass (or length, given proteins and nucleic acids are linear macromolecules) of molecule  
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differs from protein to protein. At a given pH therefore, and under non-denaturing conditions, 
the electrophoretic separation of proteins is determined by both size and charge of the 
molecules. 
Nucleic acids however, remain negative at any pH used for electrophoresis and in addition 
carry a fixed negative charge per unit length of molecule, provided by the phosphate group of 
each nucleotide of the nucleic acid. Electrophoretic separation of nucleic acids therefore is 
strictly according to size. 
 
3.10.1 SDS-PAGE of Proteins  
Sodium dodecyl sulphate (SDS) is an anionic detergent which denatures proteins by 
"wrapping around" the polypeptide backbone  and SDS binds to proteins fairly specifically in 
a mass ratio of 1.4:1. In so doing, SDS confers a negative charge to the polypeptide in 
proportion to its length. It is usually necessary to reduce disulphide bridges in proteins before 
they adopt the random-coil configuration necessary for separation by size: this is done with 2-
mercaptoethanol or dithiothreitol. In denaturing SDS-PAGE separations therefore, migration 
is determined not by intrinsic electrical charge of the polypeptide, but by molecular weight. 
This is done by SDS-PAGE of proteins or agarose gel electrophoresis of nucleic acids of 
known molecular weight along with the protein or nucleic acid to be characterised. A linear 
relationship exists between the logarithm of the molecular weight of an SDS-denatured 
polypeptide, or native nucleic acid, and its Rf, the ratio of the distance that the protein has 
moved from its point of origin (the beginning of the separating gel) relative to the distance the 
tracking dye has moved (the gel front). The Rf is calculated as the ratio of the distance 
migrated by the molecule to that migrated by a marker dye-front. A simple way of 
determining relative molecular weight by electrophoresis (Mr) is to plot a standard curve of 
distance migrated vs. log10MW for known samples, and read off the logMr of the sample 
after measuring distance migrated on the same gel. 
There are two types of buffer systems in electrophoresis, continuous and discontinuous. A 
continuous system has only a single separating gel and uses the same buffer in the tanks and 
the gel. In a discontinuous system, a non-restrictive large pore gel, called a stacking gel, is 
layered on top of a separating gel called a resolving gel. Each gel is made with a different 
buffer, and the tank buffers are different from the gel buffers. The resolution obtained in a 
discontinuous system is much greater than that obtained with a continuous system.  
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Gel preparation 
Two glass plates were assembled with two side spacers and clamps as shown by instructions. 
The resolving and stacking gels were prepared on ice to avoid the rapid polymerization. The 
specific compositions  were reported below: 
 
Resolving Gels: Acrylamide concentration of 16% in 0.25 M Tris-HCl pH 8.8 
Reagents  Volume (ml to make 10 ml) 
40% Acrylamide  4 
water (distilled)  2,05 
1 M Tris-HCl pH 8.8  3,75 
10% SDS  0,1 
10%APS 0,1 
TEMED 0,01 
Stacking Gels: Acrylamide concentration of  4.5% in 0.125 M Tris-HCl pH 6.8 
Reagents  Volume (ml to make 5 ml) 
40% Acrylamide  0,66 
water (distilled)  2,8 
1 M Tris-HCl pH 6.8  0,5 
10% SDS  0,04 
10%APS 0,04 
TEMED 0,01 
 
Tab. 3.3 In the table the composition of  Resolving and Stacking Gels are reported. 
The ingredients were added to the reaction tube in the order shown above and gently mixed, 
ensuring that no air bubbles were formed. The Resolving Gel solution was poured into glass 
plate carefully assembled. The gel was overlaid with isopropanol to ensure a flat surface and 
to exclude air. The isopropanol was washed off after gel had set (+15 min). After mixing the 
Stacking Gel solution was poured onto top of set. The comb was inserted before and removed 
after polymerization. The gels were assembled in the tank filled with electrophoresis buffer 
composed of 196mM glycine, 0.1% SDS, 50mM Tris-HCl pH 8.3. The liquid samples were 
diluted with the solution composed of 125mM Tris-HCl pH 6.8, 10% 2-mercaptoethanol, 
10% SDS, 10% glycerol, containing a little bromophenol blue, while the pellet were 
resuspended in the same solution and then diluted with water. The samples were boiled for 5 
min at 95°C in a waterbath and injected by a micro-syringe (Hamilton) buffer on stacking 
gels. The apparatus was connected with a voltage of 60V and, after the tracer was run through 
the Stacking Gel, the voltage was increased to100V.At the end of the run, the gels were 
covered with staining solution composed of  0.2% Coomassie Brilliant Blue, 45:45:10 %  
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methanol:water:acetic acid. The gels were sealed in a plastic box and leave 2 hours at 37°C on 
shaker. The gels were destained with 25% 65% 10% methanol water acetic acid mix, with 
shaking.  
3.11 LARGE SCALE PROTEIN PRODUCTION  
The proteins were produced on a large scale to obtain sufficient amount for NMR analysis. 
The protein sample production followed the steps described in the diagram reported in figure 
3.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4 Protein production steps. 
 
The growths were performed in 3 litres of  medium and ampicillin (100µg/ml) using the same 
conditions of the expression screening (paragraph 3.7). The cell were harvested by 
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centrifugation and stored at -80°C. The cellular pellet was resuspended in lisys buffer and 
cells were disrupted by three passages through French press (SIM Aminco) at 10000 psi. The 
cell lysate was separated from cell debris and unbroken cells by centrifugation for 30 min at 
14000 rpm in Beckman JA 25.50 centrifuge. If the recombinant proteins were produced in a 
soluble form, the supernatant containing the protein was applied on cromatography columns 
(paragraph 3.12) to isolate the protein sample.  
 
Purification of the soluble proteins, was made using a standard protocol for Histidine-tagged 
(or GST-tagged) proteins. The purification techniques are described in paragraph 3.12. The 
following steps were adopted: 
¾  metal chelate (or GST) affinity chromatography (nickel chelate HiTrap and GStrap, 
Amersham-Biosciences);  
¾  cleavage with Factor Xa (Amersham) for Histidine-tagged proteins or with Actev 
Protease (Invitrogene) for the others tags;  
¾  metal chelate and GST affinity chromatography to remove the tag and uncleaved 
protein;  
¾  size exclusion chromatography (Superdex 75 Hiload 16/60 column, Pharmacia 
Biotech);  
¾  anion exchange chromatography (diethylaminoethyl, DEAE column, Whatman) or 
cation  exchange chromatography with Macro Prep S supports (SO3
-, BIORAD). 
Purification of  insoluble and unfolded proteins required a denaturation refolding step on the 
nickel chelate column. Briefly, after loading the His6-tagged protein sample on the Hitrap 
column, a denaturation solution (50mM Tris  pH 8.0, 200mM NaCl, 7M Guanidinium 
chloride) was passed through the column, for four hours at flow 0.5 ml/min. Guanidinium was 
slowly removed from the column by a 16 hours continuous gradient against (50mM Tris  pH 
8.0, 200mM NaCl), to allow protein refolding. After elution of the protein from the Hitrap 
column the proteins were digested and isolated as just described. 
All purification steps were performed at 4°C and checked by SDS-PAGE. 
The concentration of purified protein samples were determined by measuring the absorbance 
at 276 nm, using the specific extinction coefficients as calculated by ProtPar parameters tools 
(http://us.expasy.org/tools/protparam.html).  
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3.12 PROTEIN PURIFICATION TECHNIQUES 
Biomolecules were purified by using techniques that separate according to differences in 
specific properties as summarized  in table 3.4 and  showed in figure 3.5. 
 
Property  Technique 
Biorecognition (ligand specificity) Affinity  chromatography 
Charge   Ion exchange chromatography 
Size  Gel filtration (size exclusion) 
Hydrophobicity  Hydrophobic interaction chromatography 
Reverse phase chromatography 
 
Tab. 3.4 Properties of the purification techniques. 
 
 
 
Fig. 3.5 Separation principles in chromatographic purification  (Affinity Chromatography Principles and 
Methods, 2001). 
 
The techniques used for the purification of recombinant proteins during this thesis work, are 
below illustrated. 
 
3.12.1 Gel filtration  
By gel filtration, the molecules mixed in a solution are separated according to differences in 
their sizes as they pass through  a column packed with a chromatographic medium which is a 
gel. It is also called size exclusion or gel permeation chromatography. In gel filtration 
chromatography, the stationary phase consists of porous beads with a well-defined range of 
pore sizes. The stationary phase for gel filtration is said to have a fractionation range, meaning 
that molecules within that molecular weight range can be separated.  
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A gel is a heterogeneous phase system in which a continuous liquid phase, usually  aqueous, 
is contained within the pores of a continuous solid phase, the gel matrix. In gel made for gel 
filtration, the pores have a carefully controlled range of sizes, and the matrix is chosen for its 
chemical and physical stability, and inertness (lack of adsorptive properties). Gels  may be 
formed from polymers by cross-linking dextran. Some polymers, like agarose, form gels 
spontaneously under the appropriate conditions. For example, composite gels, such as 
Superdex, may be prepared by grafting a second polymer onto a pre-formed matrix. Dextran 
chains are covalently bonded  to a highly cross-linked agarose gel matrix. Composite gels are 
of interest since they can combine valuable properties from more than one gel-forming 
system. 
The pores in the gel matrix which are filled by the liquid phase are comparable in size to the 
molecules we may wish to separate. Relatively to small molecules can diffuse  into the gel 
from a surrounding solution, whereas relatively large molecules will be prevented by their 
size from diffusing into the gel to the same degree. Sufficiently large molecules are 
completely unable to diffuse into the gel and are thus confined to the solution outside. In a gel 
filtration, particles in bead form are packed to form a separation bed through which a buffer 
solution, the eluent, is passed (Gel filtration Principles and Methods,1998). 
Sample molecules which are to be separated are added in solution as a zone to the top of the 
bed. The sample zone moves down the bed as eluent is added to the top. The small molecules 
which diffuse into the gel beads are delayed in their passage down the column compared  with 
the large molecules which cannot diffuse  into the gel and move continuously  down the 
column  in the flowing eluent. The large molecules thus leave the column first, followed by 
the smaller molecules in the order of their sizes. 
Characteristics of the sample which are important for the results include its volume and 
viscosity. The volume of the sample will influence the size of column which will be needed, 
and the viscosity must not be so large as to cause hydrodynamic instability. It is the viscosity 
which places an upper limit on the sample concentration. pH, ionic strength and composition 
are not significant as long as  they don’t affect the size or stability of the molecules to be 
separated  and are not outside the  stability range of the gel filtration medium. 
The most important characteristic of a gel filtration column is the way in which the gel is 
packed. If the column is evenly packed so the sample zone is not unnecessarily broadened as 
it passes down the column then good results can be obtained. If the column is packed 
unevenly then good results will never be obtained  from it.  The length of the column, cm, is 
significant since it affects both the resolution and the time taken to eluite it.  
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The composition of the eluent is unimportant for the separation mechanism. The eluent can 
thus be whatever is convenient for, with regards to the overall requirements  of the 
experiments. The rate at which the eluents flows through the column affects not only the 
speed at which the separation is obtained but also the resolution that can be achieved. At least 
for large molecules, lower is the flow rate, better is the resolution.  
Results in gel filtration are typically expressed in the form of an elution diagram showing the 
variation of solute concentration in the eluent with the volume of eluent passed through the 
column. For protein and nucleic acid work and in many other applications continuous 
detection using a UV-monitor and a recorder gives an immediate permanent record, a 
chromatogram. Solutes normally give symmetrical peaks. 
The use of gel filtration for the determination of molecular weight or size, particularly of 
proteins is well documented. 
Several models have been proposed to describe the behaviour of solutes during gel filtration. 
Most have regarded the partition of solute molecules  between the gels particles and 
surrounding fluid as an entirely steric effect. Larger are the molecular dimension of the solute 
and greater is the gel forbidden proportion. Proteins that are small enough can fit inside all the 
pores in the beads and are said to be included. These small proteins have access to the mobile 
phase inside the beads as well as the mobile phase between beads and elute last in a gel 
filtration separation. Proteins that are too large to fit inside any of the pores are said to be 
excluded. They have access only to the mobile phase between the beads and, therefore, elute 
first. 
Proteins of intermediate size are partially included - meaning they can fit inside some but not 
all of the pores in the beads. These proteins will then elute between the large ("excluded") and 
small ("totally included") proteins.  
In practice, gel filtration can be used to separate proteins by molecular weight at any point in 
a purification of a protein. It can also be used for buffer exchange - a protein dissolved in a 
sodium acetate buffer, pH 4.8, can be applied to a gel filtration column that has been 
equilibrated with tris buffer, pH 8.0. Using the tris buffer, pH 8.0, as the mobile phase, the 
protein moves into the tris mobile phase as it travels down the column, while the much 
smaller sodium acetate buffer molecules are totally included in the porous beads and travels 
much more slowly than the protein (Gel filtration Principles and Methods,1998). 
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3.12.2 Affinity chromatography 
Affinity chromatography separates proteins on the basis of a reversible interaction between a 
protein (or group of proteins) and a specific ligand coupled to a chromatographic matrix. The 
technique is ideal for a capture or intermediate step in a purification protocol and can be used 
whenever a suitable ligand is available for the protein of interest. With high selectivity , hence 
high resolution, and high capacity for the protein of interest, purification levels in the order of 
several thousand-fold with high recovery of active material are achievable. Target protein are 
collected in a purified, concentrated form.Biological interactions between ligand and target 
molecule can be a result of electrostatic or hydrophobic interactions, van der Waals’ forces 
and hydrogen bonding. To elute the target molecule from the affinity medium the interaction 
can be reversed, either specifically using a competitive ligand, or non-specifically, by 
changing the pH, ionic strength or polarity.In a single step, target molecules can be purified 
from complex biological mixtures, native forms can be separated from denatured forms of the 
same substance and small amounts of biological material can be purified from high level of 
contaminating substances.Successful affinity purification requires a biospecific ligand that 
can be covalently attached to a chromatographic matrix. The coupled ligand must retain its 
specific binding affinity for the target molecules and, after washing away unbound material, 
the binding between the ligand and target molecule must be reversible to allow the target 
molecules to be removed in an active form. Any component can be used  as a ligand to purify 
its respective binding partner (Affinity Chromatography Principles and Methods, 2001). Some 
typical biological interactions, frequently used in affinity chromatography, are listed in the 
table below: 
 
Ligand  Target molecule 
Glutathione Glutathione-S-transferase or GST fusion protein 
Metal ions  Poly (His) fusion protein, native proteins with histidine, cysteine 
and/or tryptophan residues on their surfaces 
Enzyme  Substrate analogue, inhibotor, cofactor 
Antibody  Antigen, virus, cell 
Lectin  Polysaccharide, glycoprotein, cell surface receptor, cell 
Nucleic acid  Complementary base sequence, histones, nucleic acid polymerase, 
nucleic acid binding protein 
Hormone, vitamin  Receptor, carrier protein 
 
Tab. 3.5 Typical biological interactions, frequently used in affinity chromatography. 
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The purification of recombinant proteins can often be simplified by incorporating a tag of 
known size into the protein. As well as providing a marker for expression  and facilitating 
detection of the recombinant protein, an important role for the tag is to enable a simple 
purification by affinity chromatography. 
In this work, the affinity columns used for recombinant protein purifications are GSTrap Fast 
Flow 5ml (Amersham Pharmacia Biotech) and HiTrap chelating HP column (Amersham 
Pharmacia Biotech). In figure 3.6 the principal steps of the affinity chromatography 
purification are shown.  
 
 
Fig. 3.6 Steps of a poly (His) or GST fusion protein purification using a pre-packed  column. 
 
In the table below (3.6) the composition of the specific buffers for GSTrap and HiTrap 
columns are reported. 
 
  Binding buffer   Wash buffer  Elution buffer 
GSTrap  PBS pH 7.3 
(140mM NaCl; 2,7mM KCl; 
10mM Na2HPO4; 1,8mM 
KH2PO4) 
PBS pH 7.3 
 
50mM Tris HCl  pH 8 
10mM Reduced Glutathione 
HiTrap  20mM Tris HClpH 8 
 
-20mM Tris HCl  pH 8 
- 20mM Tris HClpH 6 
  100mM KCl  
20mM Tris HCl  pH 8 
300mM Imidazol  
 
Tab.  3. 6 Composition of the specific buffers for GSTrap and HiTrap columns. 
 
3.12.3 Ion exchange chromatography 
Separation in ion exchange chromatography depends upon the reversible adsorption of 
charged solute molecules to immobilized ion exchange groups of opposite charge. Most ion 
exchange experiments are performed in five main stages. These steps are illustrated 
schematically in figure 3.7. The first stage is equilibration in which the ion exchanger is 
brought to a starting state, in terms of pH and ionic strength, which allows the binding of the 
desired solute molecules. The exchanger groups are associated at this time with exchangeable  
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counter-ions (usually simple anions or cations, such as chloride or sodium). The second stage 
is sample application and adsorption, in which solute molecules, carrying the appropriate 
charge, displace counter-ions and bind reversibly to the gel. Unbound substances can be 
washed out from the exchanger bed using starting buffer. In the third stage, substances are 
removed from the column by changing to elution conditions unfavourable for ionic bonding 
of the solute molecules. This normally involves increasing the ionic strength of the eluting 
buffer or changing its pH. In Figure 3.7 desorption is achieved by the introduction of an 
increasing salt concentration gradient and solute molecules are released from the column in 
the order of their strengths of binding, the most weakly bound substances being eluted first. 
The fourth and fifth stages are the removal from the column of substances not eluted under 
the previous experimental conditions and re-equilibration at the starting conditions for the 
next purification (Ion Exchange Chromatography Principles and Methods, 2001). 
. 
 
 
 
 
 
Fig. 3.7 Ion exchange chromatography steps: 1. Starting conditions; 2. Adsorption of sample substances; 3. 
Start of desorption; 4. End of desorption; 5. Regeneration (Ion Exchange Chromatography Principles and 
Methods, 2001). 
 
 
Separation is obtained since different substances have different degrees of interaction with the 
ion exchanger due to differences in their charges, charge densities and distribution of charge 
on their surfaces. These interactions can be controlled by varying conditions such as ionic 
strength and pH. The differences in charge properties of biological compounds are often 
considerable, and since ion exchange chromatography is capable of separating species with 
very minor differences in properties, e.g. two proteins differing by only one charged amino 
acid, it is a very powerful separation technique. 
 1.                  2.                 3.                 4.                 5.  
       Starting buffer counter ions 
 
       Gradient ions 
 
 
        Substances to be separated  
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In ion exchange chromatography one can choose whether to bind the substances of interest 
and allow the contaminants to pass through the column, or to bind the contaminants and allow 
the substance of interest to pass through. Generally, the first method is more useful since it 
allows a greater degree of fractionation and concentrates the substances of interest. In addition 
to the ion exchange effect, other types of binding may occur. These effects are small and are 
mainly due to van der Waals forces and non-polar interactions.  
An ion exchanger consists of an insoluble matrix to which charged groups have been 
covalently bound. The charged groups are associated with mobile counterions. These counter-
ions can be reversibly exchanged with other ions of the same charge without altering the 
matrix. It is possible to have both positively and negatively charged exchangers.  
Positively charged exchangers have negatively charged counter-ions (anions) available for 
exchange and are called anion exchangers. Negatively charged exchangers have positively 
charged counter-ions (cations) and are termed cation exchangers. 
The matrix may be based on inorganic compounds, synthetic resins or polysaccharides. 
The characteristics of the matrix determine its chromatographic properties such as efficiency, 
capacity and recovery as well as its chemical stability, mechanical strength and flow 
properties. The nature of the matrix will also affect its behaviour towards biological 
substances and the maintenance of biological activity. 
The presence of charged groups is a fundamental property of an ion exchanger. The type of 
group determines the type and strength of the ion exchanger; their total number and 
availability determines the capacity (Ion Exchange Chromatography Principles and Methods, 
2001). There is a variety of groups which have been chosen for use in ion exchangers; some 
of these are shown in Table 3.7. 
 
 
Anion exchangers  Functional group 
Diethylaminoethyl (DEAE)  -O-CH2-CH2-N+H(CH2CH3)2 
Quaternary aminoethyl (QAE)  -O-CH2-CH2-N+(C2H5)2-CH2-CHOH-CH3 
Quaternary ammonium (Q)  -O-CH2-CHOH-CH2-O-CH2-CHOH-CH2-N+(CH3)3 
Cation exchangers  Functional group 
Carboxymethyl (CM)  -O-CH2-COO 
Sulphopropyl (SP)  -O-CH2-CHOH-CH2-O-CH2-CH2-CH2SO3 
Methyl sulphonate (S)  -O-CH2-CHOH-CH2-O-CH2-CHOH-CH2SO3 
 
Tab. 3.7 Functional groups used on ion exchangers.  
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Some properties of strong ion exchangers are: 
• Sample loading capacity does not decrease at high or low pH values due to loss of charge 
from the ion exchanger. 
• A very simple mechanism of interaction exists between the ion exchanger and the solute. 
• Ion exchange experiments are more controllable since the charge characteristics of the 
media do not change with changes in pH. This makes strong exchangers ideal for working 
with data derived from electrophoretic titration curves. 
 
 
3.11 PRELIMINARY SCREENING OF PROTEIN FOLDING  
The purified samples were analysed by NMR spectroscopy to verify the folding. The folding 
analysis of the protein samples was performed at CERM (Resonance Magnetic European 
Centre) in Florence by qualified staff. 
NMR samples were prepared by dissolving the protein in 400 µl of the solution containing 
100 mM NaCl and 50 µl of D2O. The final concentration was ranged between 0.2 and 5 mM. 
The pH of the protein solution was adjusted at 7. 
The NMR experiments were acquired on AVANCE 900, AVANCE 800, AVANCE 700 and 
DRX 500 spectrometers operating at the nominal proton frequencies of 900.13,  800.13, 
700.13 and 500.13 MHz. 900, 800 and 500 MHz spectrometers are equipped with a triple 
resonance (TXI) 5 mm cryoprobe with a z-axis pulse field gradient. All NMR experiments but 
that used to determine the temperature dependence of the HSQC signals, were performed at 
298 K. All the spectra were processed with the Bruker XWINNMR software package and 
analyzed by the program CARA (ETH Zurich). The samples were left at 4° C between the 
measurements.  
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4  RESULTS 
 
4.1 PROTEIN SELECTION 
This work was faced to the production of recombinant proteins belonging to the calcium-
binding family and their targets. The aim was to obtain pure recombinant protein samples 
correctly folded for structural characterization by NMR. 
  
 
Tab. 4.1 Proteins selected for the project. aa: number of aminoacidics; MW: molecular weight (Da); I.N.: 
identification number. In red the proteins for which the Gateway entry clone was not obtained.    
Protein 
category  I.N.  Protein Name  aa  MW 
(Da) 
calmodulin 
targets 
1a)  
1b)  
1c)  
2a)  
2b)  
3)    
4a)  
4b)  
4c)  
5a)  
5b)  
6a)  
6b)  
7)   
8)   
 
Neuromodulin  
Neuromodulin GAP-43 5-226 
Neuromodulin GAP-43 41-226 
Endothelial differentiation-related factor 1 ISO-α 
Endothelial differentiation-related factor 1 ISO-β 
Brain-specific polypeptide (PEP-19) 
Cyclin-dependent Kinase inhibitor1 (P21) 
Cyclin-dependent Kinase inhibitor1(P21) fragment 1-160 aa 
Cyclin-dependent Kinase inhibitor1 (P21) fragment 25-164 aa 
RNA-binding protein EWS Q01844  
RNA binding protein EWS, fragment 256-447aa 
similar to CAVP-target protein (IQ) 
similar to CAVP-target protein (IQ) splicing variant of CAVP-target  
SH3 adapter protein SPIN 90: 722 aa, fragment 1-81 aa 
Tuberous sclerosis TSC2  C-terminale domain, 1531-1758 aa 
 
238 
222 
186 
148 
139 
62 
164 
160 
139 
656 
191 
316 
264 
81 
228 
 
24802 
22959 
18812 
16369 
15480 
6660 
18119 
17610 
15560 
68478 
20273 
34985 
28687 
9109 
56890 
EF-Hands 9)   
10)  
11)  
12)  
13)  
14)  
15)  
16a)  
16b)  
17)  
18)   
19)  
20)  
21)  
22a)  
22b)  
22c)  
23a) 
23b)  
24)  
26)  
27)  
28)  
 
Calcineurin B Homologous Protein (CHP1) 
Calcineurin B Homologous Protein 2 (CHP2)  O43545 196 aa 
Tescalcin 
Visinin-Like Protein 1 
Visinin-Like Protein 3 (Hippocalcin-Like Protein 1) 
Calcyphosine 
Calcyphosine Isoform 2 
Calneuron Q 
Calneuron Q N-Terminal Domain  33-104  aa 
Guanylyl Cyclase Activating Protein 1 P43080  
Guanylyl Cyclase Activating Protein 2 Q  
Guanylyl Cyclase Activating Protein 3 O95843  
S100A2 
S100A16 
Peflin 
Peflin ESP1 (EFH1_2),116-182 aa 
Peflin ESP2 (EFH3_4) ,183 – 250 aa 
ALG-2 ESP1 (EFH1_2) 
ALG-2 ESP2 (EFH3_4) 
EP15_HUMAN - ESP1 (EH1) 15-85 aa 
S100A10 
Calmodulin Like to Skin Protein (CLSP) 
Hippocalcin 
 
195 
196 
214 
191 
193 
189 
162 
219 
72 
201 
200 
209 
97 
103 
284 
67 
66 
67 
66 
71 
97 
146 
193 
 
22325 
22321 
24750 
22011 
22182 
20967 
24837 
24837 
8170 
22912 
23478 
23822 
10985 
11801 
30381 
7814 
8005 
7746 
7773 
7759 
11203 
15920 
22153 
Hippocalcin 
target 
29)   BIR3-NAIP fragment 278-344 aa  68  7610.6  
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The protein targets, with known sequence but unknown structure, were selected from a 
genomic databank, on the base of the relevance of their human cellular function. Moreover, to 
face one of the essential parameter for NMR structural determination, only proteins with size 
less than 30kDa were chosen. In the table 4.1 the proteins selected are listed with the 
respective aminoacidic number (aa) and molecular weight (MW). An Identification Number 
(I.N.) was assigned to each protein as showed in the table 4.1. 
 
 
4.2 CLONING OF THE GENES CODING FOR THE SELECTED PROTEINS, IN 
THE GATEWAY pENTR/D-TOPO VECTOR       
The nucleotide sequences coding for the proteins reported in table 4.1 were amplified from 
cDNA by PCR using specific primers. The sequence of the genes and primers is reported in  
Annex 1.  
Following the cloning protocol of the Gateway, the genes coding for the recombinant proteins 
were extracted from agarose gel and cloned into the pENTR/ D-TOPO by BP recombination 
reaction as describe at par 3.3.   
The BP recombination reaction mixtures were used to transform competent TOP10 E.coli 
cells. For each transformation, six well-spaced colonies were selected to extract the plasmids 
and verify the correct insertion of the genes. This check was performed by PCR using 
Universal M13 Forward and Reverse primers. In the table 4.2 the expected dimensions of the 
amplification fragments are reported for each protein.  
The PCR products were analysed by agarose gel electrophoresis. The agarose gels of the 
samples correctly amplified are reported in figure 4.1. (i.e. which gave DNA fragments with 
right size, see Table 4.2). 
 
 
 
 
 
 
 
 
 
 
  
61 
I.N. proteins 
Amplified 
fragment 
dimension (bp) 
I.N. proteins 
Amplified 
fragment 
dimension (bp) 
1a  1077  15  849 
1b  1028  16a  1019 
1c  920  16b  578 
2a  806  17  965 
2b  779  18  962 
3  548  19  989 
4a  854  20  653 
4b  842  21  671 
4c  782  22a  1214 
5b  938  22b  563 
6a  1310  22c  566 
6b  1159  23a  563 
7  605  23b  560 
8  1046  24  575 
9  952  26  653 
10  950  27  800 
11  1004  28  941 
12  935  29  566 
13  941     
14  929     
 
Tab. 4.2 Expected dimensions of the amplified fragments obtained using M13 Universal Primers. 
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Fig. 4.1. Agarose gels with thw DNA fragments obtained by amplification of the genes cloned in pENTR/D-
TOPO using M13 Universal Primers. The standard (St) is composed of ten fragments having known number of 
base pairs (bp): 1031 bp; 900 bp; 800 bp; 700 bp; 600; 500 bp; 400 bp; 300 bp; 200 bp; 100 bp and 80 bp. 
 
The sequences of the entry clones (pENTR/D-TOPO) were analyzed by single run sequencing  
using the Universal Forward and Reverse M13 primers, which was performed at Primm 
Biotech. The sequencing results confirmed that the genetic sequences of the entry clones were 
St   24           St    23A        St     22a         A  St     23b        19   St   21     25    St    26     
St   18          St   22c           St       /      7
4a  St   1a        2b    St   3         St     4c        14      St        /      5b        St   12   15       St     11         St   28  10
20   St       22b   St     
29   St  
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corrected for all the samples, with the exception of those coding for the proteins evidenced 
with red colour in table 4.1.   
 
4.3 CLONING OF THE GENES CODING FOR THE SELECTED PROTEINS, IN 
THE GATEWAY DESTINATION VECTORS       
For this and the next operative steps, the thesis' work was limited to the proteins reported in 
table 4.3 for time reason. Indeed, along a PhD thesis work the preliminary list of proteins of 
interest was too long to be completed in areasonable time. The selection of subset was 
performed by taking into account the highest representativeness of cases. The genes coding 
for the proteins of table 4.3, were transferred from the pENTR/D-TOPO to five destination 
vector described in paragraph 3.6. 
 
Tab. 4.3. Proteins selected to continue the  work of thesis. 
 
4.3.1 Destination vectors 
The destination vectors reported in figure 4.2 were used to perform the LR recombination 
reactions. The pDEST-15 is composed of 7013 base pairs (bp) and contains the gene for the 
expression of the GST-tag; the pDEST-17 is composed of 6354 bp and contains the gene for 
the expression  of the (His)6-tag; the pETG-20A is composed of 7449 bp and contains the 
gene for the expression (His)6 + TrxA- tag; the pETG-30A is composed of 7784 [bp] and 
contains the gene for the expression of the (His)6+ GST-tag; the pETG-60A is composed of 
8597 bp and contains the gene for the expression of the(His)6+ NusA-tag. During the 
recombination, the fragment included between the attR1 and attR2 sites, and containing the 
sequence coding for chloramphenicol resistance, is exchanged. The destination vectors are 
Protein 
category  I.N.  Protein Name  aa 
calmodulin 
targets 
2a)  
2b)  
4b)  
4c)  
7)   
8)   
Endothelial differentiation-related factor 1 ISO-α 
Endothelial differentiation-related factor 1 ISO-β 
Cyclin-dependent Kinase inhibitor1(P21) fragment 1-160 aa 
Cyclin-dependent Kinase inhibitor1 (P21) fragment 25-164 aa 
SH3 adapter protein SPIN 90: 722 aa, fragment 1-81 aa 
Tuberous sclerosis TSC2  C-terminale domain, 1531-1758 aa 
148 
139 
62 
164 
81 
228 
EF-Hands 9)   
10)  
26)  
27)  
28)  
 
S100A2 
S100A16 
S100A10 
Calmodulin Like to Skin Protein (CLSP) 
Hippocalcin 
 
195 
103 
97 
146 
193 
 
Hippocalcin 
target 
29)   BIR3-NAIP fragment 278-344 aa  68  
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ampicillin-resistant in an external region from the att sites. T7 promoter and T7 term identify 
the sites from which the amplification of the genetic sequences starts, during the PCR 
reaction.  
         
 
 
 
 
 
 
 
A. 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
 
 
D. 
 
 
 
 
 
 
 
 
 
E. 
 
Fig. 4.2 Schematic representations of the destination vectors: A=pDEST15; B=pDEST17; C=pETG-20A; 
D=pETG-30A; E=pETG-60A.  
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It was chosen to clone the proteins in five different destination vectors to test rapidly more 
vector-host combinations to increase the successful probabilities in protein expression 
strategies. Additionally, certain affinity tags have a beneficial effect on protein solubility 
especially in bacterial protein expression. Although the advantages of affinity tags greatly 
outweigh their potential problems, it is important to consider that any tag can potentially 
interfere with folding, function or crystallization of the target proteins (Pascal et al,. 2003).  
 
4.3.2. LR recombination reaction and transformation to competent E.coli host strains 
The  LR recombination reaction was performed in a way slightly different from that 
suggested by the Gateway protocol. In fact, each gene coding for the selected proteins, was 
transferred from the pENTR/ D-TOPO not to a single pDEST, but directly in a single step, to 
a mixture of 5 destination vectors: pDEST-15; pDEST-17; pETG-20A; pETG-30A; pETG-
60A (paragraph4.3.1). This strategy allows a notable reduction of time and consumption of 
reagents, which is of particular concern considering the high cost of the LR Clonase enzyme. 
In each reaction mix a quantitatively casual recombination between the pENTR/ D-TOPO and 
each destination vector was expected to happen. To identify the pDEST containing the genes, 
the reaction mix of each genes was transformed in three different E.coli strains, (BL21GOLD, 
plys and Codon plus) and plated on selective media containing ampicillin. As the destination 
vectors contain the gene for the ampicillin-resistance, only the cells able to grow in the 
presence of this antibiotic were defined “correctly transformed”, having acquired one of the 5 
destination vectors. All the transformations in the three E.coli host strains produced colonies 
on selective LB agar plates. 25 colonies were selected from each plate and used for the protein 
expression screening (paragraph 4.4) by which the identity of the pDEST, acquired from each 
colony, was established on the basis of the size of the protein produced.    
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4.4 PROTEIN EXPRESSION SCREENING 
To characterize the identity of the plasmid acquired from each transformed colony, the cells 
were grown in 5 ml of LB medium and after induction with IPTG, the protein expression was 
analyzed by SDS-page. With the Gateway recombination system, the proteins were expressed 
fused with other proteins or polypeptides called "tag", to simplify the successive purification 
steps. Every fusion tag has a specific molecular weight reported in table 4.4.  
 
Destination 
vectors  pDEST-17 pDEST-15 pETG-20A pETG-30A pETG-60A 
Fusion tags  (His)6-tag GST  TrxA+(His)6-
tag 
GST+(His)6-
tag 
NusA+(His)6-
tag 
MW (Dalton)  4300  25000 16650 28977 58857 
 
Tab. 4.4 Molecular Weight, in Dalton, of the fusion tag expressed by the destination vectors pDEST-15; 
pDEST-17; pETG-20A; pETG-30A; pETG-60A. 
 
 
The molecular weight of each recombinant protein, fused to each tag, was obtained adding the 
MW of the fusion tag with the MW of the protein and is reported in tab.4.5. 
 
Fusion TAG 
Proteins  (His)6-tag 
MM=4300 Da 
GST 
MM=25000 
Da 
TrxA+(His)6-
tag 
MM=16650 
Da 
GST+(His)6-
tag 
MM=28977 
Da 
NusA+(His)6-
tag 
MM=58857 
Da 
S100A2 
MW=10985.2 Da  15285.2 Da  35985.2 Da  27635.2 Da  39962.2 Da  69842.2 Da 
S100A16 
MW=11801.4 Da 
16101.4 Da  36801.4 Da  28451.4 Da  40778.4 Da  70658.4 Da 
S100A10 
MW=11203.1 Da 
15503.1 Da  36203.1 Da  27853.1 Da  40180.1 Da  70060.1 Da 
Endothelial 
differentiation-
related factor 1 – 
isoform α (EDF-1 
iso α) 
MW=16368.6 Da 
20668.6 Da  41368.6 Da  33018.6 Da  45345.6 Da  75225.6 Da 
Endothelial 
differentiation-
19780.5 Da  41480.5 Da  32130.5 Da  44457.5 Da  74337.5 Da  
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related factor 1 – 
isoform β (EDF-1 
iso β) 
MW=15480.5 Da 
Cyclin-dependent 
kinase inhibitor 1 
(P21) 
 - fragment 1-160  
(P21-160)  
 
MW=17609.6 Da 
21909.6 Da  22609.6 Da  34259.6 Da  46586.6 Da  76466.6 Da 
Cyclin-dependent 
kinase inhibitor 1 
(P21)  
- fragment 1-140  
(P21-140) 
 
MW=15560.3 Da 
19860 Da  41560.3 Da  32210.3 Da  44537.3 Da  74417.3 Da 
SH3 adapter protein 
SPIN90 - fragment 1-
81 (SH3-81) 
MW=9109.3 Da 
13409.3 Da  35109.3 Da  25759.3 Da  38086.3 Da  67966.3 Da 
Tuberous sclerosis 
2 protein 
TSC2_HUMAN C-
terminal domain 
1531-1758 (TSC2-
228)  
MW=26011.6 Da 
30311.6 Da  52011.6 Da  42661.6 Da  54988.6 Da  84868.6 Da 
Hippocalcin 
MW=22296.2 Da 
26596.2 Da  47296.2 Da  38946.2 Da  51273.2 Da  81153.2 Da 
BIR3-NAIP 
fragment 278-344 
aa 
MW=7610.6 Da 
11910.6 Da  32610.6 Da  24260.6 Da  36587.6 Da  66467.6 Da 
 
Tab. 4.5  Molecular Weigh (expressed in Dalton) of the recombinant proteins fused with each of the tags 
expressed by destination vectors: pDEST-15; pDEST-17; pETG-20A; pETG-30A; pETG-60A. 
 
 
The SDS-page protein profile of each culture of the screening was compared to that of protein 
MW standards. Figure 4.3 shows the SDS PAGE of the two standards used for this expression 
screening . From this comparative analysis, it was possible to obtain the MW of the protein 
overexpressed by each culture  and then to recognize the pDEST plasmid carrying the gene , 
of each colony. 
 
  
68 
97.4     KDa 
66.2     KDa 
45        KDa 
 
 
31      KDa 
 
21.5   KDa 
 
14.4   KDa 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3 The standards are made of proteins with known molecular weight. The proteins of Low range standard  
(1) have the following MW: 97.4 kDa, 66.2 kDa, 45  kDa, 31 kDa, 21.5 kDa, 14.4 kDa. The proteins of Protein 
Molecular Weight Marker (2) have the following MW: 116 kDa, 66.2 kDa, 45 kDa, 35 kDa, 25 kDa, 18.4 kDa, 
14.4  kDa. 
 
STANDARD 1 
Low  range 
STANDARD 2 
Protein Molecular Weight Marker 
 
 
 
 
 
 
 
 
 
 
116    KDa 
66.2   KDa 
45      KDa 
35      KDa 
 
25      kDa 
 
18.4    kDa
 
14.4    kDa
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4.4.1 Expression screening of the protein S100A2   
The expression of the S100A2 protein in three E.coli BL21 host strains (Codon plus, Plys and 
Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the figure 4.4 the gels 
concerning the expression of S100A2 are reported. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.4. SDS-PAGE of the expression of S100A2 protein in different E.coli strains. Page A (line 2-15) and B 
(lines1, 3-12): expression in Plys. Page B (lines 13), C (lines 1-3), D (lines 2-13): expression in Gold. In page C 
(lines 5-15) and D (lines 1-2 and 4-15) is reported the expression in Codon plus. The samples loaded in each line 
are classified with a letter, corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), 
and a number, given to each colony, as showed in table G. The Low Range standard in all gels, contains six 
proteins with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 A B C  D  E F 
1  st  p15 G2 C+12 st  st 
2  p1  st  G3 C+13  G5  G19 
3  p2 p16  G4  St  G6 G20 
4  p3 p17  st  C+14 G7 G21 
5  p4 p18 C+1 C+15 G8 G22 
6  p5 p19 C+2 C+16 G9 G23 
7  p6 p20 C+3 C+17  G10  G24 
8  p7 p21 C+4 C+18  G11   
9  p8 p22 C+5 C+19  G12   
10  p9 p23 C+6 C+20  G14   
11  p10 p24  C+7  C+21 G15   
12  p11 p25  C+8  C+22 G17   
13  p12 G1  C+9 C+23 G18   
14  p13 / C+10  C+24  G13   
15  p14 / C+11  C+25 /   
  1       2         3       4      5       6       7        8       9      10     11    12     13    /    / 
A. 
B. 
C. 
D. 
E. 
F.
  1       2        3       4        5       6       7        8       9      10      11   12     13   14   15  
  1       2        3       4        5       6       7        8       9      10    11   12     13    14    15  
  1       2        3       4       5       6       7        8       9      10    11   12     13    14    15  
  1       2        3       4       5       6       7        8       9      10      11   12     13    14    15  
 1       2        3       4        5       6       7        8        9      10      11     12     13    14      / 
  1      2       3       4       5        6       7      /       /       /   
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From the observation of the gels in figure 4.4, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein S100A2 calculated as described in table 
4.5, it is possible to deduce which plasmid has been acquired from each colony. The results of 
this screening can be summarized as follow: 
¾  the pDEST17 plasmid has been acquired from the colonies Codon plus BL21 numbers 
16, BL21 GOLD numbers 1, 2, 12, 19, 20, 21, 24, 6, 8, 14 and 13 and finally from the 
colonies BL21 pLys numbers 7, 16, 21 and 23. In fact all these colonies present an 
over-expressed band of around 15000 Da; 
¾  the pETG20A plasmid has been acquired from the colonies BL21Codon plus 23, 
BL21 GOLD 5 and 7, and finally from the colonies BL21 pLys 9, presenting an over-
expressed band of around 27600 Da; 
¾  the pETG30A plasmid has been acquired only from the colony BL21 pLys numbers 
19, showing an over-expressed band of around 39900 disposed between the two bands 
of the standard with MM respectively of 31 kDa and 45 kDa; 
¾  the pETG60A plasmid, instead, has been acquired from the colonies BL21 pLys 13, 14 
and 22 and from the colony BL21 GOLD 16, showing an over-expressed band of 
around 69800 Da disposed between the two bands of the standard with MM 
respectively of 66.2 kDa and 97.4 kDa; 
¾  finally, any colony has acquired the pDEST15, since any band of around 36 KDa can 
be observed on the gel. 
The results of the expression screening of S100A2 protein are summarized in table 4.6. 
 
  pDEST15   pDEST17  pETG20A  pETG30A  pETG60A 
pLys  /  7,16,21,23 9  19 13,14,22 
Codon plus  /  16 23  / / 
GOLD  / 
1,2,12,19,20,21,
24,6,8,14,13  5,7 / 16 
 
Tab. 4.6 Results of the S100A2 expression screening. The number in red refer to the colonies that were selected 
to perform the solubility screening (paragraph 4.5).  
  
71 
4.4.2 Expression screening of the protein S100A16   
The expression of the S100A16 protein in three E.coli BL21 host strains (Codon plus, Plys 
and Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the figure 4.5 the gels 
concerning the expression of S100A16 are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.5 SDS-PAGE of the expression of S100A16 protein in different E.coli strains. Page A (line 2-15) and B 
(lines1, 3-12): expression in Codon plus. Page B (lines 13-15), C (lines 1-2, 4-15), D (lines 1-3, 5-9): expression 
in Plys. In page D (lines 10-15), E (lines 2-11) and F(lines 1-4) is reported the expression in GOLD. The samples 
loaded in each line are classified with a letter, corresponding to the initial of the host strain (C+= Codon plus, G= 
 A B C  D  E  F 
1  st  C+15 p4 p18  st  G20 
2  C+1  st  p5 p19 G7 G21 
3  C+2 C+16 st   p20 G8 G23 
4  C+3 C+17 p6  St  G9 G24 
5  C+4 C+18 p7 p21  G10  st 
6  C+5 C+19 p8 p22  G11   
7  C+6 C+20 p9 p23  G12   
8  C+7  C+21 p10 p24 G14   
9  C+8  C+22 p11 p25 G15   
10  C+9 C+23  p12 G1 G17   
11  C+10 C+24 p13 G2 G18   
12  C+11 C+25 p14 G3  /   
13  C+12 p1 p15  G4  /   
14  C+13 p2 p16  G5  /   
15  C+14 p3 p17  G6  /   
G.
E. 
D. 
A. 
B. 
C. 
F. 
   1    2      3     4      5       6      7       8      9    10    11    12     13   14   15  
   1    2      3     4      5       6      7       8      9    10    11    12   13   14   15   
   1    2      3     4      5       6      7       8      9    10    11  12     13   14   15   
   1    2      3     4      5       6      7       8      9    10    11    12     13   14   15  
   1    2      3     4     5     6      7     8     9    10    11     
   1    2      3     4      5         
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Gold, p= pLys), and a number, given to each colony, as showed in table G. The Low Range standard in all gels, 
contains six proteins with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
From the observation of the gels in figure 4.5, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein S100A16 calculated as described in 
table 4.5, it is possible to deduce which plasmid has been acquired from each colony. The 
results of this screening can be summarized as follow: 
¾  the pDEST17 has been acquired from the colonies BL21Codon plus numbers 19 and 
25, BL21 GOLD numbers 3, 4, 5, 20 and finally from the colonies BL21 pLys 
numbers 1, 6, 11, 14, 15, 23, 24, showing an over-expressed band of around 16000 
Da; 
¾  the pETG20A plasmid has been acquired from the colonies BL21Codon plus 5, 7, 9, 
12, 13, 17, 22, BL21 GOLD 1, 2, 6, 11, 14, 16 and 21, showing an over-expressed 
band of around 28400 Da; 
¾  the pETG30A plasmid has been acquired only from the colony BL21 GOLD numbers 
10, presenting a band of MM of around 39900 disposed between the two bands of the 
standard with MM respectively of 31 kDa and 45 kDa; 
¾  the pETG60A plasmid, instead, has been acquired from the colonies BL21 pLys 13, 14 
and 22 and from the colony BL21 GOLD 16, showing an over-expressed band of 
around 69800 Da disposed between the two bands of the standard with MM 
respectively of 66.2 kDa and 97.4 kDa; 
¾  finally, any colony has acquired the pDEST15, since any band of around 36 KDa can 
be observed on the gel.  
The results of the expression screening of S100A16 protein are summarized in table 4.7. 
 
  pDEST15   pDEST17  pETG20A  pETG30A  pETG60A 
Codon plus  /  19,25 
5,7,9,12,13,17,2
2 
/ / 
pLys  / 1,6,11,14,15,23,24 / /  5,12 
GOLD  / 3,4,5,20 
1,2,6,11,14,16,2
1 
10  / 
 
Tab. 4.7 Results of the S100A16 expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5).  
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4.4.3 Expression screening of the protein S100A10   
The expression of the S100A10 protein in three E.coli BL21 host strains (Codon plus, Plys 
and Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the figure 4.6 the gels 
concerning the expression of S100A10 are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6 SDS-PAGE of the expression of S100A10 protein in different E.coli strains. Page A (line 2-15) and B 
(lines1, 3-12): expression in Codon plus. Page B (lines 13-15), C (lines 1-2, 4-15), D (lines 1-3, 5-9): expression 
in Plys. In page D (lines 10-15), E (lines 1-4, 6-15) and F(lines 1-5) is reported the expression in GOLD. The 
samples loaded in each line are classified with a letter, corresponding to the initial of the host strain (C+= Codon 
plus, G= Gold, p= pLys), and a number, given to each colony, as showed in table G. The Low Range standard in 
 A B C  D  E  F 
1  C+1 C+15 p4 p18 G7 G21 
2  C+2  st  p5 p19 G8 G22 
3  C+3 C+16 st   p20 G9 G23 
4  C+4 C+17 p6  St  G10 G24 
5  C+5 C+18 p7 p21  st  G25 
6  C+6 C+19 p8 p22  G11  st 
7  C+7 C+20 p9 p23  G12   
8  C+8  C+21 p10 p24 G13   
9  C+9  C+22 p11 p25 G14   
10  C+10 C+23 p12 G1 G15   
11  C+11 C+24 p13 G2 G16   
12  C+12 C+25 p14 G3 G17   
13  C+13 p1 p15  G4  G18   
14  C+14 p2 p16  G5  G19   
15  st  p3 p17  G6  G20   
        1        2        3     4     5     6     7     8     9    10   11 12   13   14    15 
 1      2       3    4       5    6      7     8     9    10    11   12   13    14    15 
 1      2       3     4       5       6      7      8       9     10     11   12   13   14   15 
 1      2       3     4       5       6      7      8       9     10     11   12   13   14   15 
 1      2       3     4       5       6      7      8       9     10     11   12   13   14   15 
 1      2       3      4       5       6       
A. 
B. 
C. 
D. 
E.
F.
G. 
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all gels, contains six proteins with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 
KDa). 
 
From the observation of the gels in figure 4.6, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein S100A10 calculated as described in 
table 4.5, it is possible to deduce which plasmid has been acquired from each colony. The 
results of this screening can be summarized as follow: 
¾  The pDEST17 has been acquired from the colonies BL21Codon plus numbers 4, 10 
and 22 showing an overexpressed band of around 15500 Da; 
¾  the pETG20A plasmid has been acquired from the colonies BL21Codon plus 22, 
BL21 and BL21 pLys 7 and 22, showing an over-expressed band of around 27800 Da; 
¾  the pETG30A plasmid has been acquired only from the colony BL21 pLys 1, 11 and 
21, BL21 Codon plus 8 and 9, showing an over-expressed band of around 40100 Da 
disposed between the two bands of the standard with MM respectively of 31 kDa and 
45 kDa; 
¾  the pETG60A plasmid, instead, has been acquired from the colonies BL21 pLys 2, 
showing an over-expressed band of around 70000 Da disposed between the two bands 
of the standard with MM respectively of 66.2 kDa and 97.4 kDa; 
¾  Finally, any colony has acquired the pDEST15, since any band of around 36 KDa can 
be observed on the gel. 
 The results of the expression screening of S100A10 protein are summarized in table 4.8. 
 
  pDEST15  pDEST17  pETG20A  pETG30A  pETG60A 
Codon 
plus   / /  22 8, 9  / 
pLys  / /  7, 22  1, 11, 21  2 
GOLD  /  4, 10, 22  1  / / 
 
Tab. 4.8 Results of the S100A10 expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5). 
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4.4.4 Expression screening of the isoform α of the Endothelial differentiation-related 
factor  (EDF-1 iso α) protein 
 
The expression of the EDF-1 iso α protein in three E.coli BL21 host strains (Codon plus, Plys 
and Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the figure 4.7 the gels 
concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A B C D  E F 
1  st  G11 C+4  St  p13 C+18 
2  G1  st  C+5  St  St  C+19 
3  G2 G12  st  p1 p14  C+20 
4  G3 G13 C+6  p2 p15  C+21 
5  G4 G14 C+7  p3 p16  st  
6  G5 G15 C+8  p4 p17   
7  G6 G16 C+9  p5 p18   
8  G7 G17  C+10 p6 p19   
9  G8 G18  C+11 p7 p20   
10  G9 G19  C+12 p8     
11  G10 G20 C+13  p9     
12  / /  C+14  p10     
13  / /  C+15  p11     
14  / /  C+16  p12     
15  / /  C+17  /    
C. 
B. 
D. 
E. 
F. 
 1    2    3    4    5   6    7    8   9    10   11  12   13    14    15 
1   2    3    4    5    6     7     8    9       10      11    12    13     
 1    2    3    4    5      6     7    8     9        10        11         1   2    3   4    5    6   7   8   9       10    11   12    13    14     
1   2   3   4   5    6   7   8   9   10  11 12 13 14 15 
1  2   3  4   5 
A. 
G. 
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Fig. 4.7 SDS-PAGE of the expression of EDF-1 iso α   protein in different E.coli strains. Page A and B: 
expression in GOLD. Page C and F: expression in Codon plus. In page D and E is reported the expression in 
Plys. The samples loaded in each line are classified with a letter, corresponding to the initial of the host strain 
(C+= Codon plus, G= Gold, p= pLys), and a number, given to each colony, as showed in table G. The Protein 
Molecular Weight Marker Standard in all gels, contains seven proteins with known molecular weight (11.6KDa, 
66.2KDa,  45KDa, 35KDa, 25KDa, 18.4 KDa, 14.4KDa). 
 
 
From the observation of the gels in figure 4.7, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein EDF-1 iso α calculated as described in 
table 4.5, it is possible to deduce which plasmid has been acquired from each colony. The 
results of this screening can be summarized as follow: 
¾  any colony has acquired the pDEST17, since it’s not observed any bands of around 
18400 Da; 
¾  the pETG20A plasmid has been acquired from the colonies BL21 Codon plus 
5,9,12,16,18,20, from the colonies BL21 pLys 9,10,15 and from the colonies BL21 
Glold 10 and 19, showing an over-expressed band of around 33 kDa; 
¾  the pETG30A plasmid has been acquired from the colony Codon plus 3, 11, 15 from 
the colonies BL21 pLys 2, 6, 11 and from the colonies BL21 Glold 1, 9, 11, 12, 18, 
showing an over-expressed band of around 45300 Da; 
¾  the pETG60A plasmid has been acquired from the colonies BL21 Codon plus 3, 4, 6, 
8, 10, 13, 17, 19 from the colonies BL21 pLys 1, 3, 4, 5, 8,12,13,17 and from the 
colonies BL21 Glold 5, 6, 7, 13, 15 and 20, showing an over-expressed band of around 
75 kDa, disposed between the two bands of the standard with MM respectively of 116 
kDa and 66.2 kDa; 
¾  finally, any colony has acquired the pDEST15, since any band of around 41 KDa can 
be observed on the gel.  
The results of the expression screening of EDF-1 iso α protein are summarized in table 4.9. 
  pDEST15  pDEST17  pETG20A  pETG30A  pETG60A 
Codon 
plus   /  / 
5,9,12,16, 
18,20 
3,11,15  3,4,6,8,10,13,17,19 
GOLD  /  /  10,19 1,9,11,12,18  5,6,7,13,15,20 
pLys   /  /  9,10,15 2,6,11 
1,3,4,5,8,12,13,17 
18,19,20 
 
Tab. 4.9 Results of the S100A10 expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5).  
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4.4.5 Expression screening of the isoform β Endothelial differentiation-related factor 1 
(EDF-1 iso β) protein 
 
The expression of the EDF-1 iso β protein in three E.coli BL21 host strains (Codon plus, Plys 
and Gold) was verified by SDS-PAGE as described in paragraph3.7. In the figure 4.8 the gels 
concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 SDS-PAGE of the expression of EDF-1 iso  β  protein in different E.coli strains. Page A and B (lines 1-
6): expression in Codon plus. Page B (lines 8-15) and C (lines 1-5): expression in GOLD. In page D is reported 
the expression in Plys. The samples loaded in each line are classified with a letter, corresponding to the initial of 
the host strain (C+= Codon plus, G= Gold, p= pLys), and a number, given to each colony, as showed in table E. 
The Low Range standard in all gels, contains six proteins with known molecular weight (97.4KDa, 66.2KDa,  
45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
 A B C  D 
1  St  C+15 G9  St 
2  C+1 C+16  G10 P8 
3  C+2 C+17  G11  P12 
4  C+3 C+18  G12  P13 
5  C+4 C+19  G13  P18 
6  C+5 C+20 St   
7  C+6  St  G15  
8  C+7 G1  G16  
9  C+8 G2  G17  
10  C+9 G3  G18  
11  C+10 G4 G19   
12  C+11 G5 G20   
13  C+12 G6  /   
14  C+13 G7  /   
15  C+14 G8  /   
C. 
B. 
    1   2  3   4  5   6   7   8    9   10    11   12   13  14   15 
       1    2    3      4      5 
   1   2   3  4   5   6   7   8      9  10    11  12   /   / 
    1   2  3  4   5   6   7   8    9    10    11  12   13  14   15 
 1   2    3  4   5   6    7    8   9    10     11    12    13    14    15 
A. 
D. 
E. 
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From the observation of the gels in figure 4.8, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein EDF-1 iso β calculated as described in 
table 4.5, it is possible to deduce which plasmid has been acquired from each colony. The 
results of this screening can be summarized as follow: 
¾  any colony has acquired the pDEST15 and pDEST17, since any bands with MW 
compatible with the recombinant protein can be observed one; 
¾  the pETG20A plasmid has been acquired from the colonies BL21 Codon plus 10 and 
from the colonies BL21 Gold 2 and 6, showing an ove-expressed band of around 32 
kDa; 
¾  the pETG30A plasmid has been acquired from the colonies BL21 pLys 13 and 18 and 
from the colonies BL21 Gold 4, 5, 8, 15, 20 showing an over-expressed band of 
around 44450 Da; 
¾  the pETG60A plasmid has been acquired from the colonies BL21 Codon plus 2, 11, 
17, from the colony BL21 pLys 12 and from the colonies BL21 Glold 1, 3, 7, 9, and 
18, showing an over-expressed band of around 75 kDa, disposed between the two 
bands of the standard with MW respectively of 116 kDa and 66.2 kDa. 
 
The results of the expression screening of EDF-1 iso β protein are summarized in table 4.10. 
 
  pDEST15  pDEST17  pETG20A  pETG30A  pETG60A 
Codon 
plus   /  /  10  /  2,11,17 
GOLD   /  /  2,6 
4,5,8 
15,20 
1,3,7 
9,18 
pLys  /  /  /  13,18  12 
 
Tab. 4.10 Results of the EDF-1 iso β  expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5). 
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4.4.6 Expression screening of a fragment of Cyclin-dependent kinase inhibitor 1 (P21), 
aa 1-160,  (P21-160) 
 
The expression of the P21-160 protein in three E.coli BL21 host strains (Codon plus, Plys and 
Gold) was verified by SDS-PAGE as described in paragraph3.7. In the figure 4.9 the gels 
concerning the expression are reported 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A B  C D 
1  C+5  G9  St  p15 
2  C+6 G10 p1  St 
3  C+7 G11 p2  p16 
4  st  St  p3 p17 
5  C+8 G12 p4  p18 
6  C+9 G13 p5  p19 
7  C+17 G14  p6  p20 
8  G1 G15  p7 p21 
9  G2  G16 p8 C+10 
10  G3  G17 p9 C+11 
11  G4  G18 p10 C+12 
12  G5  G19 p11 C+13 
13  G6  G20 p12 C+14 
14  G7  G21 p13 C+15 
15  G8  G22 p14 C+16 
D. 
C. 
B. 
A. 
1        2     3   4     5      6     7      8      9   10   11 12  13  14 15
1      2      3    4     5       6       7    8      9  10   11 12  13  14 15
1       2      3   4     5      6      7      8      9  10   11 12  13  14 15
1      2      3    4      5      6      7      8      9   10   11 12  13  14 15
E. 
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Fig. 4.9 SDS-PAGE of the expression of P21-160 protein in different E.coli strains. Page A (lines 1-3, 5-7) and 
D (lines 9-15): expression in Codon plus. Page A (lines 8-15) and B (lines 1-3, 5-15): expression in GOLD. In 
page C and D (lines 1, 3-8) is reported the expression in Plys. The samples loaded in each line are classified with 
a letter, corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), and a number, given 
to each colony, as showed in table E. The Protein Molecular Weight Marker Standard in all gels, contains seven 
proteins with known molecular weight (11.6KDa, 66.2KDa,  45KDa, 35KDa, 25KDa, 18.4 KDa, 14.4KDa). 
 
 
From the observation of the gels in figure 4.9, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein P21-160 calculated as described in table 
4.5, it is possible to deduce which plasmid has been acquired from each colony. The results of 
this screening can be summarized as follow: 
¾  the pDEST17 plasmid has been acquired from the colonies BL21 Codon plus 11, from 
the colonies BL21 Gold 4, 5, and from the colony BL21 pLys 14, showing an over-
expressed band of around 22 kDa; 
¾  the pETG20A plasmid has been acquired from the colonies BL21 Gold 6, 7, 11, 16 
and 18, and from the colony BL21 pLys 9, 10, 15 and 20, showing an over-expressed 
band of around 34.2 kDa; 
¾  the pETG30A plasmid has been acquired from the colonies BL21 Codon plus 6, 7, 8, 
10 and from the colonies BL21 Gold 2, 8, 9 and 10, showing an over-expressed band 
of around 47 kDa; 
¾  the pETG60A plasmid has been acquired from the colonies BL21 Codon plus 9, 12, 
13 14, from the colony BL21 pLys 1, 2, 5, 6, 11, 13, 17, 19 and from the colonies 
BL21 Glold 1, 3, 12,13, 14 and 15, showing an over-expressed band of around 76 
kDa, disposed between the two bands of the standard with MW respectively of 116 
kDa and 66.2 kDa. 
The results of the expression screening of P21-160 protein are summarized in table 4.11. 
 
  pDEST17  pETG20A  pETG30A  pETG60A 
Codon plus   11  /  6,7,8,10 9,12,13,14 
GOLD  4,5 6,7,11,16,18 2,8,9,10 
1,3,12,13,14 
15 
pLys  14 9,10,15,20 / 
1,2,5,6,11 
13,17,19 
 
Tab. 4.11 Results of the P21-160 expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5).  
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4.4.7 Expression screening of a fragment of Cyclin-dependent kinase inhibitor 1 (P21), 
aa 25-164, (P21-140) 
 
The expression of the P21-140 protein in three E.coli BL21 host strains (Codon plus, Plys and 
Gold) was verified by SDS-PAGE as described in paragraph3.7. In the figure 4.10 the gels 
concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.10. SDS-PAGE of the expression of P21-140 protein in different E.coli strains. Page A and B (lines 1-6): 
expression in Codon plus. Page B (lines 8-15), page C and D (lines 1-3, 9-14): expression in GOLD. In page D is 
reported the expression in Plys (lines 6-8).  The samples loaded in each line are classified with a letter, 
corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), and a number, given to each 
colony, as showed in table E. The Low Range standard in all gels, contains six proteins with known molecular 
weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 A B C  D 
1  C+1 C+15 G9 G23
2  C+2 C+16  G10  G24
3  C+3 C+17  G11  G25
4  C+4 C+18  G12 St 
5  C+5 C+19  G13  / 
6  C+6 C+20  G14 p1 
7  C+7  St  G15 p2 
8  C+8 G1  G16  p3 
9  C+9 G2  G17  G12 
10  C+10 G3 G18  G13 
11  C+11 G4 G19  G16 
12  C+12 G5 G20  G22 
13  C+13 G6 G21  G17 
14  C+14 G7  St  G18 
15  St  G8 G22  / 
D. 
C. 
B. 
    1     2      3      4      5       6      7      8      9    10    11  12   13  14    15 
   1    2   3   4   5   6   7    8   9   10    11   12   13   14   
1      2      3      4     5       6       7      8       9   10   11 12  13  14 15
 1   2    3   4    5    6    7    8   9      10     11     12      13    14    15 
A. 
E. 
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From the observation of the gels figure 4.10, it is possible to notice that many samples show 
an over-expressed band with  a specific molecular weight. Comparing the MW of this band, 
with the hypothetical MW of the recombinant protein P21-140 calculated as described in table 
4.5, it is possible to deduce which plasmid has been acquired from each colony. The results of 
this screening can be summarized as follow: 
¾  any colony has acquired the pDEST17 plasmid, since any band with MW compatible 
with the recombinant protein can be observed on the gel. 
¾  the pDEST15 plasmid has been acquired from the colonies BL21 Gold 4, 11, 12, and 
from the colony BL21 pLys 3, showing an over-expressed band of around 41.5 kDa; 
¾  the pETG20A plasmid has been acquired from the colonies BL21 Codon plus 1, 3, 6, 
8, 9, 11, 13, 15, 16,17 18, 20 and from the colonies BL21 GOLD 1, 2, 5, 6, 9, 15, 16, 
17, 19, 20, 21, 22, 23, 24, showing an over-expressed band of around 32.2 kDa; 
¾  the pETG30A plasmid has been acquired from the colonies BL21 Codon plus 10 and 
19, and from the colonies BL21 GOLD 3, 7, 8, 10, 13, 14, 18 and 25, showing an 
over-expressed band of around 45 kDa; 
¾  at last, the pETG60A plasmid has been acquired from the colonies BL21 Codon plus 
5, from the colony BL21 pLys 1, and from the colonies BL21 Glold 8, showing an 
over-expressed band of around 74.4 kDa, disposed between the two bands of the 
standard with MW respectively of 116 kDa and 66.2 kDa. 
The results of the expression screening of P21-140 protein are summarized in table 4.12. 
 
  pDEST15  pDEST17  pETG20A  pETG30A  pETG60A 
Codon 
plus  
/ / 
1,3,6,8,9,11,13 
15,16,17,18,20 
10,19  5 
GOLD   4,11,12 / 
1,2,5,6,9,15,16,17 
19,20,21,22,23,24 
3,7,8,10 
13,14,18,25 
8 
pLys  3 /  /  / 
 
1 
 
Tab. 4.12 Results of the P21-140 expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5). 
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4.4.8 Expression screening of a fragment of the SH3 adapter protein SPIN90, aa 1- 81, 
(SH3-81)  
 
The expression of the SH3 adapter protein SPIN90 protein in three E.coli BL21 host strains 
(Codon plus, Plys and Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the 
figure 4.11 the gels concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11. SDS-PAGE of the expression of SH3 adapter protein SPIN90 protein in different E.coli strains. Page 
A and B (lines 1-6): expression in Codon plus. Page B (lines 8-15), page C and D (lines 1-3, 9-14): expression in 
GOLD. In page D is reported the expression in Plys (lines 6-8 The samples loaded in each line are classified with 
a letter, corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), and a number, given 
to each colony, as showed in table D. The Low Range standard in all gels, contains six proteins with known 
molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
From the observation of the gels in figure 4.11, it is possible to notice that many samples 
show an over-expressed band with  a specific molecular weight. Comparing the MW of this 
band, with the hypothetical MW of the recombinant SH3 adapter protein SPIN90 calculated 
as described in table 4.5, it is possible to deduce which plasmid has been acquired from each 
colony. The results of this screening can be summarized as follow: 
 A B  C 
1  P3 C+1 G10 
2  P4 C+2 G11 
3  P5 C+3 G12 
4  P6 C+4 G13 
5  P7 C+5 G14 
6  St  C+6 G15 
7  G1 C+7 G16 
8  G2 C+8 G17 
9  G3 C+9 G18 
10  G4 C+10 G19 
11  G5 C+11 G20 
12  G7 C+12 G21 
13  G8 / G22 
14  G9 P1 G23 
15  P2  St  St 
B. 
A. 
C. 
 1    2    3    4    5    6    7    8    9      10       11    12    13     14      15 
 1   2    3    4     5    6    7    8    9       10       11     12    13    14    15 
D.
 1    2   3   4     5    6    7    8    9    10     11    12      13    14     15  
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¾  the pDEST17 plasmid, has been acquired from the colonies BL21 Codon plus 110, 
from the colonies BL21 GOLD 7, 14, 23, and from the colony BL21 pLys 7, showing 
an over-expressed band of around 13.4 kDa; 
¾  the pDEST15 plasmid has been acquired from the colonies BL21 Codon plus 2, 12 
and from the colonies BL21 GOLD 11, 12, 13, showing an over-expressed band of 
around 35 kDa; 
¾  the pETG20A plasmid has been acquired from the colonies BL21 Codon plus 7, 8, 11, 
showing an over-expressed band of around 26 kDa; 
¾  the pETG30A plasmid has been acquired from the colony BL21 pLys 2, showing an 
over-expressed band of around 38 kDa; 
¾  finally, the pETG60A plasmid has been acquired from the colony BL21 Codon plus 3, 
showing an over-expressed band of around 68 kDa, disposed between the two bands 
of the standard with MW respectively of 116 kDa and 66.2 kDa. 
The results of the expression screening of SH3 adapter protein SPIN90 protein are 
summarized in table 4.13. 
 
  pDEST15  pDEST17  pETG20A  pETG30A  pETG60A 
Codon 
plus  
2,12  10 7,8,11  /  3 
GOLD   11,12,13  7,14,23  / /  / 
pLys  /  7  /  2  / 
 
Tab. 4.13 Results of the SH3 adapter protein SPIN90 expression screening. The number in red refer to the 
colonies that were selected to perform the solubility screening (paragraph 4.5). 
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D.
4.4.9 Expression screening of the C-terminal domain Tuberous sclerosis 2 protein 
TSC2_HUMAN, aa 1531 – 1758, (TSC2-228)  
 
The expression of the TSC2-228 protein in three E.coli BL21 host strains (Codon plus, Plys 
and Gold) was verified by SDS-PAGE as described in paragraph3.7. In the figure 4.12 the 
gels concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.12 SDS-PAGE of the expression of TSC2-228 protein in different E.coli strains. Page B (lines 13-15), C 
and D (lines 1-8): expression in Codon plus. Page A and B (lines 1, 3-12): expression in GOLD. In page D is 
reported the expression in Plys (lines 9-11, 13-15). The samples loaded in each line are classified with a letter, 
corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), and a number, given to each 
colony, as showed in table E. The Low Range standard in all gels, contains six proteins with known molecular 
weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
From the observation of the gels in figure 4.12, it is possible to notice that many samples 
show an over-expressed band with  a specific molecular weight. Comparing the MW of this 
band, with the hypothetical MW of the recombinant protein TSC2 calculated as described in 
 A B C  D 
1  G1 G15  C+17  C+18 
2  G2  St  C+4 C+19 
3  G3 G16 C+5 C+20 
4  G4 G17 C+6 C+21
5  G5 G18 C+7 C+22
6  G6 G19 C+8 C+23
7  G7 G20 C+9 C+24
8  G8 G21  C+10  C+25
9  G9  G22  St  p1 
10  G10  G23  C+11 p2 
11  G11  G24  C+12 p3 
12  G12  G25  C+13  St 
13  G13 C+1 C+14  P4 
14  G14 C+2 C+15  P5 
15  St  C+3 C+16  P6 
A. 
E.
C. 
B. 
  1   2    3   4   5    6   7    8   9   10     11   12     13    14     15 
  1   2   3    4   5   6   7   8    9   10     11   12     13    14     15 
  1   2   3   4    5   6   7    8   9   10     11   12     13    14     15    1   2   3   4    5   6   7    8   9   10     11   12     13    14     15  
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table 4.5, it is possible to deduce which plasmid has been acquired from each colony. The 
results of this screening can be summarized as follow: 
¾  any colony has acquired the pDEST15 plasmid, since any bands with MW compatible 
with the recombinant protein can be observed on the gel.  
¾  the pDEST17 plasmid has been acquired from all the colonies BL21 Codon plus, from 
the colony BL21 GOLD 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and  from the 
colonies BL21 pLys 4 and 5, showing an over-expressed band of around 30 kDa; 
¾  the pETG20A plasmid has been acquired from the colony BL21 GOLD 6 and from the 
colony BL21 plys 1, showing an over-expressed band of around 45 kDa;  
¾  the pETG30A plasmid has been acquired from the colony BL21 GOLD 19 and from 
the colonies BL21 plys 3 and 6, showing an over-expressed band of around 45 kDa; 
¾  finally, any colony has acquired the pETG-60A plasmid, since any bands with MW 
compatible with the recombinant protein can be observed on the gel. 
The results of the expression screening of TSC2-228 protein are summarized in table 4.14. 
 
  pDEST15 pDEST17  pETG20A  pETG30A  pETG60A 
Codon 
plus  
/ 
1,2,3,4,5,6,7,8,9,10,11,12
,13,14,15,16,17,18 
19,20,21,22,23,24,25 
/ / / 
GOLD   / 
2,3,4,5,7,8,9,1011, 
12,13,14,15 
6 19 / 
pLys  /  4,5  1 3,6 / 
 
Tab. 4.14 Results of the TSC2-228 expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5). 
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4.4.10 Expression screening of the protein Hippocalcin  
 The expression of the Hippocalcin protein in three E.coli BL21 host strains (Codon plus, 
Plys and Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the figure 4.13 
the gels concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13 SDS-PAGE of the expression of Hippocalcin protein in different E.coli strains. Page A (lines 1-13),: 
expression in Plys. Page A (line 15), B  (lines 1-14) and C(lines 1-5): expression in Codon plus. In page C (lines 
7-15) and D (lines 1-8, 12-14):  is reported the expression in GOLD. The samples loaded in each line are 
classified with a letter, corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), and a 
number, given to each colony, as showed in table E. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
From the observation of the gels in figure 4.13, it is possible to notice that many samples 
show an over-expressed band with  a specific molecular weight. Comparing the MW of this 
band, with the hypothetical MW of the recombinant protein Hippocalcin calculated as 
 A B C  D 
1  p1 C+2  C+16  G10 
2  p2 C+3  C+17  G11 
3  p3 C+4  C+18  G12 
4  p4 C+5  C+19  G13 
5  p5 C+6  C+1  G14
6  p6 C+7 St  G15
7  p7 C+8 G1  G16
8  p8 C+9 G2  G17
9  p9 C+10 G3  / 
10  p10 C+11 G4  / 
11  p11 C+12 G5  / 
12  p12 C+13 G6 G18
13  p13 C+14 G7 G19
14  St  C+15 G8 G20
15  C+20  St  G9  St 
1    2     3     4     5      6      7      8      9    10    11  12   13   14  15 
A. 
B. 
C. 
D.
E.
1     2      3      4      5       6     7     8      9     10     11   12   13   14   15 
 1     2      3      4      5      6     7     8      9     10     11   12   13   14   15 
 1     2      3      4      5      6     7     8      9     10     11   12   13   14   15  
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described in table 4.5, it is possible to deduce which plasmid has been acquired from each 
colony. The results of this screening can be summarized as follow: 
¾  the pDEST17 plasmid has been acquired from the colonies BL21 Codon plus 4, 8, 9, 
10, 12,13, 14, 19, from the colonies BL21 GOLD 1, 3, 8, 9, 12, 13, 14, 19 and  from 
the colonies BL21 pLys 8, 4, 5 and10, showing an over-expressed band of around 27 
kDa; 
¾  the pETG20A plasmid has been acquired from the colonies BL21 Codon plus 3, 7, 1 
and from the colony BL21 GOLD 20, showing an over-expressed band of around 40 
kDa;  
¾  the pETG30A plasmid has been acquired from the colonies BL21 GOLD 2, 4, 11, 
showing an over-expressed band of around 51 kDa; 
¾  the pETG-60A plasmid, has been acquired from the colony Codon plus 2, showing an 
over-expressed band of around 80 kDa; 
The results of the expression screening of Hippocalcin protein are summarized in table 4.15. 
 
  pDEST17  pETG20A  pETG30A  pETG60A 
Codon plus  4,8,9,10,12,13,14, 19  3,7,1 /  2 
GOLD   1,3,8,9,12,13,14,19  20 2,4,11 / 
pLys  8,4,5,10 /  /  / 
 
Tab. 4.15 Results of the Hippocalcin expression screening. The number in red refer to the colonies that were 
selected to perform the solubility screening (paragraph 4.5). 
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4.4.11 Expression screening of a fragment of the BIR3-NAIP protein, aa 278-344  
The expression of the Bir 3  protein in three E.coli BL21 host strains (Codon plus, Plys and 
Gold) was verified by SDS-PAGE as described in paragraph 3.7. In the figures 4.14 the gels 
concerning the expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.14 SDS-PAGE of the expression of BIR3-NAIP fragment protein in different E.coli strains. Page A (lines 
1-9): expression in gold. Page A (line 11-15), B  (lines 1-13, 15): expression in Codon plus. In page C (lines 1-6, 
8-15) and D (lines 1-6, 8):  is reported the expression in plys. The samples loaded in each line are classified with 
a letter, corresponding to the initial of the host strain (C+= Codon plus, G= Gold, p= pLys), and a number, given 
to each colony, as showed in table E. The Low Range standard in all gels, contains six proteins with known 
molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
 
 
 A B C D 
1  G12 C+6  p1  P15 
2  G13 C+7  p2  P16 
3  G14 C+8  p3  P17 
4  G15 C+9  p4  P18 
5  G16 C+10  p5  P19 
6  G17 C+11  p6  P20 
7  G18 C+12  St  St 
8  G19 C+13  p7  C+20 
9  G20 C+14  p8   
10  St  C+15 p9   
11  C+1 C+16 p10   
12  C+2 C+17 p11  
13  C+3 C+18 p12  
14  C+4  St  p13   
15  C+5 C+19 p14   
1   2    3    4   5   6   7   8  9    10    11   12    13    14     15 
C. 
A. 
B. 
D.
 1     2      3      4      5      6     7     8      9     10     11   12   13   14   15 
 1     2      3      4      5      6     7     8      9     10     11   12   13   14   15 
 1      2      3      4      5      6      7      8      
E.  
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From the observation of the gels in figure 4.14, it is possible to notice that many samples 
show an over-expressed band with  a specific molecular weight. Comparing the MW of this 
band, with the hypothetical MW of the recombinant protein Bir3 calculated as described in 
table 4.5, it is possible to deduce which plasmid has been acquired from each colony. The 
results of this screening can be summarized as follow: 
The results of the expression screening of BIR3-NAIP fragment  protein are summarized in 
table 4.16. 
 
  pDEST17  pETG20A  pETG30A  pETG60A 
Codon plus   20,17  7 14  / 
GOLD   9,10,12,15,18,19  13 8 / 
pLys  15,20,5,6,9  /  / / 
 
Tab. 4.16 Results of the BIR3-NAIP fragment expression screening. The number in red refer to the colonies that 
were selected to perform the solubility screening (paragraph 4.5). 
 
 
 
 
 
 
 
 
 
4.5 PROTEIN SOLUBILITY SCREENING 
After the analysis of the protein expression on SDS-PAGEs, we have made a solubility test 
for each colony to verify if the proteins were expressed in inclusion bodies or in soluble form 
(paragraph 3.8). For each recombinant protein, at least a colony for type of host strain and for 
type of destination vector were selected. Such colonies are highlighted in red in the table 
4.6,7,8,9,10,11,12,13,14,15,16. 
The proteins solubility was checked by SDS-page verifying the presence of the protein in the 
soluble fraction (S.F.) or in the inclusion bodies (I.B.), loaded in adjacent lines. 
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C.
1   2    3   4   5   6    7    8   9    10     11    12    13    14    15 
 1   2    3   4   5    6    7    8    9     10     11    12    13    14    15 
    1     2      3       4       5      6      7      8       9      10      
B.
A.
4.5.1 Solubility screening of the protein S100A2  
The figure 4.15 shows the SDS-page concerning the solubility screening of the  protein 
S100A2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.15 Solubility screening of the protein S100A2. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
The S100A2 protein was expressed in an insoluble form by all the colonies. Only the colony 
pLys 13 (figure 4.15 page A, line 14-15 selected in yellow) expressed the 30% of the protein 
in a soluble form, fused with NusA+(His)6 tag.  
 A  B  C 
1  st   st  st  
2  P19 ( S.F .)  P14 ( S.F .)  G2 (S.F.) 
3  P19 (I.B.)  P14 (I.B.)  G2 (I.B.) 
4  P7 (S.F.)  P22 (S.F.)  G12 (S.F.) 
5  P7 (I.B.)  P22 (I.B.)  G12 (I.B.) 
6  P16 (S.F.)  C+16 (S.F.)  G5 (S.F.) 
7  P16 (I.B.)  C+16 (I.B.)  G5 (I.B.) 
8  P21 (S.F.)  C+23 (S.F.)  G16 (S.F.) 
9  P21 (I.B.)  C+23 (I.B.)  G16 (I.B.) 
10  P23 (S.F.)  G8 (S.F.)  / 
11  P23 (I.B.)  G8 (I.B.)  / 
12  P9 (S.F.)  G1 (S.F.)  / 
13  P9 (I.B)  G1 (I.B.)  / 
14  P13 (S.F.)  /  / 
15  P13 (I.B.)  /  /  
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 1      2     3     4       5      6     7       8       9    
 1   2    3  4   5   6    7    8   9    10     11    12    13    14    15 
 1   2   3   4   5    6    7    8   9    10      11    12    13    14    15 
 A. 
B. 
 C. 
4.5.2 Solubility screening of the protein S100A16  
The figure 4.16 hows the SDS-page concerning the solubility screening of the  protein 
S100A16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.16  Solubility screening of the protein S100A16. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
Observing the gels in figure 4.16, it’s possible to note that the colonies pLys 12, GOLD 16, 
GOLD 10 and pLys 5 express the protein partially in a soluble form (lines selected in blue). In 
fact, the protein’s band is visible in both the fractions. In particular, the colonies pLys 12 and 
pLys 5 express the protein fused with the NusA+(His)6 fusion tag (line 13-14 page A, line 3-4 
page C), the colony GOLD 16 expresses the protein fused with the TrxA+(His) 6tag (line 12-
13 page B), while the colony  GOLD 10 expresses the protein fused with the GST+ (His) 6tag 
(line 14-15 page B).  
 A  B  C 
1  C+19 (S.F.)  C+7 (S.F.)  G5 (S.F.) 
2  C+19 (I.B.)  C+7 (I.B.)  G5 (I.B.) 
3  C+25 (S.F.)  st  p12 (S.F.) 
4  C+25 (I.B.)  C+17 (S.F.)  p12 (I.B.) 
5  P6 (S.F.)  C+17 (I.B.)  C+3 (S.F.) 
6  P6 (I.B.)  C+22 (S.F.)  C+3 (I.B.) 
7  P14 (S.F.)  C+22 (I.B.)  p22 (S.F.) 
8  P14 (I.B.)  G6 (S.F.)  p22 (I.B.) 
9  P15 (S.F.)  G6 (I.B)  st 
10  P15 (I.B.)  G11 (S.F.)  / 
11  G4 (S.F.)  G11 (I.B.)  / 
12  G4 (I.B.)  G16 (S.F.)  / 
13  P5 (S.F.)  G16 (I.B.)  / 
14  P5 (I.B..)  G10 (S.F.)  / 
15  st   G10 (I.B.)  /  
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A
B. 
   1   2     3    4   5    6    7    8    9    10     11     12    13    14     15 
   1    2    3    4    5    6   7    8   9     10     11     
4.5.3 Solubility screening of the protein S100A10  
The figure 4.17 shows the SDS-page concerning the solubility screening of the  protein 
S100A10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.17 Solubility screening of the protein S100A10. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
Only the colony pLys 2 (figure 4.17 page A, line 7-8, selected in pink) express the protein, 
partially in a soluble form, fused with NusA+(His)6 tag.  
 
 A  B 
1  C+8(S.F.) P22  (S.F.) 
2  C+8(I.B.) P22  (I.B.) 
3  C+22 (S.F.)  G1 (S.F.) 
4  C+22 (I.B.)  G1 (I.B.) 
5  P1 (S.F.)  G4 (S.F.) 
6  P1 (I.B.)  G4 (I.B.) 
7  P2(S.F.) G10  (S.F.) 
8  P2 (I.B.)  G10 (I.B.) 
9  P11 (S.F.)  G22 (S.F.) 
10  P11 (I.B.)  G22 (I.B.) 
11  P21 (S.F.)  st 
12  P21 (I.B.)  / 
13  P7 (S.F.)  / 
14  P7 (I.B.)  / 
15  st   /  
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4.5.4 Solubility screening of the isoform α of the Endothelial differentiation-related 
factor 1 (EDF-1 iso α)  
 
The figure 4.18 shows the SDS-page concerning the solubility screening of the protein EDF-1 
iso α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.18  Solubility screening of the protein EDF-1 iso α. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Protein Molecular Weight Marker Standard in all gels, 
contains seven proteins with known molecular weight (11.6KDa, 66.2KDa,  45KDa, 35KDa, 25KDa, 18.4 KDa, 
14.4KDa). 
 
 
Observing the gels in figure 4.18 , it’s possible to note that all the colonies express the protein 
in inclusion bodies unless the colony GOLD 5, selected in yellow, expressing the protein 
partially in a soluble form fused with NusA+(His)6 tag.  
 
 A  B 
1  C+3 (I.B.)  st 
2  C+3 (S.F.)  G5 (I.B.) 
3  st  G5 (S.F.) 
4  C+4 (I.B.)  G10 (I.B.) 
5  C+4 (S.F.)  G10 (S.F.) 
6  C+5 (I.B.)  G12 (I.B.) 
7  C+5 (S.F.)  G12 (S.F.) 
8  C+16 (I.B.)  G19 (I.B.) 
9  C+16 (S.F.)  G19 (S.F.) 
10   P5  (I.B.) 
11   P5  (S.F.) 
12   P6  (I.B.) 
13   P6  (S.F.) 
14   P9  (I.B.) 
15    P9 (S.F.) 
A. 
 1     2     3   4     5     6     7    8     9      
 1    2    3    4     5    6      7    8     9       10        11      12      13     14      15 
B.  
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4.5.5 Solubility screening of the isoform β  of theEndothelial differentiation-related 
factor 1 (EDF-1 isoβ)  
 
The figure 4.19 shows the SDS-page concerning the solubility screening of the protein EDF-1 
isoβ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.19  Solubility screening of the EDF-1 isoβ protein. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
The figure 4 shows that all the colonies express the protein in inclusion bodies with the 
exception of the colony pLys 13 expressing the protein partially in a soluble, form fused with 
GST+(His)6 tag.  
 
 A  B  C 
1  st  st  G7 (S.F.) 
2  G1 (I.B.)  G5 (S.F.)  G7 (I.B.) 
3  G1 (S.F.)  G5 (I.B)  st 
4  G2 (I.B.)  G6 (S.F.)  G15 (S.F.) 
5  G2 (S.F.)  G6 (I.B)  G15 (I.B.) 
6  G4 (I.B.)  G8 (S.F.)  P18 (S.F.) 
7  G4 (S.F.)  G8 (I.B)  P18 (I.B.) 
8  C+2 (I.B.)  G9 (S.F.)  C+11 (S.F.) 
9  C+2 (S.F.)  G9 (I.B)  C+11 (I.B.) 
10  C+10 (I.B.)  G3 (S.F.)  / 
11  C+10 (S.F.)  G3 (I.B)  / 
12  P12 (I.B.)  G18 (S.F.)  / 
13  P12 (S.F.)  G18 (I.B.)  / 
14  P13 (I.B.)  G20 (S.F.)  / 
15  P13 (S.F.)  G20 (I.B.)  / 
B. 
C. 
 1   2    3   4    5     6   7    8   9      /                                       / 
 1   2   3   4   5     6   7    8   9      10     11    12     13    14     15 
   1    2   3   4   5    6   7   8   9     10    11   12     13    14      15 
A. 
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4.5.6 Solubility screening of a fragment of the Cyclin-dependent kinase inhibitor, aa 1-
160, (P21-160)  
 
The figure 4.20 shows the SDS-page concerning the solubility screening of the  P21-160 
protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.20  Solubility screening of the protein P21-160. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Protein Molecular Weight Marker Standard used is 
composed of even proteins with known molecular weight (11.6KDa, 66.2KDa,  45KDa, 35KDa, 25KDa, 18.4 
KDa, 14.4KDa). 
 
All the colonies express the protein in inclusion bodies, as showed in figure 4.20. The protein 
bands are coherent with the expression screening. 
 A  B 
1  C+3 (I.B.)  st 
2  C+3 (S.F.)  G4 (I.B.) 
3  C+4 (I.B.)  G4 (S.F.) 
4  C+4 (S.F.)  G8 (I.B.) 
5  C+6 (I.B.)  G8 (S.F.) 
6  C+6 (S.F.)  G11(I.B.) 
7  C+11 (I.B.)  G11 (S.F.) 
8  C+11 (S.F.)  G13 (I.B) 
9  st  G13 (S.F.) 
10   P9  (I.B.) 
11   P9  (S.F.) 
12    P13(I.B.) 
13    P13 (S.F.) 
14    P14 (I.B.) 
15    P14 (S.F.) 
A. 
  1     2    3    4    5   6   7     8    9       10       11      12       13       14        15 
    1            2          3          4         5         6       7        8      9 
B.  
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4.5.7 Solubility screening of a fragment of the Cyclin-dependent kinase inhibitor 1 (P21), 
aa 25-164,  (P21-140)  
 
The figure 4.21 shows the SDS-page concerning the solubility screening of the protein P21-
140. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.21  Solubility screening of the protein P21-140. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
All the colonies express the protein in inclusion bodies, as showed in figure 4.21. The protein 
bands are coherent with the expression screening. 
 
 A  B  C 
1  P1 (I.B.)  C+18(I.B.)  G8 (I.B) 
2  P1 (S.F.)  C+18(S.F.)  G8 (S.F.) 
3  P3 (I.B.)  C+9 (I.B.)  G4 (I.B) 
4  P3 (S.F.)  C+9 (S.F.)  G4 (S.F.) 
5  G17 (I.B.)  C+8 (I.B.)  G11 (I.B) 
6  G17 (S.F.)  C+8 (S.F.)  G11 (S.F.) 
7  G9 (I.B.)   C+10 (I.B.)  G12 (I.B) 
8  G9 (S.F.)  C+10 (S.F.)  G12 (S.F.) 
9  G3 (I.B.)  C+19 (I.B.)  st 
10  G3 (S.F.)  C+19 (S.F.)   
11  G7 (I.B.)  C+5 (I.B.)   
12  G7 (S.F.)  C+5 (S.F.)   
13  st  st   
B. 
   1    2   3    4    5     6    7     8    9      10      11     12     13     
     1     2     3   4   5   6   7    8   9     10     11  12     13  
  1   2    3    4    5     6   7     8    9       
A
C.  
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4.5.8 Solubility  screening of a fragment of the SH3 adapter protein SPIN90, aa 1-81, 
(SH3-81)   
 
The figure 4.22 shows the SDS-page concerning the solubility screening of the SH3-81. All 
the colonies express the protein in inclusion bodies. The protein bands are coherent with the 
expression screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22  Solubility screening of the protein SH3-81. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. The Low Range standard in all gels, contains six proteins 
with known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
All the colonies express the protein in inclusion bodies, as showed in figure 4.22. The protein 
bands are coherent with the expression screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A  B 
1  / P2  (I.B.) 
2  st  P2 (S.F.) 
3  C+10 (I.B.)  C+3 (I.B.) 
4  C+10 (S.F.)  C+3 (S.F.) 
5  P7 (I.B.)  C+7 (I.B.) 
6  P7 (S.F.)  C+7 (S.F.) 
7  G7 (I.B.)  C+12 (I.B.) 
8  G7 (S.F.)  C+12 (S.F.) 
9  G14 (I.B.)  G13 (I.B.) 
10  G14 (S.F.)  G13 (S.F.) 
11  G23 (I.B.)  st 
12  G23 (S.F.)   
 1      2        3      4      5       6      7       8       9   10   11    12    
 1      2       3    4      5       6     7      8      9    10    11       
A. 
B.  
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4.5.9 Solubility screening of the C-terminal domain of the Tuberous sclerosis 2 protein 
TSC2_HUMAN, aa 1531 – 1758, (TSC2-228)  
 
The figure 4.23 shows the SDS-page concerning the solubility screening of the protein TSC2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.23  Solubility screening of the protein TSC2. For each sample, the soluble fraction (S.F.) and the inclusion 
bodies (I.B.) were loaded in adjacent lines. Low Range standard in all gels, contains six proteins with known 
molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
All the colonies express the protein in inclusion bodies, as showed in figure 4.23. The protein 
bands are coherent with the expression screening. 
 A  B 
1  G6 (I.B.)   C+4 (I.B.) 
2  G6 (S.F.)  C+4 (S.F.) 
3  G19 (I.B.)  st 
4  G19 (S.F.)  C+18 (I.B.) 
5  G15 (I.B.)  C+18 (S.F.) 
6  G15 (S.F.)  P3 (I.B.) 
7  G13 (I.B.)  P3 (S.F.) 
8  G13 (S.F.)  P6 (I.B.) 
9  G8 (I.B)  P6 (S.F.) 
10  G8 (S.F.)  P1 (I.B.) 
11  C+1 (I.B.)  P1 (S.F.) 
12  C+1 (S.F.)  P4 (I.B.) 
13  st  P4 (S.F.) 
A. 
B. 
 1      2       3      4     5     6      7       8       9   10   11    12    13 
 1      2       3      4     5     6      7       8       9   10   11    12    13  
100 
4.5.10 Solubility screening of protein Hippocalcin  
The figure 4.24 shows the SDS-page concerning the solubility screening of the  protein 
Hippocalcin. Besides to the soluble fraction and the inclusion bodies, in figure 4.24 the 
unbroken cells were loaded, too.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.24  Solubility screening of the protein Hippocalcin. For each sample, the soluble fraction (S.F.) and the 
inclusion bodies (I.B.) were loaded in adjacent lines. Low Range standard in all gels, contains six proteins with 
known molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
All the colonies express the protein in inclusion bodies, as showed in figure 4.24. The protein 
bands are coherent with the expression screening. 
 
 A  B 
1  st  C+ 2 
2  G8 C+2(I.B.) 
3  G8 (I.B.)   C+2 (S.F.) 
4  G8 (S.F.)  st 
5  C+4 C+3 
6  C+4 (I.B.)  C+3(I.B.) 
7  C+4 (S.F.)  C+3(S.F.) 
8  P3 G8 
9  P3 (I.B.)  G8 (I.B.)  
10  P3 (S.F.)  G8 (S.F.) 
A. 
B. 
1     2   3   4    5   6   7    8    9     10 
1    2    3     4    5     6    7     8    9   10  
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4.5.11 Solubility screening of a fragment of the BIR3-NAIP protein, aa 278-344 
The figure 4.25 shows the SDS-page concerning the solubility screening of the BIR3  protein. 
Besides to the soluble fraction and the inclusion bodies, in figure 4.25 the unbroken cells were 
loaded too. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.25  Solubility screening of the Bir3 protein. For each sample, the soluble fraction (S.F.) and the inclusion 
bodies (I.B.) were loaded in adjacent lines. Low Range standard in all gels, contains six proteins with known 
molecular weight (97.4KDa, 66.2KDa,  45KDa, 31KDa, 21.5KDa, 14 KDa). 
 
 
All the colonies express the protein in inclusion bodies, as showed in figure 4.25. The protein 
bands are coherent with the expression screening. 
 
 A  B  C 
1  G18 G13  C+14 
2  G18 (I.B.)   G13 (I.B.)   C+14 (I.B.) 
3  G18 (S.F.)  G13 (S.F.)  C+14 (S.F.) 
4  st  C+ 7   
5  P15  st   
6  P15 (I.B.)  C+7 (I.B.)   
7  P15 (S.F.)  C+7(S.F.)   
8  C+ 20  G8   
9  C+20 (I.B.)  G8 (I.B.)    
10  C+20 (S.F.)  G8 (S.F.)   
B. 
 1       2     3     4     5     6    7     8    9  10 
 1       2     3     4     5    6    7     8   9  10 
A. C.
1       2     3       4  
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4.5.12 Expression and solubility screening results  
In the table 4.17 the expression and solubility screening results are summarized. 
 
Tab. 4.17 Expression and solubility screening results. For each sample, the E.coli host strains (Plys, Codon, 
Gold) which express the proteins with the different destination vectors are indicated. S.F.: soluble fraction; 
I.B.:inclusion bodies. 
 
As showed in table 4.17, all the selected proteins were well expressed with almost three of the 
five fusion tags in all E. coli host strains. Moreover, from the solubility screening, it results 
that the calmodulin targets proteins were expressed in inclusion bodies by all the host strains 
with an only one exception, the protein endothelial differentiation-related factor1 (EDF-1). 
On the contrary, there is a large variability in the solubility of the EF-hand proteins; in fact, in 
most cases, the proteins were produced in inclusion bodies and only with few tags, different 
Expression 
screening 
Solubility 
screening  Protein 
category  Protein Name  pDEST
-17 
pDEST
-15 
pETG-
20A 
pETG-
30A 
pETG-
60A  S.F  I.B. 
Endothelial differentiation-
related  factor 1 ISO-α    
Plys 
Codon 
Gold 
Plys 
Codon 
Gold 
Plys 
Codon 
Gold 
x x 
Endothelial differentiation-
related  factor 1 ISO-β     Codon 
Gold 
Plys  
Gold 
Plys 
Codon 
Gold 
x x 
Cyclin-dependent Kinase 
inhibitor 
1(P21) fragment 1-160 aa 
Plys 
Codon 
Gold 
/  Plys  
Gold 
Codon 
Gold 
Plys 
Codon 
Gold 
 x 
Cyclin-dependent Kinase 
inhibitor1  
(P21) fragment 25-164 aa 
  Codon 
Gold 
Codon 
Gold 
Codon 
Gold 
Plys 
Codon 
Gold 
 x 
SH3 adapter protein SPIN 90 
 722 aa, fragment 1-81 aa 
Plys 
Codon 
Gold 
Codon 
Gold 
Codon 
 
Plys  
 
Codon 
 
 x 
calmodulin 
targets 
Tuberous sclerosis TSC2  
C-terminale domain, 1531-
1758aa 
Plys 
Codon 
Gold 
  Plys  
Gold 
Plys  
Gold   
 x 
S100A2 
 
Plys 
Codon 
Gold 
 
Plys 
Codon 
Gold 
Plys  Plys 
Gold 
x x 
S100A16 
 
Plys 
Codon 
Gold 
  Codon 
Gold 
 
Gold 
 
Plys 
x x 
S100A10 
  Gold 
   
Plys 
Codon 
Gold 
Codon 
Plys  Plys 
x x 
EF-Hands 
Hippocalcin 
 
Plys 
Codon 
Gold 
/  Codon 
Gold  Gold  Codon 
 
 x 
Hippocalcin 
target 
BIR3-NAIP fragment 278-344 
aa 
Plys 
Codon 
Gold 
/  Codon 
Gold 
Codon 
Gold   
 x  
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for each protein, were expressed in soluble form (S100A2  fused with NusA+(His)6 tag; 
S100A16 fused with the NusA+(His)6  fusion tag, TrxA+(His)6  tag and GST+(His)6  tag; 
S100A10 fused with NusA+(His)6 tag). This result is very important for the successive 
protein purification steps on a larger scale. In fact, a soluble protein, fused with a specific 
affinity tag could be easily purified using a few chromatographic passages. 
 
 
4.6 SEQUENCING 
Before the large scale protein production, the selected plasmids were sequenced to confirm 
the correct insertion of the genes. The sequencing was performed by PRIMM laboratory in 
Milan. The sequencing results confirmed that the sequence of all samples was correct.  
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4.7  CLONING, PRODUCTION AND PURIFICATION OF Calmodulin like to skin 
protein (CLSP)   
 
CLSP is a 146 residue (15.92 kDa) protein that shares 49% of identity with CaM. At variance 
with the ubiquitous CaM, CLSP is reported to be expressed only in epithelial cells, where it 
may be involved in the Ca
2+-dependent differentiation process of keratinocytes to 
corneocytes. Particularly, it is expressed at very late stages of differentiation just underneath 
the stratum corneum and is considered to play an important role in this process (Babini et al., 
2005). The characteristic of the protein and his domains are reported in the table 4.18. 
  
>Q9NZT1|CALL5_HUMAN Calmodulin-like protein 5 - Homo sapiens (Human) 
MAGELTPEEEAQYKKAFSAVDTDGNGTINAQELGAALKATGKNLSEAQLRKLISEVDSDG 
DGEISFQEFLTAARKARAGLEDLQVAFRAFDQDGDGHITVDELRRAMAGLGQPLPQEELD 
AMIREADVDQDGRVNYEEFARMLAQE 
 
Number of amino acids: 146 
Molecular weight: 15920.5 
Theoretical pI: 4.34 
Amino acid composition: 
Ala (A)  21   14.4% 
Arg (R)   9    6.2% 
Asn (N)   4    2.7% 
Asp (D)  14    9.6% 
Cys (C)   0    0.0% 
Gln (Q)  10    6.8% 
Glu (E)  17   11.6% 
Gly (G)  13    8.9% 
His (H)   1    0.7% 
Ile (I)   5    3.4% 
Leu (L)  14    9.6% 
Lys (K)   6    4.1% 
Met (M)   4    2.7% 
Phe (F)   6    4.1% 
Pro (P)   3    2.1% 
Ser (S)   5    3.4% 
Thr (T)   6    4.1% 
Trp (W)   0    0.0% 
Tyr (Y)   2    1.4% 
Val (V)   6    4.1% 
Asx (B)   0    0.0% 
Glx (Z)   0    0.0% 
Xaa (X)   0    0.0% 
 
Total number of negatively charged residues (Asp + Glu): 31 
Total number of positively charged residues (Arg + Lys): 15 
Formula: C682H1085N195O236S4 
Total number of atoms: 2202 
 
FT   DOMAIN             8-43        EF-hand 1. 
FT   DOMAIN            44-77        EF-hand 2. 
FT   DOMAIN           78-113        EF-hand 3. 
FT   DOMAIN          114-146        EF-hand 4. 
Tab. 4.18 Principal chemical and physical characteristics of CLSP.  
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The protein is highly homologus to calmodulin but the differences in the sequence are 
sufficient to impose a very different structure. The structure of the protein expressed in E.coli 
wasn’t resolved by NMR, since the N-terminal domain is highly flexible. Consequently we 
have decided to produce the two domains separately. The cloning of CLSP and his N-terminal 
and C-terminal domains was conduced using the standard protocol as described in the 
following chapter. 
 
4.7.1 Amplification and Cloning of the gene and DNA fragments coding for CLSP and 
for  its N-terminal (N-CLSP) and C-terminal (C-CLSP) domains 
 
The nucleotide sequence coding for human Calmodulin like to skin protein (CLSP)  was 
amplified from cDNA by PCR using the primers oCLSPFor and oCLSPRev, whose sequence 
is reported in table 4. The amplified fragment of 441 bp was purified from agarose gel and 
blunt-end ligated into the expression vector pQE30Xa (QIAGEN) at the StuI site. The 
sequence of the gene in the plasmid pQE-CLSP so far obtained, was confirmed by single run 
sequencing  using standard forward and  reverse primers for pQE30Xa, which was performed 
at Primm Biotech. 
 
Primer for amplification of the gene coding for the full length CLSP protein 
oCLSPFor [forward]  5’ATGGCCGGTGAGCTGACTCCT 3’ 
oCLSPRev [reverse]  5’TCACTCCTGGGCGAGCATCCT 3’ 
 
Primer for amplification of the DNA fragment coding for the N-terminal CLSP 
domain (M1 – A76) 
 
oNCLSPFor [forward]  5’ ATGGCCGGTGAGCTGACTCCT 3’ 
oNCLSPRev [reverse]  5’ TCAGGCCTTCCTTGCCGCCGT 3’ 
 
Primer for amplification of the of the DNA fragment coding for the C-terminal CLSP 
domain (A76 - E146) 
 
oCCLSPFor [forward]  5’ GCCAGGGCCGGCCTGGAGGAC 3’ 
oCCLSPRev [reverse]  5’ TCACTCCTGGGCGAGCATCCT 3’ 
 
Tab. 4.19 Sequences of the primers used to amplify the genes coding for CLSP and its N-terminal and C-
terminal domains. 
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The DNA fragments coding for the N–terminal CLSP domain (N-CLSP, corresponding to the 
CLSP sequence from M1 to A76) and C–terminal CLSP domain (C-CLSP corresponding to 
the CLSP sequence from A76 to E146), were sub-cloned from plasmid pQE-CLSP using the 
primers described in table 1 for PCR amplification of pQE-CLSP. After extraction from 
agarose gel the fragments (of 231 bp and 216 bp respectively) were ligated to the pQE30Xa 
plasmid at the StuI site, and the constructs (pQE-NCLSP and pQE-CCLSP) were sequenced 
as described for the full length gene (Babini et al, 2006). The DNA fragments coding for 
CLSP and the N–terminal CLSP domain were amplified by PCR using TAQ Polymerase to 
verify the correct insertion of the genes in the vector. In the figure 4.26 the agarose gel of the 
amplified fragments is reported.  
 
 
 
 
 
 
 
 
 
Fig. 4.26 Agarose gels concerning the amplification of the plasmidic fragments obtained using the primer 
reported in table 4.23. CLSP (line 1, 3). N–terminal CLSP domain (line 2, 4). C–terminal CLSP domain (line 5). 
Near the figure the used standard was reported. 
 
 
4.7.2 Expression of recombinant CLSP (rCLSP) and of its C-terminal (rC-CLSP) and N-
terminal (rN-CLSP) domains  
 
The host strain used for expression of recombinant CLSP, C-CLSP and N-CLSP in the vector 
pQE30Xa was E.coli XL1Blue. Cells containing pQE-CLSP,  pQE-CCLSP and pQE-NCLSP 
were grown in 3 liters of Luria Bertani medium (LB) at 37°C. Ampicillin (100 µg/ml) was 
added to the media as a selectable marker. After about 15 h from induction, cells were 
harvested by centrifugation. Protein expression was verified by SDS-PAGE as showed in 
figure 4.27. 
 
 
 
 
 1    2    3    4   5   St  
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Fig. 4.27: Page A: SDS-page concerning the expression of rCLSP (Line 1). Standard Protein Molecular Weight 
Marker (line 2). Page B: SDS-page concerning the expression of rC-CLSP (Line )1. Standard Protein Molecular 
Weight Marker (line 2). Page C: SDS-page concerning the expression of rN-CLSP (Line 1). Standard Low  
range (line 2). 
 
 
4.7.3 Purification of recombinant CLSP (rCLSP) and of its C-terminal (rC-CLSP) and 
N-terminal (rN-CLSP) domains 
 
The proteins rCLSP, rC-CLSP, rN-CLSP were expressed in soluble form, so the supernatant 
obtained from the crude extract, and containing the soluble recombinant protein, was applied 
to a chromatography column.  
The vector pQE30Xa allows the expression of the recombinant protein fused to an esa-
hystidine chain which can be removed by the enzyme FactorXa (Amersham). So, purification 
of the soluble rC-CLSP was made using the following steps:  
 
9  metal chelate affinity chromatography to purify the protein before the cleavage. The 
presence of the protein in the Hitrap eluted was confirmed by SDS-PAGE, as showed 
in figure 4.28. 
 
 
 
 
 
 
Fig. 4.28 SDS-page of rC-CLSP domain sample after the elution from Hitrap column (line 2, 3). 
Standard Low  range (line 1). 
 
9  cleavage with Factor Xa. For removal of the histidine tag, the purified fusion protein 
was dialysed in FactorXa cleavage buffer [20mM TrisHCl, 1 mM CaCl2, 100 mM 
B.
rCLSP
A. 
rC-CLSP 
C. 
rN-CLSP 
12 12 12
1      2      3  
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NaCl,  pH 8.0], concentrated to 5 ml and then digested with FactorXa for 15 hours at 
4°C.  
9  metal chelate affinity chromatography to isolate the protein from the tag detained on 
column and than eluited with 300mM Imidazol (line 4). In figure 4.29 the protein 
before the digestion (line 1), the cut (line 3) and the His6-tag (line4) were showed.  
 
 
 
 
 
 
 
 
 
 
Fig. 4.29 : SDS-page of rC-CLSP domain before the digestion (line 1). In line 3 was loaded the sample 
after Hitrap chromatography (line 3) and the His6-tag (line4). 
 
9  size exclusion chromatography  
9  anion exchange chromatography  
 
 
 
 
 
 
 
 
 
 
Fig. 4.30 : SDS-page of final purified rC-CLSP domain. 
 
  
Purified c-CLSP concentration was determined by measuring absorbance at 276 nm, using the   
extinction coefficient ε276  = 1450 M
-1cm
-1
,  as calculated  by ProtPar parameter tools 
(http://expasy.org/tools/protoaram.html). 
Purification of  rCLSP and rN-CLSP, both produced in a soluble form, required a 
denaturation refolding step on the nickel chelate column. Briefly, after loading the  His6-
tagged protein sample on the Hitrap column, a denaturation solution [50mM Tris  pH 8.0, 
  1      St     3       4 
12 
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200mM NaCl, 7M Guanidinium chloride] was passed through the column, for four hours at 
flow 0.5 ml/min. Guanidinium was slowly removed from the column by a 16 hours 
continuous gradient against [50mM Tris  pH 8.0, 200mM NaCl], to allow protein refolding. 
After elution of the protein from the Hitrap column the cleavage  and the other purification 
steps were the same used for the C-terminal domain. 
The concentrations of rCLSP and rN-CLSP were determined by measuring absorbance at 
276nm, using the respective extinction coefficient ε276 = 3400 M
-1cm
-1 for rCLSP
 ε276 = 1450 
M
-1cm
-1 for rN-CLSP (Babini et al., 2005). 
 
 
4.7.4 Preliminary screening of folding of CLSP (rCLSP) and of its C-terminal (rC-
CLSP) and N-terminal (rN-CLSP) domains 
 
The 1H-NMR spectrum of the whole CLSP protein is reported in figure 4.31, being the 
protein constituted by both the N-terminal and C-terminal domains. The presence of very few 
signals more downfield than 9.0 ppm and more upfield than 0.5 ppm indicates that the protein 
was not firmly structured. In fact, the signals above 9.0 ppm concern the NH amide groups 
which are not exchangeable with the solvent, because are well buried within the 
macromolecular frame. Only a compact structure avoids the access of solvent to sites inside 
the globular domains. On the contrary, flexible and opened structures permit the chemical 
exchanges of protons between all amide groups and water, resulting in the disappearing of 
signals belonging to the NH groups in the protein backbone. For what it concerns the signals 
below 0.5 ppm, they belong to methyl groups of hydrophobic sidechains, which usually are 
well embedded within the protein core, thus resulting in a deshielding of the respective nuclei 
that resonate at very low fields. Only immobile sidechains have hydrogen nuclei falling in 
such a region, since methyl groups belonging to aminoacids located in flexible parts of the 
protein have chemical shifts at around 1 ppm, e.g. in the most crowded area of the NMR 
spectrum of a protein.  
The protein unfolding implicates a major molecular flexibility that allows to the solvent to 
penetrate in proximity of all amidic groups and exchanges its own protons with them.  
Additionally, the presence of a whole ensemble of signals, appearing as a very broad bump in 
the range between 6.5 and 9.0 ppm indicates a lack of univocity for the amidic signals. This 
phenomenon is attributable to the fact that the observed protons are part of a very mobile 
regions of the molecule, not stabilized by hydrogen bonds or Van der Waals interactions, as 
usually found in well folded structures. This fact implicates some dispersion in the position of  
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the atom of amidic hydrogen which causes a "broadening" of the corresponding NMR signals. 
In other words, the NH protons of all aminoacids should fall all at the same chemical shift, 
but in the protein they experience a different environment, since the macromolecule 
constitutes an anisotropic medium. The result is that each NH proton has its own resolved 
position in the NMR spectra. When the protein is very flexible, the aminoacids behave as 
being free and not constrained to a specific position. For this reason their chemical shifts 
become similar to each other and all of them overlap in a very restricted area. The same 
information is easily verified by inspecting the 
1H-
15N-HSQC, a 2D spectrum, showing the 
scalar correlations between amidic nitrogens and the protons directly bound to them. 
Comments on the interpretations of such a spectrum will be given below.  
As mentioned before, the presence of methyl groups involved in the formation of hydrophobic 
patches produces 1H-NMR spectra characterized by the existence of signals below 0.5 ppm. 
In the spectrum reported in figure 4.47, only five signals could be recognized in such a region, 
having very low intensity, lower than that is expected from a so high concentration, as that for 
the protein sample used to record the present spectrum. The presence of these signals is 
compatible with a co-presence, in solution, of a small molar fraction of correctly folded 
protein together with a large fraction of unfolded protein.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.31: 1D-NMR spectrum of protein CLSP  
 
Another hypothesis is based on the fact that this molecule is constituted by a couple of 
domains tethered together by a linker. Thus, one domain may be characterized by a stable fold 
while the other one may have high flexibility. This hypothesis is based on the observation that  
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five methyl signals at about 0.5 ppm (each signal integrating three protons) have much 
smaller intensity than that of the signal falling at 6.6 ppm presumably due to a single proton.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.32 : 2D-HSQC NMR spectrum of CLSP protein. 
 
The spectrum shown in figure 4.32 is relative to a 
1H-
15N HSQC NMR experiment. This kind 
of spectrum has a higher resolving power (ability of discriminate between two signals) with 
respect to the 1D one, by increasing the number of dimensions on which each signals could be 
positioned.  This 2D spectrum is characterized by a correlation peak between the frequency of 
the amidic proton with that one of the amidic nitrogen bonded to it. Each correlation signal 
corresponds to one aminoacid, so that by counting all spots in this spectrum it is possible to 
get the protein sequence length. The inspection of the spectrum in figure 4.32 gives the 
following information: 
1) the sample has a high spectroscopic purity since all the signals have similar intensity. 
Aminoacidic impurities appear as signals with factionary intensity; 
2) many signals are grouped in a very restricted region of the spectrum. This implicates a 
reduced or absent anisotropy of their chemical environment. The latter is obtained only by a 
well defined structure. In the hypothetical case of a completely linear protein, the resultant 2D 
spectrum would be characterized by only one broad peak collecting all signals.  
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The present spectrum, instead, indicates the coexistence of two types of protons: one 
belonging to a flexible molecular region and the other one belonging to part of the molecule 
characterized by a rigid structure. 
The more reliable hypothesis concerning CLSP implicates a rigid structure for one domain 
and a flexible structure for the other one. To verify such a hypothesis, the two domains were 
separately expressed by applying the above described molecular biology techniques. 
The spectra recorded on the isolated C-terminal domain are reported in figure 4.33 (
1H-NMR) 
and in the figure 4.34 (
1H-
15N HSQC).  This domain shows spectra compatible with a rigid 
structure, since very intense methyl signals below 0.5 ppm, and well resolved amidic signals 
above 8.0 ppm are observable.  
The spectra of the isolated N-terminal domain are reported in figure 4.35 (
1H-NMR) and in 
the figure 4.36 (
1H-
15N HSQC). In the 
1H-NMR spectrum, the methyl signals are completely 
absent. Also the HSQC spectrum of the N-terminal domain presents grouped signals in two 
restricted regions, indicative of an isotropic environment which arises from a flexible domain. 
The N-terminal, however, is not purified in an unfolded state, since its 1H-NOESY spectrum 
shows cross-peaks indicative of the presence of secondary elements such as α-helices. 
Anyway, despite the presence of secondary structure, the N-terminal domain of CLSP could 
not be “photographed” by NMR. This result is indicative of high protein dynamism which, 
may be speculated, is strictly connected with its function (Capozzi et al, 2006). 
On the contrary, the C-terminal domain, whose structural characterization was subsequently 
performed, shows a spectrum with completely dispersed signals in the region of the amidic 
groups (Babini et al., 2006). This finding demonstrates a different structural behaviour of two 
domains of the same protein, sharing two identical structural motifs, both consisting of a 4-
helix bundle, but the N-terminal one with high flexibility, and the C-terminal one structurally 
ordered.  
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Fig. 4.33 1D-NMR spectrum of rC-CLSP domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.34 2D-HSQC NMR spectrum of rCc-CLSP domain. 
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Fig. 4.35: 1D-NMR spectrum of rN-CLSP domain. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.36 2D-HSQC NMR spectrum of r N-CLSP domain. 
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In the figure 4.37 the models of CLSP (A.) and of its N-terminal domain (C.) are reported. 
The models have been calculated by a colleague in our research group, on the basis of the 
available information. In figure 4.53 B, the NMR structure of the C-terminal domain, resolved 
by using the samples prepared in the present research project, is showed (2B1U PDB, Babini 
et al., 2006). The structure of the whole protein was calculated by merging the calculated 
structure of the N-terminal domain and that recorded on the C-terminal domain. The figure 
shows that the C-terminal domain (B.) is more compact, while the N-terminal domain permits 
only a few interactions among the aminoacids belonging to helix 1 and helix 3 (Babini et al., 
2006). For this reason, a more flexible domain was expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.37 A. Model calculated for the protein CLSP composed by four EF-hand motifs. The two globular 
domains, connected by a short flexible linker, are able to bind four calcium ions. B. NMR structure of C-terminal 
domain resolved by using the protein samples obtained in the present research project. C. A model calculated for 
the N-terminal domain of the same protein. 
 
A. 
B.  C.  
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4.8 PRODUCTION AND PURIFICATION OF RECOMBINANT S100A16 PROTEIN 
 
S100A16 protein is a new and unique member of the EF-hand Ca
2+-binding proteins. S100 
proteins are cell- and tissue-specific and are involved in many intra- and extracellular 
processes through interacting with specific target proteins. In the central nervous system S100 
proteins are implicated in cell proliferation, differentiation, migration, and apoptosis as well 
as in recognition. S100 proteins became of major interest because of their close association 
with brain pathologies, for example depression or Alzheimer’s disease (Cox JA et al, 2006). 
The amonoacidic sequence and composition is reported below. 
 
>Q96FQ6|S10AG_HUMAN Protein S100-A16 - Homo sapiens (Human) 
MSDCYTELEKAVIVLVENFYKYVSKYSLVKNKISKSSFREMLQKELNHMLSDTGNRKAAD 
KLIQNLDANHDGRISFDEYWTLIGGITGPIAKLIHEQEQQSSS 
 
Number of amino acids: 103 
Molecular weight: 11801.4 
Theoretical pI: 6.28 
 
Amino acid composition: 
Arg (R)   3   2.9% 
Asn (N)   6   5.8% 
Asp (D)   6   5.8% 
Cys (C)   1   1.0% 
Gln (Q)   5   4.9% 
Glu (E)   8   7.8% 
Gly (G)   5   4.9% 
His (H)   3   2.9% 
Ile (I)   8   7.8% 
Leu (L)  10   9.7% 
Lys (K)  10   9.7% 
Met (M)   3   2.9% 
Phe (F)   3   2.9% 
Pro (P)   1   1.0% 
Ser (S)  11  10.7% 
Thr (T)   4   3.9% 
Trp (W)   1   1.0% 
Tyr (Y)   5   4.9% 
Val (V)   5   4.9% 
Asx (B)   0   0.0% 
Glx (Z)   0   0.0% 
Xaa (X)   0   0.0% 
 
Total number of negatively charged residues (Asp + Glu): 14 
Total number of positively charged residues (Arg + Lys): 13 
Formula: C522H828N140O163S4 
Total number of atoms: 1657 
Formula: C522H828N140O163S4 
Atoms number: 1657 
 
FT   DOMAIN            12-47        EF-hand 1. 
FT   DOMAIN            54-89        EF-hand 2. 
 
Tab. 4.20 Principal chemical and physical characteristics of S100a16 protein.  
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4.8.1 Large scale production of recombinant protein S100A16  
The recombinant protein S100A16 was produced on a large scale to obtain sufficient amount 
for NMR analysis. The host strain used for expression of the S100A16 gene, cloned in the 
vector pETG-30A was E.coli BL21 GOLD (colony 10) expressing the protein partially in 
soluble form, fused with GST+(His)6-tag. The growth was performed in 3 litres of 2xYT 
medium and ampicillin (100µg/ml) as describe at par 3.11. The protein was expressed 
partially in soluble form with a yield of protein of 20mg/L. From each growing culture 1 ml 
of broth was taken to verify the presence of the protein by SDS-page as showed in figure 4.38.  
 
 
 
 
 
 
 
 
 
Fig. 4.38 SDS-page concerning the expression of S100A16 protein. Line 1, 2, 3, 5, 6 and 7: the over-expressed 
bands correspond to S100A16 protein fused with the specific GST-(His)6 tag (40.8 KDa). Line 4: Protein 
Molecular Weight Marker Standard composed of seven proteins with known molecular weight (11.6KDa, 
66.2KDa,  45KDa, 35KDa, 25KDa, 18.4 KDa, 14.4KDa) 
 
 
 
4.8.2 Purification of recombinant protein S100A16 
The soluble fraction was separated from cell debris and unbrocken cells by centrifugation. 
Supernatant containing soluble recombinant protein was applied to a chromatography column. 
Purification of the soluble S100A16 was made using a standard protocol for Histidine-tagged 
and GST-tagged proteins as described at par3.12.2. The steps followed were: 
9  metal chelate affinity chromatography and glutathione affinity chromatography 
(GSTrap, Amersham-Biosciences) to purify the protein before the cleavage. The 
presence of the protein in the GSTrap eluted was confirmed by SDS-PAGE, as 
showed in figure 4.39. 
 
 
S100A16 + GST-(His)6 tag 
1        2       3     4     5       6     7  
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Fig. 4.39 SDS-page of protein S100A16 eluted from GSTrap column. The protein sample (line 4) was 
isolated from many of the other bacterial proteins visible in the flow through (line 2) and in the column 
washing (line 3). Line 1: Protein Molecular Weight Marker Standard described in figure 4.26. 
 
9  cleavage with Actev Protease to remove GST-(His)6 tag.. As showed in figure 4.40 B, 
the cleavage was correctly performed, in fact after 15 hours in the sample are visible 
three bands corresponding to cut protein (S100A16, 11.8 KDa), to uncut protein 
(S100A16+ GST-(His)6 tag, 40.8 KDa) and to GST-(His)6 tag (29 KDa). 
 
 
 
 
 
 
 
 
Fig. 4.40 A. SDS-page of S100A16 a after purifications into His-tag and GST-tag affinity columns 
before cleavage (line 2), Standard (line 1). B. Protein sample after digestion with Actev Protease (line 
3), Standard (line 1).  
 
 
After the cleavage, in the reaction mixture  a fine particulate was visible. To verify the 
presence of the protein, the sample was centrifuged for a few minutes and the pellet 
was loaded on SDS-page (figure 4.41). As showed in the line 2 of the page, many 
bacterial protein precipitated together with some S100A16.  
 
 
 
 
 St      2        3      4  
S100A16+  
GST-(His)6 
 tag 
1        2     
A. 
GST-(His)6 tag 
S100A16 
S100A16+ GST-(His)6  
tag
1        2       3     
B. 
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Fig. 4.41 SDS-page concerning the pellet debris formed during the digestion with Actev (line 2). 
Standard (line 1). 
 
The tendency to precipitate could be due to a not correct folding state or to the fact that 
the experimental conditions chosen for maximal activity of the Actev protease are not 
the optimal for the proteins. 
To find the right conditions for the protein stability, the protein was dialysed with 
eight different buffers,  whose composition is reported in tab 4.21. After a few hours 
from the beginning of the dialyses, it was evident that the protein was more stable in 
the buffer G, selected in yellow in the table, as only in this buffer precipitation was not 
observed. 
 
Buffer Composition 
A  Na Acetate pH 4.8/5; 0.5 mM CaCl2  
B  Tris HCl pH 8.8; 0.5 mM CaCl2  
C  Tris HCl pH 7.5; 0.5 mM  CaCl2; 100 mM NaCl  
F  Tris HCl pH 7.5; 2 mM DTT; 100 mM NaCl  
G  Tris HCl pH 7.5; 2 mM DTT; 5 mM EDTA; 100 mM NaCl 
H  phosphate pH 7.0 
I  Na Acetate pH 4.8/5; 0.5 mM CaCl2; 500 mM NaCl  
L  Tris HCl pH 8.8 ; 0.5 mM  CaCl2; 500 mM NaCl 
 
Tab. 4.21 In the table the composition of the buffer used for the stability test of the S100A16 protein 
are reported. 
 
At this purification step the protein was stable at pH 7.5, in reduced condition (DTT) 
and in the presence of 5 mM EDTA and 100 mM NaCl. So the successive purification 
steps were conduced using these experimental conditions. To increase the protein 
1          2    
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stability, the cleavage buffer (describe at par 3.11) was added with 5mM EDTA  and 
2mM DTT. 
9  glutathione affinity chromatography to remove the GST-(His)6 tag and uncut protein. 
In figure 4.42 is visible the cut S100A16 protein (line 1), isolated with GStrap FF 
column. The uncut fraction and GST (line 2), detained on column, were eluted with 
10mM reduced glutathione. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.42 SDS-page of  S100A16 cut (line 1), isolated with GStrap FF column. The uncut fraction and 
GST (line 2), were detained on column. Standard (line 3). 
 
 
9  size exclusion chromatography to isolate the protein from the impurities. The purity of 
the final sample was checked by SDS-page figure 4.43. 
 
 
 
 
 
 
 
 
 
Fig.4. 43 SDS-page of  the purified S100A16 (line 2).Standard (line 3). 
 
Purified S100A16 concentration (4mM) was determined by measuring absorbance at 276nm, 
using the respective extinction coefficient ε276 = 12950 M
-1cm
-1
,  as calculated by ProtPar 
parameter tools (http://expasy.org/tools/protoaram.html). 
1        2       3     
1        2   
121 
 4.8.3 Preliminary screening of folding of recombinant protein S100A16 
The purified samples, estimated to have concentration >1mM, were analysed by NMR 
spectroscopy to verify the folding state. The presence of specific signals in the 1D- and 
1H-
NOESY spectra is an indication of the correct structural state of the protein. In figure 4.44, the 
1D-NMR spectrum of S100A16 shows the presence of signals in the 8-10 ppm range, 
corresponding to amidic protons of polypeptide chains, explainable with the presence of 
secondary structure elements (α-helix).  
 
 
Fig.4.44  1D-NMR spectrum of S100A16.  
 
 
Moreover, the presence of very sharp signals in the aromatic region (6-8 ppm), indicative of 
long relaxation times, shows that the protein is in a monomeric form. The 2D-1H-NOESY 
spectrum shown in figure 4.45, is compatible with a stable structure,  because of the presence 
of a high number of cross-peaks between the aromatic (6-8 ppm) and aliphatic (0-4 ppm) 
regions, indicating stable interactions between aminoacids. 
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Fig. 4.45 2D-1H-NOESY NMR spectrum of S100A16 protein. 
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4.9 PRODUCTION AND PURIFICATION OF THE ISOFORM α OF THE Endothelial 
differentiation-related factor 1  (EDF-1) 
 
Endothelial Differentiation Factor (EDF)-1 is a calmodulin binding protein involved in the 
repression of endothelial cell differentiation, a crucial, late step in angiogenesis (Bolognese et 
al, 2006). EDF-1-CaM interaction is modulated by the concentrations of Ca
2+ and by the 
phosphorylation of EDF-1 by protein kinase C.EDF-1 is the human homologue of the 
silkworm multiprotein bridging factor (MBF)-1, a transcriptional cofactor that mediates 
transactivation by stabilizing the protein-DNA interaction. Interestingly, a neuronal 
calmodulin-binding peptide, termed CAP 19,  is the rat homologue of EDF-1. Human and rat 
proteins possess a putative IQ domain that could mediate their binding to CaM. Indeed, 
calmodulin-binding proteins share a conserved region of about 20 amino acids, designated the 
IQ motif, that contains a CaM-binding domain and a protein kinase C (PKC) phosphorylation 
site. The IQ motif was originally identified in neuromodulin that concentrates CaM at specific 
sites in neurons (Avon et al., 2000). The characteristic of the protein are reported below. 
 
>O60869|EDF1_HUMAN Endothelial differentiation-related factor 1 - Homo 
sapiens (Human). 
MAESDWDTVTVLRKKGPTAAQAKSKQAILAAQRRGEDVETSKKWAAGQNKQHSITKNTAK 
LDRETEELHHDRVTLEVGKVIQQGRQSKGLTQKDLATKINEKPQVIADYESGRAIPNNQV 
LGKIERAIGLKLRGKDIGKPIEKGPRAK 
 
Number of amino acids: 148 
Molecular weight: 16368.6 
Theoretical pI: 9.95 
 
Amino acid composition: 
Ala (A)  15    9.9% 
Arg (R)  10    6.6% 
Asn (N)   5    3.3% 
Asp (D)   8    5.3% 
Cys (C)   0    0.0% 
Gln (Q)  11    7.2% 
Glu (E)  11    7.2% 
Gly (G)  13    8.6% 
His (H)   3    2.0% 
Ile (I)  10    6.6% 
Leu (L)  10    6.6% 
Lys (K)  20   13.2% 
Met (M)   1    0.7% 
Phe (F)   1    0.7% 
Pro (P)   5    3.3% 
Ser (S)   7    4.6% 
Thr (T)  11    7.2% 
Trp (W)   2    1.3% 
Tyr (Y)   1    0.7% 
Val (V)   8    5.3% 
Asx (B)   0    0.0% 
Glx (Z)   0    0.0% 
Xaa (X)   0    0.0% 
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Total number of negatively charged residues (Asp + Glu): 19 
Total number of positively charged residues (Arg + Lys): 30 
Formula: C708H1194N222O220S1 
Total number of atoms: 2345 
Charge at pH 7.5: 1.0703084178577 
 
Tab. 4.22 Principal chemical and physical characteristics of EDF-1.  
 
 
4.9.1 Large scale production of recombinant protein EDF-1 iso α   
The recombinant EDF-1 isoα  protein was produced on a large scale to obtain sufficient 
amount for NMR analysis. The host strain used for expression of the gene cloned in the vector 
pETG-20A was E.coli BL21 Codon plus (16 colony) expressing the protein fused with 
Trx+(His)6-tag in inclusion bodies. The growth was performed in 3 litres of 2xYT medium 
and ampicillin (100µg/ml) as describe at par 3.11. At the end of the growth, after 9 hours from 
induction,  21 gr of cellular pellet were collected. The presence of the protein in the culture 
was verified by SDS-page as showed in figure 4.46. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.46 SDS-page concerning the expression of EDF-1 iso α protein. Line  2, 3, 4, 5, 6 and 7: the over-
expressed bands correspond to EDF-1 iso α protein fused with the specific Trx-(His)6 tag (33 KDa). Line 1: 
Protein Molecular Weight Marker Standard composed of seven proteins with known molecular weight 
(11.6KDa, 66.2KDa,  45KDa, 35KDa, 25KDa, 18.4 KDa, 14.4KDa) 
 
 
4.9.2 Purification of recombinant protein EDF-1 iso α 
The EDF-1 iso α was produced in inclusion bodies. Purification of EDF-1 iso α  was made 
using a standard protocol for Histidine-tagged with a denaturation refolding step on the nickel 
chelate column. The steps followed were:  
 
9  denaturation refolding step on the nickel chelate column. The inclusion bodies were 
isolated, solubilized  and refolded as describe at paragraph 3.11 At the end of the 
  1     2      3      4      5     6     7   
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Trx-(His)6 tag 
EDF-1 iso α   
1        2       3     
refolding step, the protein was eluted from Hitrap column with 300mM Imidazol. The 
presence of the protein was confirmed by SDS-PAGE, as showed in figure 4.47. The 
presence of the protein’ band proves that the protein, previously solubilized with 6 M 
Guanidin, was retained from the column and was refolded. Moreover, being the eluted 
solution clear, the protein seems to have acquired a soluble and stable structure. 
 
 
 
 
 
 
 
 
Fig. 4.47 SDS-page of EDF-1 iso α protein eluted from Hitrap column after refolding step (line 1). Line 
2: Protein Molecular Weight Marker Standard described in figure 4. 
 
 
9  cleavage with Actev Protease to remove Trx-(His)6 tag. As showed in figure 4.48, the 
cleavage was correctly occurred, in fact in the third line of the page a double band is 
clearly observed, one correspondent to the protein (16.7 KDa) and an other one to his 
tag (16.6 KDa). In the second line, the protein sample before the digestion was loaded.  
 
 
 
 
 
 
 
 
 
 
Fig. 4.48 SDS-page of EDF-1 iso α before the cleavage (line 2). Protein sample after digestion with 
Actev Protease (line 3), Standard (line 1).  
 
 
9  The purification of the cut protein was made by cationic exchange chromatography. 
The column was conditioned with Hepes buffer pH 7.4. At this pH condition, the 
EDF-1 iso α +Trx-(His)6 tag 
1         2  
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protein was retained on the column for its positive charge, while Trx-(His)6-tag, 
negatively charged, was eluted during the loading. The protein was eluted by 
continuous gradient against Hepes buffer pH 7.4 and 1M NaCl, until NaCl 
concentration was 400mM, at a flow rate of 0.5 ml/min. In figure 4.49 the SDS-page 
showing the protein during the different steps is reported.  
 
 
 
 
 
 
 
 
 
Fig. 4.49 SDS-page of EDF-1 concerning the purification steps: protein before cut (line 2), protein cut 
(line 3), protein detained on column and successively eluted with NaCl 400mM (line 4), fusion tag [Trx-
(His)6] eluted during loading (line 5). 
 
 
Purified EDF-1 concentration, 1mM, was determined measuring the absorbance at 276 
nm, using the extinction coefficient ε276 = 12450 M-1cm-1, as calculated by ProtPar 
parameters tools (http://us.expasy.org/tools/protparam.html). 
 
 
4.9.3 Preliminary screening of folding of recombinant protein EDF-1 iso α 
The purified samples were analysed by NMR spectroscopy to verify the folding state. The 
presence of specific signals in the monodimensional and HSQC spectra is an indication of the 
correct structural status of the protein in the sample. The monodimensional spectrum of EDF-
1 is reported in figure 4.50. The absence of broad signals indicates that the protein does not 
form aggregates in its quaternary structure, but is a stable monomeric form. Moreover, the 
presence of signals in the 7.5-11 ppm range where the amidic protons resonates, indicates that 
the backbone of the protein chain is protected, well inside the protein globule, against the 
exchange with solvent.  
Signals in the methyl spectral region (0.0-1.0 ppm) are not as well resolved as typical of rigid 
structures. In order to have a proof of the correct folding of the protein, the sample was 
investigated by analysis of its HSQC spectrum. The figure 4.51, shows the HSQC spectrum 
 1      2      3        4       5  
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characterized by the presence of signals spread in both the 1H and 15N, dimensions 
suggesting a stable tertiary structure typical of a correct folding. 
 
 
Fig.4.50 1D-NMR spectrum of EDF-1 iso α.  
 
 
Fig. 4.51 2D-HSQC NMR spectrum of EDF-1 iso α.  
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4.9.4 Stability test of recombinant protein EDF-1 iso α 
The protein structure wasn’t determined since a proteasic activity was observed, confirmed  
by electrophoresis analysis (appearance of bands corresponding to fragments of the protein). 
The structural NMR analysis requires many days for spectra acquisition during which the 
sample should be stable. Some test to find better experimental conditions and block the 
protein degradation were conduced. 
 
1.  The protein was dialysed in different conditions reported in tab .  The degradative state 
was checked after 2 hours , 20 hours and 4 days by SDS-page in figure 4.52 
 
Buffer 1  Buffer 2  Buffer 2 
Tris 50 mM 
NaCl 200 mM 
PMSF 1mM 
pH 6.5 
Phosphate 20mM 
Inhibitor Protease cocktail 
pH 7.2 
Tris 50 mM 
NaCl 200 mM 
pH 8.0 
 
Tab. 4.23. In the table the composition of the tested buffer are reported.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.52 SDS-pages concerning the degradative state of the EDF-1 iso α sample after 2 hours (Page A), 
20 hours (Page B) and after 4 days (page C),  in the three different conditions (lines 1, 2, 3) reported in 
table 4.23. 
 
 
Observing the gels  it’s possible to note that the buffer 2 was the worst condition, 
although also in the other conditions the degradation wasn’t stopped. 
 
2.  During the cationic exchange chromatography, the buffers reported in table 4.24 were 
experimented. The inhibitor protease cocktail,  PMSF 1mm and EDTA 5mM were 
added after the elution of the cut protein from the column. After six days the samples 
were checked by SDS-page in figure 4.53.  
A. 
B. 
C. 
12 3 12 3 12 3 
129 
Buffer 4  Buffer 5  Buffer 6  Buffer 7 
MOPS pH 7.4 
PMSF 1mM 
cocktail 
MOPS pH 7.4 
PMSF 1mM 
EDTA 5mM 
cocktail 
HEPES pH 7.4 
PMSF 1mM 
cocktail 
HEPES pH 7.4 
PMSF 1mM 
EDTA 5mM 
cocktail 
 
Tab. 4.24 In the table the composition of the tested buffer are reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.53 SDS-pages concerning the degradative state of the EDF-1 iso α sample in different conditions. 
Line 2: buffer4; line3: buffer5; line 3: buffer6; line 5: buffer7 
 
 
Also in this case the sample degradation wasn’t blocked, even if the buffer 6 and 7 
seemed to be better than 4 and 5 one. 
 
 
 
 
 
 
 
 
 
 
 
 1      2       3      4       5  
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
131 
5 CONCLUSIONS 
 
In the last decade, the number of available allergen sequences has rapidly increased due to the 
introduction of molecular biology techniques for allergen characterization. Sequence analysis 
of allergen-encoding cDNAs revealed the presence of typical calcium-binding motifs, termed 
EF-hands, within allergens from various sources. Parvalbumin represented the first calcium-
binding allergen described. It represents the major allergen in fish and belongs to a subfamily 
of closely related calcium-binding proteins that contain two functional and one silent EF-hand 
motif.  
This thesis work is part of a high-throughput project faced to the production of recombinant 
proteins belonging to one of the principal classes of the calcium-binding proteins causing 
food allergies, and their targets, selected for their relevance in cellular metabolism of all 
organisms. It has been demonstrated that calcium binding to the loop induces conformational 
changes that causes the recognition of the IgE-allergen (Dissertori O. et al., 2007). These 
results indicate that the interaction of these proteins with the physiological calcium plays an 
important role in the biologic and allergenic activity. The thesis’ aim was to obtain pure 
recombinant soluble protein for structural characterization by NMR. This information is 
essential to understand the mechanism of protein functions and for the general purpose of 
identifying new drug targets.  
The cloning and the high-throughput expression were performed by applying the Gateway 
system. The Gateway technology is a universal cloning method based on a site-specific 
recombination which provides a rapid and highly efficient way to move DNA sequences into 
multiple vector system. One of the advantages of this method is the opportunity to use 
different types of DNA sequences (PCR products, cDNA clones, restriction fragments) and 
multiple destination vectors. In fact, the DNA sequences initially are inserted in a plasmid 
(pENTR) and then transferred in multiple destination vectors (pDEST) with an only one 
recombination reaction. The destination vectors are characterized by specific fusion tag 
(protein or peptide), which allows to simplify the subsequent purification steps by specific 
affinity chromatography columns. Additionally, certain affinity tags have a beneficial effect 
on protein solubility especially in bacterial protein expression. This is an important problem 
in the recombinant proteins production. It often happens, in fact, that the recombinant protein 
produced in a host organism is not correctly structured. Each protein, in this sense, has a 
different “behaviour” and the more applied strategy to increase the successful probabilities in 
protein expression consists in the experimentation of more vector-host combinations. On this  
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subject, in the protein expression of complex multicellular organisms, big advantages could 
be derived by the employment of organisms different from Escherichia coli (the simplest and 
by far the most widely used organism for protein expression) as the yeast (Saccharomices 
cerevisiae) or insect (Baculovirus). In these cells some of the post-translational modifications 
typical of the eukaryotic cells, which could be essential for the acquisition of the correct 
three-dimensional protein structure, can happen. In definitive, once a pENTR containing the 
gene of interest is generated, with single recombination reaction it is possible to transfer 
simultaneously the gene to different pDEST, and to obtain the protein expressed with 
different peptide or fusion proteins in different host organism. 
The genes coding for the selected recombinant proteins were successfully cloned into pENTR 
plasmids by recombination reaction. This result was obtained for 32 of the 39 genes initially 
selected. Subsequently the genes were successfully transferred from each pENTR into five 
different expression vectors (pETG-20A, pETG-30A, pETG-60A, pDEST17, pDEST15) 
carrying specific protein fusion tags. For protein expression three different E.coli host strains 
were used (BL21 Gold, pLys, Codon plus) and tested for the expression screening which 
showed that the selected proteins were well expressed with almost three of the five fusion tags 
in all E. coli host strains. Moreover, from the solubility screening, it results that the 
Calmodulin targets proteins were expressed in inclusion bodies by all the host strains with an 
only one exception, the protein Endothelial differentiation related factor1 (EDF-1). There is 
instead a big variability in the solubility of the EF-hand proteins; in fact, in most cases, the 
proteins were produced in inclusion bodies and only with few tags, different for each protein, 
were expressed in soluble form. This result is very important for the successive protein 
purification steps on a larger scale. In fact, a soluble protein, fused with a specific affinity tag 
could be easily purified using a few chromatographic passages. This is the case of the of the 
recombinant protein S100A16, and of the C-terminal domain of the protein CLSP, which 
were extracted from 3 litres of bacterial culture and purified with only up to three steps, until 
a sample was obtained with high concentration suitable for the preliminary folding analysis 
by NMR. 
Purification of recombinant CLSP and of its N-terminal domain, both produced in a soluble 
form, required a denaturation refolding step on the nickel chelate column. The same protocol 
was applied for the calmodulin target Endothelial differentiation-related factor1 (EDF-1), 
isoform α, produced in inclusion bodies. The method allowed the production of pure protein 
samples, perfectly soluble and with a sufficient concentration for the NMR analysis.   
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In the results chapter, the spectra obtained at the European Centre of Magnetic Resonances 
(CERM) of the University of Florence are reported. From the spectra analysis, it results that 
the C-terminal domain of the protein CLSP was correctly folded and the protein structure was 
subsequently determined (Babini et al., 2005).  
The S100A16 NMR spectra showed that the soluble protein sample was correctly folded. 
Such a result opens the way to the subsequent step of structure characterization. Actually, the 
protein structure is unpredictable by bioinformatics methods (homology modelling), because 
of the low sequence homology with proteins with known structure.  
The NMR spectra of EDF-1 and of N- terminal CLSP reveal that the proteins are very 
flexible, such as that it is impossible to obtain the mean structure by NMR. This result is not 
indicative of an unfolded protein; on the contrary, the protein dynamics may be strictly 
related, and point, to its physiological functions (Capozzi et al, 2006).  
In the light of the results gained during this thesis work, only a high throughput strategy 
permits one to characterized at least one method useful to obtain a protein sample suitable for 
structural studies. Moreover, we found out that a number of soluble proteins, expressed and 
purified with protocols as much as possible optimized, even after the application of many 
alternative refolding procedures, show high flexibility. The flexibility is implicitly related to 
the physiological mechanism by which these proteins developed their function and, probably, 
their allergenicity was derived from this peculiarity. These proteins are also able to assume 
more exchangeable conformations, so that almost one of them may be recognized as an 
allergen. This result was clearly stressed in a paper, recently published by our group {REF, 
which reviews and extrapolates a general trait on the dynamics of this class of proteins as 
emerging by studies published by most of the research groups involved in this field. In fact, as 
it is concluded in this work, the structure of EF-hand proteins is highly variable and couldn’t 
be always “photographed” by NMR; this is the reason by which we have considered the 
necessity to adopt a high-throughput cloning strategies to define, by chances, the conditions to 
obtain at least one quasi-stable structure, that permits to build calculated models, where it is 
possible to find the one responsible of the IgE recognition.  
By this way, it is possible to foresee a structural conformation of the protein which is 
superimposable with the structure of a certain allergen, in order to hypothesize a potential 
cross-reactivity. 
Last, but not least, the results obtained during the present PhD thesis’s work permits, once 
more, to point out that the simple aminoacidic sequence is not sufficient to define the protein  
134 
properties. Rather, it is required that the structural characterization, in a natural state, must be 
performed to evaluate the potential activities of proteins.  
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Annex 1 
 
Nucleotidic sequences of the proteins selected for the research project with the specific 
primers designed to amplify the genes from cCDNA. 
 
Proteins Nucleotidic  sequence 
caccATGCTGTGCTGTATGAGAAGAACCAAACAGGTTGAAAAAAATGATGACGACCAAAAGATTGAACAAGATG
GTATCAAACCAGAAGATAAAGCTCATAAGGCCGCAACCAAAATTCAGGCTAGCTTCCGTGGACACATAACAAGG
AAAAAGCTCAAAGGAGAGAAGAAGGATGATGTCCAAGCTGCTGAGGCTGAAGCTAATAAGAAGGATGAAGCCCC
TGTTGCCGATGGGGTGGAGAAGAAGGGAGAAGGCACCACTACTGCCGAAGCAGCCCCAGCCACTGGCTCCAAGC
CTGATGAGCCCGGCAAAGCAGGAGAAACTCCTTCCGAGGAGAAGAAGGGGGAGGGTGATGCTGCCACAGAGCAG
GCAGCCCCCCAGGCTCCTGCATCCTCAGAGGAGAAGGCCGGCTCAGCTGAGACAGAAAGTGCCACTAAAGCTTC
CACTGATAACTCGCCGTCCTCCAAGGCTGAAGATGCCCCAGCCAAGGAGGAGCCTAAACAAGCCGATGTGCCTG
CTGCTGTCACTGCTGCTGCTGCCACCACCCCTGCCGCAGAGGATGCTGCTGCCAAGGCAACAGCCCAGCCTCCA
ACGGAGACTGGGGAGAGCAGCCAAGCTGAAGAGAACATAGAAGCTGTAGATGAAACCAAACCTAAGGAAAGTGC
CCGGCAGGACGAGGGTAAAGAAGAGGAACCTGAGGCTGACCAAGAACATGCCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:ONEUaF3 22  CACCATGCTGTGCTGTATGA
GA 
1a) + 
NEUROMODULIN -  
P17677 - 238 aa  
 
Reverse:ONEUaR4 20  TCAGGCATGTTCTTGGTCAG 
CaccATGAGAAGAACCAAACAGGTTGAAAAAAATGATGACGACCAAAAGATTGAACAAGATGGTATCAAACCAG
AAGATAAAGCTCATAAGGCCGCAACCAAAATTCAGGCTAGCTTCCGTGGACACATAACAAGGAAAAAGCTCAAA
GGAGAGAAGAAGGATGATGTCCAAGCTGCTGAGGCTGAAGCTAATAAGAAGGATGAAGCCCCTGTTGCCGATGG
GGTGGAGAAGAAGGGAGAAGGCACCACTACTGCCGAAGCAGCCCCAGCCACTGGCTCCAAGCCTGATGAGCCCG
GCAAAGCAGGAGAAACTCCTTCCGAGGAGAAGAAGGGGGAGGGTGATGCTGCCACAGAGCAGGCAGCCCCCCAG
GCTCCTGCATCCTCAGAGGAGAAGGCCGGCTCAGCTGAGACAGAAAGTGCCACTAAAGCTTCCACTGATAACTC
GCCGTCCTCCAAGGCTGAAGATGCCCCAGCCAAGGAGGAGCCTAAACAAGCCGATGTGCCTGCTGCTGTCACTG
CTGCTGCTGCCACCACCCCTGCCGCAGAGGATGCTGCTGCCAAGGCAACAGCCCAGCCTCCAACGGAGACTGGG
GAGAGCAGCCAAGCTGAAGAGAACATAGAAGCTGTAGATGAAACCAAACCTAAGGAAAGTGCCCGGCAGGACGA
GGGTtga  
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:ONEUbF3 21  CaccATGAGAAGAACCAAAC
A 
1b) + 
NEUROMODULIN -  
P17677 - GAP-435–
226 222 aa 
 
 
Reverse:ONEUbR4 17  tcaACCCTCGTCCTGCC 
caccAGCTTCCGTGGACACATAACAAGGAAAAAGCTCAAAGGAGAGAAGAAGGATGATGTCCAAGCTGCTGAGG
CTGAAGCTAATAAGAAGGATGAAGCCCCTGTTGCCGATGGGGTGGAGAAGAAGGGAGAAGGCACCACTACTGCC
GAAGCAGCCCCAGCCACTGGCTCCAAGCCTGATGAGCCCGGCAAAGCAGGAGAAACTCCTTCCGAGGAGAAGAA
GGGGGAGGGTGATGCTGCCACAGAGCAGGCAGCCCCCCAGGCTCCTGCATCCTCAGAGGAGAAGGCCGGCTCAG
CTGAGACAGAAAGTGCCACTAAAGCTTCCACTGATAACTCGCCGTCCTCCAAGGCTGAAGATGCCCCAGCCAAG
GAGGAGCCTAAACAAGCCGATGTGCCTGCTGCTGTCACTGCTGCTGCTGCCACCACCCCTGCCGCAGAGGATGC
TGCTGCCAAGGCAACAGCCCAGCCTCCAACGGAGACTGGGGAGAGCAGCCAAGCTGAAGAGAACATAGAAGCTG
TAGATGAAACCAAACCTAAGGAAAGTGCCCGGCAGGACGAGGGTtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:ONEUcF3 18  caccAGCTTCCGTGGACA 
1c) + 
NEUROMODULIN -  
P17677 - GAP-
4341–226 186 aa 
 
Reverse:ONEUbR4  17 tcaACCCTCGTCCTGCC 
caccATGGCCGAGAGCGACTGGGACACGGTGACGGTGCTGCGCAAGAAGGGCCCTACGGCCGCCCAGGCCAAAT
CCAAGCAGGCTATCTTAGCGGCACAGAGACGAGGAGAAGATGTGGAGACTTCCAAGAAATGGGCTGCTGGCCAG
AACAAACAACATTCTATTACCAAGAACACGGCCAAGCTGGACCGGGAGACAGAGGAGCTGCACCATGACAGGGT
GACCCTGGAGGTGGGCAAGGTGATCCAGCAAGGTCGGCAGAGCAAGGGGCTTACGCAGAAGGACCTGGCCACGA
AAATCAATGAGAAGCCACAGGTGATCGCGGACTATGAGAGCGGACGGGCCATACCCAATAACCAGGTGCTTGGC
AAAATCGAGCGGGCCATTGGCCTCAAGCTCCGGGGAAAGGACATTGGAAAGCCCATCGAGAAGGGGCCTAGGGC
GAAAtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCAP19aF3 16 caccATGGCCGAGAGC 
2a) Endothelial 
differentiation-
related factor 1 
(CAP-19) ISO-α 
 
 
Reverse:OCAP19aR4 21 tcaTTTCGCCCTAGGCCCCT
T 
caccATGGCCGAGAGCGACTGGGACACGGTGACGGTGCTGCGCAAGAAGGGCCCTACGGCCGCCCAGGCCAAAT
CCAAGCAGGCTATCTTAGCGGCACAGAGACGAGGAGAAGATGTGGAGACTTCCAAGAAATGGGCTGCTGGCCAG
AACAAACAACATTCTATTACCAAGAACACGGCCAAGCTGGACCGGGAGACAGAGGAGCTGCACCATGACAGGGT
GACCCTGGAGGTGGGCAAGGTGATCCAGCAAGGTCGGCAGAGCAAGGGGCTTACGCAGAAGGACCTGGCCACGA
AAATCAATGAGAAGCCACAGGTGATCGCGGACTATGAGAGCGGACGGGCCATACCCAATAACCAGGTGCTTGGC
AAAATCGAGCGGGCCATTGGTGAGTGTCCCTCCACCCTTCGCCGGGTCCGCtga  
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
2b) Endothelial 
differentiation-related 
factor 1 (CAP-19) 
ISO-β 
 
Forward:OCAP19aF3 16 caccATGGCCGAGAGC  
136 
  Reverse:OCAP19bR4 14 tcaGCGGACCCGGC 
caccATGAGTGAGCGACAAGGTGCTGGGCCAACCAATGGAAAAGACAAGACATCTGGTGAAAATGATGGACAGA
AGAAAGTTCAAGAAGAATTTGACATTGACATGGATGCACCAGAGACAGAACGTGCAGCGGTGGCCATTCAGTCT
CAGTTCAGAAAATTCCAGAAGAAGAAGGCTGGGTCTCAGTCCtag 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OPEP19F3 20  caccATGAGTGAGCGACAAG 
3) PEP-19  
P48539  62 AA   
Reverse:OPEP19R4 24  ctaGGACTGAGACCCAGCCT
TCTT 
caccATGTCAGAACCGGCTGGGGATGTCCGTCAGAACCCATGCGGCAGCAAGGCCTGCCGCCGCCTCTTCGGCC
CAGTGGACAGCGAGCAGCTGAGCCGCGACTGTGATGCGCTAATGGCGGGCTGCATCCAGGAGGCCCGTGAGCGA
TGGAACTTCGACTTTGTCACCGAGACACCACTGGAGGGTGACTTCGCCTGGGAGCGTGTGCGGGGCCTTGGCCT
GCCCAAGCTCTACCTTCCCACGGGGCCCCGGCGAGGCCGGGATGAGTTGGGAGGAGGCAGGCGGCCTGGCACCT
CACCTGCTCTGCTGCAGGGGACAGCAGAGGAAGACCATGTGGACCTGTCACTGTCTTGTACCCTTGTGCCTCGC
TCAGGGGAGCAGGCTGAAGGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACGGCGGCAGACCAGCAT
GACAGATTTCTACCACTCCAAACGCCGGCTGATCTTCTCCAAGAGGAAGCCCtaa 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OP21aF3 18  caccATGTCAGAACCGGC 
4a) P21 P38936 
164aa   
 
 
Reverse:OP21aR4 17  ttaGGGCTTCCTCTTGG 
caccATGTCAGAACCGGCTGGGGATGTCCGTCAGAACCCATGCGGCAGCAAGGCCTGCCGCCGCCTCTTCGGCC
CAGTGGACAGCGAGCAGCTGAGCCGCGACTGTGATGCGCTAATGGCGGGCTGCATCCAGGAGGCCCGTGAGCGA
TGGAACTTCGACTTTGTCACCGAGACACCACTGGAGGGTGACTTCGCCTGGGAGCGTGTGCGGGGCCTTGGCCT
GCCCAAGCTCTACCTTCCCACGGGGCCCCGGCGAGGCCGGGATGAGTTGGGAGGAGGCAGGCGGCCTGGCACCT
CACCTGCTCTGCTGCAGGGGACAGCAGAGGAAGACCATGTGGACCTGTCACTGTCTTGTACCCTTGTGCCTCGC
TCAGGGGAGCAGGCTGAAGGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACGGCGGCAGACCAGCAT
GACAGATTTCTACCACTCCAAACGCCGGCTGATCTTCTCCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OP21aF3 18  caccATGTCAGAACCGGC 
4b) P21 P38936 
(1-160) 160 aa 
Reverse:OP21bR4 18  tcaGGAGAAGATCAGCCG 
caccGTGGACAGCGAGCAGCTGAGCCGCGACTGTGATGCGCTAATGGCGGGCTGCATCCAGGAGGCCCGTGAGC
GATGGAACTTCGACTTTGTCACCGAGACACCACTGGAGGGTGACTTCGCCTGGGAGCGTGTGCGGGGCCTTGGC
CTGCCCAAGCTCTACCTTCCCACGGGGCCCCGGCGAGGCCGGGATGAGTTGGGAGGAGGCAGGCGGCCTGGCAC
CTCACCTGCTCTGCTGCAGGGGACAGCAGAGGAAGACCATGTGGACCTGTCACTGTCTTGTACCCTTGTGCCTC
GCTCAGGGGAGCAGGCTGAAGGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACGGCGGCAGACCAGC
ATGACAGATTTCTACCACTCCAAACGCCGGCTGATCTTCTCCAAGAGGAAGCCCtaa 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OP21cF3 17  caccGTGGACAGCGAGC 
4c) P21 P38936 
140 aa   
Reverse:OP21bR4 18  tcaGGAGAAGATCAGCCG 
caccATGGCGTCCACGGATTACAGTACCTATAGCCAAGCTGCAGCGCAGCAGGGCTACAGTGCTTACACCGCCC
AGCCCACTCAAGGATATGCACAGACCACCCAGGCATATGGGCAACAAAGCTATGGAACCTATGGACAGCCCACT
GATGTCAGCTATACCCAGGCTCAGACCACTGCAACCTATGGGCAGACCGCCTATGCAACTTCTTATGGACAGCC
TCCCACTGGTTATACTACTCCAACTGCCCCCCAGGCATACAGCCAGCCTGTCCAGGGGTATGGCACTGGTGCTT
ATGATACCACCACTGCTACAGTCACCACCACCCAGGCCTCCTATGCAGCTCAGTCTGCATATGGCACTCAGCCT
GCTTATCCAGCCTATGGGCAGCAGCCAGCAGCCACTGCACCTACAAGACCGCAGGATGGAAACAAGCCCACTGA
GACTAGTCAACCTCAATCTAGCACAGGGGGTTACAACCAGCCCAGCCTAGGATATGGACAGAGTAACTACAGTT
ATCCCCAGGTACCTGGGAGCTACCCCATGCAGCCAGTCACTGCACCTCCATCCTACCCTCCTACCAGCTATTCC
TCTACACAGCCGACTAGTTATGATCAGAGCAGTTACTCTCAGCAGAACACCTATGGGCAACCGAGCAGCTATGG
ACAGCAGAGTAGCTATGGTCAACAAAGCAGCTATGGGCAGCAGCCTCCCACTAGTTACCCACCCCAAACTGGAT
CCTACAGCCAAGCTCCAAGTCAATATAGCCAACAGAGCAGCAGCTACGGGCAGCAGAGTTCATTCCGACAGGAC
CACCCCAGTAGCATGGGTGTTTATGGGCAGGAGTCTGGAGGATTTTCCGGACCAGGAGAGAACCGGAGCATGAG
TGGCCCTGATAACCGGGGCAGGGGAAGAGGGGGATTTGATCGTGGAGGCATGAGCAGAGGTGGGCGGGGAGGAG
GACGCGGTGGAATGGGCAGCGCTGGAGAGCGAGGTGGCTTCAATAAGCCTGGTGGACCCATGGATGAAGGACCA
GATCTTGATCTAGGCCCTCCTGTAGATCCAGATGAAGACTCTGACAACAGTGCAATTTATGTACAAGGATTAAA
TGACAGTGTGACTCTAGATGATCTGGCAGACTTCTTTAAGCAGTGTGGGGTTGTTAAGATGAACAAGAGAACTG
GGCAACCCATGATCCACATCTACCTGGACAAGGAAACAGGAAAGCCCAAAGGCGATGCCACAGTGTCCTATGAA
GACCCACCCACTGCCAAGGCTGCCGTGGAATGGTTTGATGGGAAAGATTTTCAAGGGAGCAAACTTAAAGTCTC
CCTTGCTCGGAAGAAGCCTCCAATGAACAGTATGCGGGGTGGTCTGCCACCCCGTGAGGGCAGAGGCATGCCAC
CACCACTCCGTGGAGGTCCAGGAGGCCCAGGAGGTCCTGGGGGACCCATGGGTCGCATGGGAGGCCGTGGAGGA
GATAGAGGAGGCTTCCCTCCAAGAGGACCCCGGGGTTCCCGAGGGAACCCCTCTGGAGGAGGAAACGTCCAGCA
CCGAGCTGGAGACTGGCAGTGTCCCAATCCGGGTTGTGGAAACCAGAACTTCGCCTGGAGAACAGAGTGCAACC
AGTGTAAGGCCCCAAAGCCTGAAGGCTTCCTCCCGCCACCCTTTCCGCCCCCGGGTGGTGATCGTGGCAGAGGT
GGCCCTGGTGGCATGCGGGGAGGAAGAGGTGGCCTCATGGATCGTGGTGGTCCCGGTGGAATGTTCAGAGGTGG
CCGTGGTGGAGACAGAGGTGGCTTCCGTGGTGGCCGGGGCATGGACCGAGGTGGCTTTGGTGGAGGAAGACGAG
GTGGCCCTGGGGGGCCCCCTGGACCTTTGATGGAACAGATGGGAGGAAGAAGAGGAGGACGTGGAGGACCTGGA
AAAATGGATAAAGGCGAGCACCGTCAGGAGCGCAGAGATCGGCCCTACtag 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OEWSaF3 22  caccATGGCGTCCACGGATT
AC 
5a) RNA-binding 
protein EWS 
Q01844 656 aa   
Reverse:OEWSaR4 18  ctaGTAGGGCCGATCTCT 
5b) RNA-binding 
protein EWS 
Q01844 256-447 
CaccCAACAGAGCAGCAGCTACGGGCAGCAGAGTTCATTCCGACAGGACCACCCCAGTAGCATGGGTGTTTATG
GGCAGGAGTCTGGAGGATTTTCCGGACCAGGAGAGAACCGGAGCATGAGTGGCCCTGATAACCGGGGCAGGGGA
AGAGGGGGATTTGATCGTGGAGGCATGAGCAGAGGTGGGCGGGGAGGAGGACGCGGTGGAATGGGCAGCGCTGG 
137 
AGAGCGAGGTGGCTTCAATAAGCC 
TGGTGGACCCATGGATGAAGGACCAGATCTTGATCTAGGCCCTCCTGTAGATCCAGATGAAGACTCTGACAACA
GTGCAATTTATGTACAAGGATTAAATGACAGTGTGACTCTAGATGATCTGGCAGACTTCTTTAAGCAGTGTGGG
GTTGTTAAGATGAACAAGAGAACTGGGCAACCCATGATCCACATCTACCTGGACAAGGAAACAGGAAAGCCCAA
AGGCGATGCCACAGTGTCCTATGAAGACCCACCCACTGCCAAGGCTGCCGTGGAATGGTTTGATGGGAAAGATT
TTCAAGGGAGCAAACTTAAAGTCTCCCTTGCTCGGAAGtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OEWSbF3 17  CaccCAACAGAGCAGCA 
191 aa  
 
 
Reverse:OEWSbR4 21  tcaCTTCCGAGCAAGGGAGA
C 
caccATGGGTCTGCGGGAGGACAGAGCCCCGGCAGCTCCCAGAGCTTCCTTCCAGGACGCCTACCTGATGAAGC
TGCGCCGCCAGACGCTCACCTTCACCACCAACCGGCTCAAGGAGTTCCTGGGCGAGCAGCGGCGGCGCCGGGCT
GAGGCTGCCACCCGCCACAAGATGTCTAAAGCAGCTCCTGCCAAAAAGCCAGTGGCTGTGGCCCCAGCTCCTGG
ATGTACCCTGGACATCAATGACCCACAGGTCCAGAGTGCGGCCATTCGTATCCAGGCCTCTTACCGGGGCCACA
GGTCCCGGAAGGAGCTGCGCGAGAAGGGGCCGCCGCGGGTGCTGGAGCCGCTGAAGGACGTGGTGCTGATCGAA
GGCAGCGCGGCCAAGCTCACTTGCCGCATTTCGGCTTTCCCGGACCCATTCATCCGCTGGAGTAAGGACGGCAA
GGAGCTACGTGACGGTCCCAAGTACCGCTACGTCTTCGAGGACCCTGACGTGGTGGCACTGGTGGTGCGCGACG
GCGAGCTGGCAGACCTGGGCCAGTACAGCATCAACGTCACCAACCCCTTCGGCCAGTGCTCCGACTCGGCGCGC
ATCCTCGTGGAAGCCGGTGAGGTGATGCCCTGCCTCATCTCCGGGTCCTTCACGGGGTTTCGCTCCCCTTTCCT
TCCGCTAGTCCCGACGAAGATTCAAAAGGGACCCGACAACACTAAGGCGCGCAAAGGCACCACCGTGACGCTGA
CTGCGGAGATCCTGGGAGAGCCTGCGCCCGACGTAGGCTGGACCAAGGACGGGGAGGACATCGAGGAGGATGAC
AGGGTGTTCTTCGAGATCGGCAGCACCACCACGACGCTGACCATTCGCCGGGCCACGCCTCAGGACAGCGGCAA
GTACGAGGTGTACGTGGAGAACAGCCTGGGCATGGACCAGAGCTTCGCTCGCGTCGACGTGGCCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCAVPF3 17  caccATGGGTCTGCGGG 
6a) similar to 
CAVP-target 
protein 
Reverse:OCAVPR4 17  tcaGGCCACGTCGACGC 
caccATGTACCGCGCGCTGTACGCGTTCCGCTCGGCGGAGCCCAACGCGCTGGCGTTCGCCGCGGGCGAGACCTT
CCTGGTGCTAGAGCGAAGCAGCGCGCACTGGTGGCTGGCCGCGCGGGCGCGCAGTGGTGAGACGGGCTACGTGC
CGCCAGCCTACCTGCGCCGCCTGCAGGGCCTGGAGCAGGATGTCCTCCAGGCCATTGACCGGGCCATCGAGGCT
GTACACAACACAGCCATGCGGGATtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OSP90F3 15  caccATGTACCGCGC 
7)  SH3 adapter 
protein SPIN90 
Q9NZQ3 FRAGMENT 
(1-81)   81 aa 
Reverse:OSP90R4 18  tcaATCCCGCATGGCTGT 
CaccGTGCAGCTCCTCGACCAGATCCCATCATACGACACCCACAAGATCGCCGTCCTGTATGTTGGAGAAGGCC
AGAGCAACAGCGAGCTCGCCATCCTGTCCAATGAGCATGGCTCCTACAGGTACACGGAGTTCCTGACGGGCCTG
GGCCGGCTCATCGAGCTGAAGGACTGCCAGCCGGACAAGGTGTACCTGGGAGGCCTGGACGTGTGTGGTGAGGA
CGGCCAGTTCACCTACTGCTGGCACGATGACATCATGCAAGCCGTCTTCCACATCGCCACCCTGATGCCCACCA
AGGACGTGGACAAGCACCGCTGCGACAAGAAGCGCCACCTGGGCAACGACTTTGTGTCCATTGTCTACAATGAC
TCCGGTGAGGACTTCAAGCTTGGCACCATCAAGGGCCAGTTCAACTTTGTCCACGTGATCGTCACCCCGCTGGA
CTACGAGTGCAACCTGGTGTCCCTGCAGTGCAGGAAAGACATGGAGGGCCTTGTGGACACCAGCGTGGCCAAGA
TCGTGTCTGACCGCAACCTGCCCTTCGTGGCCCGCCAGATGGCCCTGCACGCAAATATGGCCTCACAGGTGCAT
CATAGCCGCTCCAACCCCACCGATATCTACCCCTCCAAGTGGATTGCCCGGCTCCGCCACATCAAGCGGCTCCG
CCAGCGGATCTGCGAGGAAGCCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OTSCF3 19  CaccGTGCAGCTCCTCGAC 
8) Tuberous 
sclerosis 2 
protein  Tuberin 
TSC2_HUMAN 
P49815 C-
terminal domain  
Rap-GAP (1531 – 
1758) 228 aa 
Reverse:OTSCR4 18  tcaGGCTTCCTCGCAGAT 
caccATGGGTTCTCGGGCCTCCACGTTACTGCGGGACGAAGAGCTCGAGGAGATCAAGAAGGAGACCGGCTTTT
CCCACAGTCAAATCACTCGCCTCTACAGCCGGTTCACCAGCCTGGACAAAGGAGAGAATGGGACTCTCAGCCGG
GAAGATTTCCAGAGGATTCCAGAACTTGCCATCAACCCACTGGGGGACCGGATCATCAATGCCTTCTTTCCAGA
GGGAGAGGACCAGGTAAACTTCCGTGGATTCATGCGAACTTTGGCTCATTTCCGCCCCATTGAGGATAATGAAA
AGAGCAAAGATGTGAATGGACCCGAACCACTCAACAGCCGAAGCAACAAACTGCACTTTGCTTTTCGACTATAT
GATTTGGATAAAGATGAAAAGATCTCCCGTGATGAGCTGTTACAGGTGCTACGCATGATGGTCGGAGTAAATAT
CTCAGATGAGCAGCTGGGCAGCATCGCAGACAGGACCATTCAGGAGGCTGATCAGGATGGGGACAGTGCCATAT
CTTTCACAGAATTTGTTAAGGTTTTGGAGAAGGTGGATGTAGAACAGAAAATGAGCATCCGATTTCTTCACtaa 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCHP1F3 17  caccATGGGTTCTCGGG 
9) + Calcineurin 
B Homologous 
Protein (CHP1) 
195 aa Q99653  
 
 
Reverse:OCHP1R4 20  ttaGTGAAGAAATCGGATGC 
caccATGGGGTCGCGCAGCTCCCACGCCGCGGTCATTCCCGACGGGGACAGTATTCGGCGAGAGACCGGCTTCT
CCCAAGCCAGCCTGCTCCGCCTGCACCACCGGTTCCGGGCACTGGACAGGAATAAGAAGGGCTACCTGAGCCGC
ATGGATCTCCAGCAGATAGGGGCGCTCGCCGTGAACCCCCTGGGAGACCGAATTATAGAAAGCTTCTTCCCCGA
TGGGAGCCAGCGAGTGGATTTCCCAGGCTTTGTCAGGGTCTTGGCTCATTTTCGCCCTGTAGAAGATGAGGACA
CAGAAACCCAAGACCCCAAGAAACCTGAACCTCTCAACAGCAGAAGGAACAAACTTCACTATGCATTTCAGCTC
TATGACCTGGATCGCGATGGGAAGATCTCCAGGCATGAGATGCTGCAGGTTCTCCGTCTGATGGTTGGGGTACA
GGTGACAGAAGAGCAGCTGGAGAACATCGCTGACCGCACGGTGCAGGAGGCTGATGAAGATGGGGATGGGGCTG
TGTCCTTCGTGGAGTTCACCAAGTCCTTAGAGAAGATGGACGTTGAGCAAAAAATGAGCATCCGGATCCTGAAG
tga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCHP2F4 14  caccATGGGGTCGC 
10) Calcineurin 
B Homologous 
Protein 2 (CHP2)  
O43545 196 aa  
 
Reverse:OCHP2R4 16  tcaCTTCAGGATCCGG 
11) TESCALCIN  caccATGGGCGCTGCCCACTCCGCGTCTGAGGAGGTGCGGGAGCTCGAGGGCAAGACCGGCTTCTCATCGGATC 
138 
AGATCGAGCAGCTCCATCGGAGATTTAAGCAGCTGAGTGGAGATCAGCCTACCATTCGCAAGGAGAACTTCAAC
AATGTCCCGGACCTGGAGCTCAACCCCATCCGATCCAAAATTGTTCGTGCCTTCTTCGACAACAGGAACCTGCG
CAAGGGACCCAGTGGCCTGGCTGATGAGATCAATTTCGAGGACTTCCTGACCATCATGTCCTACTTCCGGCCCA
TCGACACCACCATGGACGAGGAACAGGTGGAGCTGTCCCGGAAGGAGAAGCTGAGATTTCTGTTCCACATGTAC
GACTCGGACAGCGACGGCCGCATCACTCTGGAAGAATATCGAAATGTGGTCGAGGAGCTGCTGTCGGGAAACCC
TCACATCGAGAAGGAGTCCGCTCGCTCCATCGCCGACGGGGCCATGATGGAGGCGGCCAGCGTGTGCATGGGGC
AGATGGAGCCTGATCAGGTGTACGAGGGGATCACCTTCGAGGACTTCCTGAAGATCTGGCAGGGGATCGACATT
GAGACCAAGATGCACGTCCGCTTCCTTAACATGGAAACCATGGCCCTCTGCCACtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OTESCF3 14  caccATGGGCGCTG 
Q96BS2 214 aa 
 
Reverse:OTESCR4 15  tcaGTGGCAGAGGGC 
caccATGGGGAAGCAGAATAGCAAACTGGCCCCTGAAGTGATGGAGGACCTGGTGAAGAGCACAGAGTTTAATG
AGCATGAACTCAAGCAGTGGTACAAAGGATTTCTCAAGGACTGTCCAAGTGGGAGGCTAAATCTCGAGGAATTT
CAGCAGCTCTATGTGAAGTTCTTTCCTTATGGAGACGCCTCCAAGTTTGCCCAGCATGCCTTCCGAACCTTCGA
CAAGAATGGGGACGGCACCATTGACTTCCGAGAGTTCATCTGCGCTCTGTCCATCACCTCCAGGGGCAGCTTTG
AGCAGAAGCTGAACTGGGCCTTCAATATGTATGACCTGGATGGTGATGGCAAGATCACCCGAGTGGAGATGCTG
GAGATCATCGAGGCTATCTACAAAATGGTAGGCACTGTGATCATGATGAAAATGAATGAGGATGGCCTGACGCC
TGAGCAGCGAGTAGACAAGATTTTCAGCAAGATGGATAAGAACAAAGATGACCAGATTACACTGGATGAATTCA
AAGAAGCTGCAAAGAGCGACCCTTCCATTGTATTACTTCTGCAGTGCGACATCCAGAAAtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OVIS1F3 21  caccATGGGGAAGCAGAATA
G 
12) visinin-like 
protein 1 191aa 
p28677  
 
 
Reverse:OVIS1R4 20  tcaTTTCTGGATGTCGCACT 
caccATGGGCAAACAGAACAGCAAGCTGCGGCCCGAGGTGCTGCAGGACCTGCGGGAGAACACGGAGTTCACCG
ACCACGAGCTGCAGGAGTGGTACAAGGGCTTCCTCAAGGACTGCCCCACCGGCCACCTGACCGTGGACGAGTTC
AAGAAGATCTACGCCAACTTCTTCCCCTACGGCGACGCTTCCAAGTTCGCCGAGCACGTCTTCCGCACCTTCGA
CACCAACGGCGACGGCACCATCGACTTCCGGGAGTTCATCATTGCGCTGAGCGTGACCTCGCGGGGCAAGCTGG
AGCAGAAGCTCAAGTGGGCCTTCAGCATGTACGACCTGGACGGCAACGGCTACATCAGCCGCAGCGAGATGCTG
GAGATCGTGCAGGCCATCTACAAGATGGTGTCGTCTGTGATGAAGATGCCGGAGGATGAGTCCACCCCGGAGAA
GCGCACAGACAAGATCTTCAGGCAGATGGACACCAACAATGACGGCAAACTGTCCTTGGAAGAATTCATCAGAG
GTGCCAAGAGCGACCCCTCCATCGTCCGCCTGCTGCAGTGCGACCCCAGCAGTGCCAGTCAGTTCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OVIS3F3 20  caccATGGGCAAACAGAACA 
13a) + visinin-
like protein 3 
(HIPPOCALCIN-
LIKE PROTEIN 
1)P37235 193aa  
 
 
Reverse:OVIS3R4 19  tcaGAACTGACTGGCACTG 
caccATGGACGCCGTGGATGCCACCATGGAGAAACTCCGGGCACAGTGCCTGTCCCGCGGGGCCTCGGGCATCC
AGGGCCTGGCCAGGTTTTTCCGCCAACTAGACCGGGACGGGAGCAGATCCCTGGACGCTGATGAGTTCCGGCAG
GGTCTGGCCAAACTCGGGCTGGTGCTGGACCAGGCGGAGGCAGAGGGTGTGTGCAGGAAGTGGGACCGCAATGG
CAGCGGGACGCTGGATCTGGAGGAGTTCCTTCGGGCGCTGCGGCCCCCCATGTCCCAGGCCCGGGAGGCTGTCA
TCGCAGCTGCATTTGCCAAGCTGGACCGCAGTGGGGACGGCGTCGTGACGGTGGACGACCTCCGCGGGGTGTAC
AGTGGCCGTGCCCACCCCAAGGTGCGCAGTGGGGAGTGGACCGAGGACGAGGTGCTGCGCCGCTTCCTGGACAA
CTTCGACTCCTCTGAGAAGGACGGGCAGGTCACACTGGCGGAATTCCAGGACTACTACAGCGGCGTGAGTGCCT
CCATGAACACGGATGAGGAGTTCGTGGCCATGATGACCAGTGCCTGGCAGCTGtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCAPSF3 16  caccATGGACGCCGTG 
14) CALCYPHOSINE 
189 AA Q13938  
 
Reverse:OCAPSR4 17  tcaCAGCTGCCAGGCAC 
caccATGCCGTTCCACCATGTGACCGCCGGCTTGTTGTACAAGGGGAATTACCTCAACCGATCGCTCTCTGCTG
GCAGTGACAGCGAACAGCTGGCTAATATCTCCGTGGAGGAGCTCGATGAAATCCGAGAGGCCTTTCGGGTTCTG
GACCGGGATGGGAACGGCTTCATCTCCAAGCAGGAGCTGGGCATGGCCATGCGCTCTTTGGGGTACATGCCAAG
CGAGGTGGAGCTGGCCATCATCATGCAGCGCTTGGACATGGACGGGGATGGCCAGGTGGATTTTGATGAATTCA
TGACCATTCTTGGCCCCAAACTGGTGTCTTCAGAAGGTCGCGATGGTTTTCTTGGGAACACGATAGACAGCATA
TTCTGGCAGTTTGACATGCAAAGGATAACTCTGGAAGAGTTGAAGCACATTCTCTATCATGCCTTCCGAGACCA
CCTAACGATGAAGGACATTGAGAACATCATTATCAATGAGGAAGAGAGCCTGAATGAGACCTCGGGGAACTGCC
AAACAGAGTTTGAAGGAGTGCATTCCCAGAAGCAGAACAGACAGACCTGCGTCCGGAAGAGCCTCATATGCGCC
TTTGCTATGGCCTTCATCATCAGTGTCATGCTGATTGCAGCCAACCAGATACTCCGGAGCGGCATGGAGtag 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCALNF3 18  caccATGCCGTTCCACCA 
16a) CALNEURON 
Q9BXU9 219 AA 
 
 
Reverse:OCALNR4 18  ctaCTCCATGCCGCTCCG 
caccATCTCCGTGGAGGAGCTCGATGAAATCCGAGAGGCCTTTCGGGTTCTGGACCGGGATGGGAACGGCTTCA
TCTCCAAGCAGGAGCTGGGCATGGCCATGCGCTCTTTGGGGTACATGCCAAGCGAGGTGGAGCTGGCCATCATC
ATGCAGCGCTTGGACATGGACGGGGATGGCCAGGTGGATTTTGATGAATTCATGACCATTCTTGGCCCCAAAtg
a 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCALNF5 18  caccATCTCCGTGGAGGA 
16b) CALNEURON 
Q9BXU9 DOMINIO 
N-TERMINALE 33-
104 72 aa 
 
 
 
Reverse:OCALNR6 17  tcaTTTGGGGCCAAGAA 
17) + GUANYLYL 
CYCLASE 
ACTIVATING 
PROTEIN 1 P43080 
201 AA  
 
caccATGGGCAACGTGATGGAGGGAAAGTCAGTGGAGGAGCTGAGCAGCACCGAGTGCCACCAGTGGTACAAGA
AGTTCATGACTGAGTGCCCCTCTGGCCAACTCACCCTCTATGAGTTCCGCCAGTTCTTCGGCCTCAAGAACCTG
AGCCCGTCGGCCAGCCAGTACGTGGAACAGATGTTTGAGACTTTTGACTTCAACAAGGACGGCTACATTGATTT
CATGGAGTACGTGGCAGCGCTCAGCTTGGTCCTCAAGGGGAAGGTGGAACAGAAGCTCCGCTGGTACTTCAAGC
TCTATGATGTAGATGGCAACGGCTGCATTGACCGCGATGAGCTGCTCACCATCATCCAGGCCATTCGCGCCATT
AACCCCTGCAGCGATACCACCATGACTGCAGAGGAGTTCACCGATACAGTGTTCTCCAAGATTGACGTCAACGG 
139 
GGATGGGGAACTCTCCCTGGAAGAGTTTATAGAGGGCGTCCAGAAGGACCAGATGCTCCTGGACACACTGACAC
GAAGCCTGGACCTTACCCGCATCGTGCGCAGGCTCCAGAATGGCGAGCAAGACGAGGAGGGGGCTGACGAGGCC
GCTGAGGCAGCCGGCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OGCA1F3 18  caccATGGGCAACGTGAT 
Reverse:OGCA1R4 15  tcaGCCGGCTGCCTC 
CACCATGGGGCAGGAGTTTAGCTGGGAGGAGGCGGAGGCAGCTGGCGAGATAGATGTGGCGGAGCTCCAGGAGT
GGTACAAGAAGTTTGTGATGGAGTGCCCCAGCGGCACACTCTTTATGCATGAGTTTAAGCGCTTCTTCAAGGTC
ACAGACGATGAGGAGGCCTCCCAGTATGTAGAGGGCATGTTCCGAGCCTTCGACAAGAATGGGGACAACACCAT
CGACTTCCTGGAGTACGTGGCAGCTCTGAATCTCGTGCTGAGGGGCACCCTGGAGCACAAGCTGAAGTGGACAT
TCAAGATCTATGATAAGGATGGCAATGGCTGCATCGACCGCCTGGAGCTACTCAACATTGTGGAGGGAATTTAC
CAGCTGAAGAAAGCCTGCCGGCGAGAGCTACAGACTGAGCAAGACCAGCTGCTCACACCCGAGGAGGTCGTGGA
CAGGATCTTCCTCCTGGTGGATGAGAATGGAGATGGCCAGCTGTCTCTGAACGAGTTTGTTGAAGGTGCCCGTC
GGGACAAGTGGGTGATGAAGATGCTGCAGATGGACATGAATCCCAGCAGCTGGCTCGCTCAGCAGAGACGGAAA
AGTGCCATGTTCTGA 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OGCAP2F1 21  CACCATGGGGCAGGAGTTTA
G 
18) + GUANYLYL 
CYCLASE 
ACTIVATING 
PROTEIN 2 Q9UMX6 
200 AA  
 
 
Reverse:OGCAP2R2 20  TCAGAACATGGCACTTTTCC 
caccATGGGGAATGGCAAATCTATAGCTGGTGATCAGAAAGCAGTTCCTACACAAGAGACCCATGTGTGGTACA
GAACATTTATGATGGAATATCCATCCGGCCTGCAAACACTACATGAATTTAAGACACTTTTGGGTCTGCAAGGT
CTGAATCAGAAGGCCAATAAACATATTGATCAAGTTTATAATACCTTTGACACGAACAAGGATGGATTTATTGA
CTTTTTGGAGTTTATTGCTGCTGTAAATCTAATCATGCAAGAAAAAATGGAGCAAAAATTAAAATGGTATTTTA
AGCTGTATGATGCTGATGGAAATGGTTCTATTGACAAAAATGAACTACTGGACATGTTCATGGCGGTACAAGCC
CTCAATGGCCAGCAAACTCTGAGTCCTGAAGAATTCATCAACTTGGTGTTCCATAAGATCGATATAAACAATGA
TGGGGAATTGACTTTAGAAGAATTTATCAATGGCATGGCAAAAGATCAGGATCTCCTGGAGATTGTTTACAAGA
GCTTCGACTTCTCCAATGTGCTGAGAGTAATCTGTAATGGGAAGCAGCCAGACATGGAGACAGACTCCTCCAAA
TCTCCTGACAAGGCTGGTCTAGGGAAGGTGAAAATGAAGtag 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OGCAP3F3 18  caccATGGGGAATGGCAA 
19a) + Guanylyl 
cyclase 
activating 
protein 3 O95843 
iso1 209 
 
 
Reverse:OGCAP3R4 27  ctaCTTCATTTTCACCTTCC
CTAGACC 
caccATGTGCAGTTCTCTGGAGCAGGCGCTGGCTGTGCTGGTCACTACCTTCCACAAGTACTCCTGCCAAGAGG
GCGACAAGTTCAAGCTGAGTAAGGGGGAAATGAAGGAACTTCTGCACAAGGAGCTGCCCAGCTTTGTGGGGGAG
AAAGTGGATGAGGAGGGGCTGAAGAAGCTGATGGGCAGCCTGGATGAGAACAGTGACCAGCAGGTGGACTTCCA
GGAGTATGCTGTTTTCCTGGCACTCATCACTGTCATGTGCAATGACTTCTTCCAGGGCTGCCCAGACCGACCCt
ga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OS102F3 21  caccATGTGCAGTTCTCTGG
A 
20) S102 P29034 
97 aa  
 
Reverse:OS102R4 16  tcaGGGTCGGTCTGGG 
caccATGTCAGACTGCTACACGGAGCTGGAGAAGGCAGTCATTGTCCTGGTGGAAAACTTCTACAAATATGTGTC
TAAGTACAGCCTGGTCAAGAACAAGATCAGCAAGAGCAGCTTCCGCGAGATGCTCCAGAAAGAGCTGAA 
CCACATGCTGTCGGACACAGGGAACCGGAAGGCTGCGGATAAGCTCATCCAGAACCTGGATGCCAATCAT 
GATGGGCGCATCAGCTTCGATGAGTACTGGACCTTGATAGGCGGCATCACCGGCCCCATCGCCAAACTCA 
TCCATGAGCAGGAGCAGCAGAGCAGCAGCtag 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OS116F3 22  caccATGTCAGACTGCTACA
CG 
21) S116 Q96FQ6 
103AA  
 
 
Reverse:OS116R4 18  ctaGCTGCTGCTCTGCTG 
caccATGGCCAGCTATCCTTACCGGCAGGGCTGCCCAGGAGCTGCAGGACAAGCACCAGGAGCCCCTCCGGGTA
GCTACTACCCTGGACCCCCCAATAGTGGAGGGCAGTATGGTAGTGGGCTACCCCCTGGTGGTGGTTATGGGGGT
CCTGCCCCTGGAGGGCCTTATGGACCACCAGCTGGTGGAGGGCCCTATGGACACCCCAATCCTGGGATGTTCCC
CTCTGGAACTCCAGGAGGACCATATGGCGGTGCAGCTCCCGGGGGCCCCTATGGTCAGCCACCTCCAAGTTCCT
ACGGTGCCCAGCAGCCTGGGCTTTATGGACAGGGTGGCGCCCCTCCCAATGTGGATCCTGAGGCCTACTCCTGG
TTCCAGTCGGTGGACTCAGATCACAGTGGCTATATCTCCATGAAGGAGCTAAAGCAGGCCCTGGTCAACTGCAA
TTGGTCTTCATTCAATGATGAGACCTGCCTCATGATGATAAACATGTTTGACAAGACCAAGTCAGGCCGCATCG
ATGTCTACGGCTTCTCAGCCCTGTGGAAATTCATCCAGCAGTGGAAGAACCTCTTCCAGCAGTATGACCGGGAC
CGCTCGGGCTCCATTAGCTACACAGAGCTGCAGCAAGCTCTGTCCCAAATGGGCTACAACCTGAGCCCCCAGTT
CACCCAGCTTCTGGTCTCCCGCTACTGCCCACGCTCTGCCAATCCTGCCATGCAGCTTGACCGCTTCATCCAGG
TGTGCACCCAGCTGCAGGTGCTGACAGAGGCCTTCCGGGAGAAGGACACAGCTGTACAAGGCAACATCCGGCTC
AGCTTCGAGGACTTCGTCACCATGACAGCTTCTCGGATGCTAtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OPEFF3 22  caccATGGCCAGCTATCCTT
AC 
22a) PEFLIN 
Q9UBV8 284 AA 
INTERA 
 
 
Reverse:OPEFR4  24 tcaTAGCATCCGAGAAGCTG
TCAT 
22b) PEFLIN Q9UBV8 
ESP1  (EFH1_2) (116-
CaccGATCCTGAGGCCTACTCCTGGTTCCAGTCGGTGGACTCAGATCACAGTGGCTATATCTCCATGAAGGAGC
TAAAGCAGGCCCTGGTCAACTGCAATTGGTCTTCATTCAATGATGAGACCTGCCTCATGATGATAAACATGTTT 
140 
GACAAGACCAAGTCAGGCCGCATCGATGTCTACGGCTTCTCAGCCCTGTGGAAATTCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OPEFEspF3 20 CaccGATCCTGAGGCCTACT 
182) 67 aa 
 
Reverse:OPEFEspR4 19 tcaGAATTTCCACAGGGCT 
CaccATCCAGCAGTGGAAGAACCTCTTCCAGCAGTATGACCGGGACCGCTCGGGCTCCATTAGCTACACAGAGC
TGCAGCAAGCTCTGTCCCAAATGGGCTACAACCTGAGCCCCCAGTTCACCCAGCTTCTGGTCTCCCGCTACTGC
CCACGCTCTG 
CCAATCCTGCCATGCAGCTTGACCGCTTCATCCAGGTGTGCACCCAGCTGtga 
 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OPEFEspF5 21  CaccATCCAGCAGTGGAAGA
A 
22c) >PEFLIN 
ESP2 (EFH3_4) 
(183 – 250) 68 
aa  
 
Reverse:OPEFEspR6 17  tcaCAGCTGGGTGCACA 
caccCAGAGCTTCCTGTGGAACGTTTTCCAGAGGGTCGATAAAGACAGGAGTGGAGTGATATCAGACACCGAGC
TTCAGCAAGCTCTCTCCAACGGCACGTGGACTCCCTTTAATCCAGTGACTGTCAGGTCGATCATATCCATGTTT
GACCGTGAGAACAAGGCCGGCGTGAACTTCAGCGAGTTCACGGGTGTGTGGAAGTACtga  
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OALG2Esp1
F1 
18 caccCAGAGCTTCCTGTG 
23a)  ALG-2 ESP1 
(EFH1_2) 67 aa 
 
Reverse:OALG2Esp1
R2 
21 tcaGTACTTCCACACACCCG
T 
caccATCACGGACTGGCAGAACGTCTTCCGCACGTACGACCGGGACAACTCCGGGATGATCGATAAGAACGAGC
TGAAGCAGGCCCTCTCAGGTTTCGGCTACCGGCTCTCTGACCAGTTCCACGACATCCTCATTCGAAAGTTTGAC
AGGCAGGGACGGGGGCAGATTGCCTTCGACGACTTCATCCAGGGCTGCATCGTCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OALG2Esp2
F1 
17 caccATCACGGACTGGC 
23b)  ALG-2 ESP2 
(EFH3_4) 66 aa 
 
Reverse:OALG2Esp2
R2 
17 tcaGACGATGCAGCCCT 
caccGGGAATCCTGTATATGAAAAATACTATAGACAGGTTGATACAGGCAATACTGGAAGGGTGTTGGCTTCTG
ATGCTGCTGCTTTCCTGAAAAAATCAGGGCTTCCAGACTTGATACTTGGAAAGATTTGGGATTTAGCCGACACA
GATGGCAAAGGTATCCTGAACAAACAAGAATTCTTTGTTGCTTTGCGTCTTGTGGCATGTGCCCAGAATtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OEP15Esp
1F3 
22 caccGGGAATCCTGTATATG
AA 
24) EP15_HUMAN 
P42566 896AA 
ESP1 (EH1) (15-
85) 71 aa 
 
 
O 
Reverse:EP15Esp1
R4 
18 tcaATTCTGGGCACATGC 
CaccCAGTATATTCAAAGCTACAAGGGATTTGTTGACATAACGGGAGAACATTTTGTGAATTC 
CTGGGTCCAGAGAGAATTACCTATGGCATCAGCTTATTGCAATGACAGCATCTTTGCTTACGAAGAACTA 
CGGCTGGACTCTTTTAAGGACTGGCCCCGGGAATCAGCTGTGGGAGTTGCAGCACTGGCCAAAGCAGGTCTTTT
CTACACAGGTATAAAGGACATCGTCCAGTGCTTTTCCTGTGGAGGGTGTTTAGAGAAATGGCAGGAAGGTGATG
ACCCATTAGACGATCACACCAGATGTTTTCCCAATTGTCCATTTCTCCAAAATATGAAGTCC 
TCTGCGGAAGTGACTCCAGACCTTCAGAGCCGTGGTtga 
 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OBIR3IIF3 25 CaccCAGTATATTCAAAGCT
ACAAG 
25) BIR3-NAIP 
(238-362) Q13075 
125 aa 
 
 
Reverse:OBIR3IIR4 19 tcaACCACGGCTCTGAAGG 
CaccATGCCATCTCAAATGGAACACGCCATGGAAACCATGATGTTTACATTTCACAAATTCGCTGGGGATAAAG
GCTACTTAACAAAGGAGGACCTGAGAGTACTCATGGAAAAGGAGTTCCCTGGATTTTTGGAAAATCAAAAAGAC
CCTCTGGCTGTGGACAAAATAATGAAGGACCTGGACCAGTGTAGAGATGGCAAAGTGGGCTTCCAGAGCTTCTT
TTCCCTAATTGCGGGCCTCACCATTGCATGCAATGACTATTTTGTAGTACACATGAAGCAGAAGGGAAAGAAGt
ag 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OS100A10F
3 
19 CaccATGCCATCTCAAATG 
 
26) S100A10 97 
aa 
 
 
Reverse:OS100A10R
4 
24 ctaCTTCTTTCCCTTCTGCT
TCAT 
27)CLSP 146 aa 
 
caccATGGCCGGTGAGCTGACTCCTGAGGAGGAGGCCCAGTACAAAAAGGCTTTCTCCGCGGTTGACACGGATG
GAAACGGCACCATCAATGCCCAGGAGCTGGGCGCGGCGCTGAAGGCCACGGGCAAGAACCTCTCGGAGGCCCAG
CTAAGGAAACTCATCTCCGAGGTTGACAGCGACGGCGACGGCGAAATCAGCTTCCAGGAGTTCCTGACGGCGGC
AAGGAAGGCCAGGGCCGGCCTGGAGGACCTGCAGGTCGCCTTCCGCGCCTTCGACCAGGATGGCGACGGCCACA
TCACCGTGGACGAGCTCAGGCGGGCCATGGCGGGGCTGGGGCAGCCGCTGCCGCAGGAGGAGCTGGACGCCATG
ATCCGCGAGGCCGACGTGGACCAGGACGGGCGGGTGAACTACGAGGAGTTCGCGAGGATGCTCGCCCAGGAGtg 
141 
a 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OCLSPF1 16  caccATGGCCGGTGAG 
Reverse:OCLSPR2 16  tcaCTCCTGGGCGAGC 
caccATGGGCAAGCAGAACAGCAAGCTGCGGCCCGAGATGTTGCAGGACCTGCGAGAGAACACAGAGTTCTCAG
AGCTGGAGCTGCAGGAGTGGTACAAGGGCTTCCTCAAGGACTGCCCCACAGGAATCCTCAATGTGGATGAGTTC
AAGAAGATCTACGCCAACTTCTTTCCCTATGGTGACGCCTCCAAGTTTGCCGAGCACGTCTTCCGCACCTTTGA
CACCAACAGCGATGGCACCATAGACTTTCGGGAGTTCATCATTGCGCTGAGCGTGACCTCGCGCGGCCGCCTGG
AGCAGAAGCTCATGTGGGCCTTCAGCATGTATGACCTGGACGGCAACGGCTACATCAGCCGGGAGGAGATGCTG
GAGATCGTGCAGGCCATTTACAAGATGGTTTCGTCCGTGATGAAGATGCCGGAGGACGAGTCGACCCCGGAAAA
GAGGACTGAGAAAATCTTCCGCCAAATGGACACAAACAACGACGGCAAGCTGTCCTTGGAGGAGTTCATCCGCG
GGGCCAAAAGCGACCCGTCCATCGTGCGTCTGCTGCAGTGCGACCCCAGCAGCGCCTCCCAGTTCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OHPCAF1 19  caccATGGGCAAGCAGAAC 
28) Hippocalcin 
193 aa 
Reverse:OHPCAR2 18  tcaGAACTGGGAGGCGCT 
caccGAAGAACTACGGCTGGACTCTTTTAAGGACTGGCCCCGGGAATCAGCTGTGGGAGTTGCAGCACTGGCCA
AAGCAGGTCTTTTCTACACAGGTATAAAGGACATCGTCCAGTGCTTTTCCTGTGGAGGGTGTTTAGAGAAATGG
CAGGAAGGTGATGACCCATTAGACGATCACACCAGATGTTTTCCCAATTGTCCATTTCTCtga 
Primers  Nucleotide number  Primer sequence 5
׀-3
׀ 
Forward:OBIR3IIF5 21 caccGAAGAACTACGGCTGG
A 
29>BIR3-NAIP 
frammento 
piccolo 68 aa mw 
7610.6 (278-344) 
 
 
 
Reverse:OBIR3IIR6 22 tcaGAGAAATGGACAATTGG
GA 
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